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Thesis abstract
Histone methyltransferases are key players in eukaryotic gene regulation. The goal of this
thesis was to study the role of the histone methyltransferase Mll2 in developing embryos
and adult mice. Targeting of mouse ES cells with a multipurpose allele and blastocyst
injection had previously generated a mouse line allowing analysis of Mll2 function by
knock-out and conditional mutagenesis using Cre/loxP. The first part of the thesis
comprised the analysis of the Mll2-/- phenotype, and included the cloning of a targeting
construct to generate an ubiquitous, ligand-regulated Cre line. In the second part, we did
conditional mutagenesis using the Rosa26-CreER(T2) line obtained from collaborators,
and achieved complete knock-out of Mll2 in most tissues of embryos, neonates and adult
mice.
Mll2 is essential during embryonic development, as mutant embryos were severely growth
retarded, had significant increases in apoptosis, and failed in gestation between E 9.5 and
E11. Conditional removal of Mll2 protein at gastrulation (E 6.5) produced a similar
phenotype at E 11. In contrast, the absence of Mll2 function after E 11 did not result in
obvious defects at E16 and indicates an essential role for Mll2 between E6 and E11.
Indeed, we identified a loss of expression of 3 important developmental regulators in
mutants of this developmental stage: Hoxb1, Mox1 and Six3 are candidate targets for Mll2
regulation that encode homeobox type transcription factors involved in specifying cellular
identity. We observed correct establishment of their developmental expression patterns,
which than decay in Mll2-/- mutants at E9.5. These data concord with and extend current
thoughts about the fly orthologue of Mll2, Trithorax, which suggest that it acts as an
epigenetic lock in chromatin to maintain expression of certain transcription factors key to
respective cellular identities, after their expression patterns have been established.
After birth, Mll2 is dispensable in most tissues, as conditional knock out in neonates and
adult mice did not produce any pathological findings except infertility of mutant males and
females. Histological analysis of testis revealed progressive loss of spermatogonia,
associated with increases in apoptosis but without overt proliferation, meiotic or
differentiation defects or loss of the supporting Sertoli cells. Consequently, in addition to
its regulation of homeotic genes during development, Mll2 is required for the maintenance
of various mitotic cell populations including ES cells, embryonal cells and germ cells.
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Dédié à ‘Mamie’ Michèle Paris
        et à Anne Glaser
Ce qu’il faut pour être heureux
Il faut penser ; sans quoi l’homme devient,
Malgré son âme, un vrai cheval de somme.
Il faut aimer ; c’est ce qui nous soutient :
Sans rien aimer, il est triste d’être homme.
Il faut avoir douce société,
Des gens savants, instruits, sans suffisance,
Et de plaisirs grande variété
Sans quoi les jours sont plus longs qu’on ne pense.
Il faut avoir un ami, qu’en tout temps
Pour son bonheur, on écoute, on consulte,
Qui puisse rendre à notre âme en tumulte,
Les maux moins vifs et les plaisirs plus grands.
Il faut, le soir, un souper délectable,
Où l’on soit libre, où l’on goûte, à propos,
Les mets exquis, les bon vins, les bon mots
Et, sans être ivre, il faut sortir de table.
Il faut, la nuit, tenir entre deux draps
Le tendre objet que notre cœur adore,
Le caresser, s’endormir dans ses bras,
Et, le matin, recommencer encore.
Voltaire
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1. Introduction
1.1 Eukaryotic transcriptional control
Amongst the most fascinating phenomena that science is exploring is the emergence of
life on our planet. All life that is known to exist on earth today, although quite diverse
in appearance, seems to be of the same form – one based on 2-deoxyribose nucleic acid
(DNA) genomes and protein enzymes. DNA, which can be described as an
informational macromolecule, is composed of two helical chains each coiled around the
same axis (Watson et al., 1953). Following the elucidation that genes correspond to
specific segments on the DNA and further progress in understanding transcriptional
control in prokaryotes, public attention has turned to understanding transcription in
eukaryotes: How are so many genes transcribed in a cell-type specific, developmentally
regulated manner? A part of the answer has been found in a mode of regulation that
involves chromatin.
1.1.1 Chromatin
The DNA of eukaryotic cells is organized and condensed by its association with small,
basic histone proteins. This package of DNA and protein is termed chromatin, a
structure that solves the problem of fitting 2 meters of DNA strands into the nucleus. In
addition, chromatin provides a dynamic platform for all DNA-mediated processes
within the nucleus.
The basic redundant unit of chromatin is the nucleosome core particle, typically an
octamer composed of the four core histones H2A, H2B, H3 and H4, with 147 bp of
DNA wrapped nearly twice around the histone core (Luger et al., 1997). Each
nucleosome is separated by 10 – 60 bp of “linker” DNA. This repetitive arrangement
establishes a chromatin fiber of ~ 10 nm diameter, which is believed to be folded into
more condensed, ~30 nm thick fibers that are stabilized by binding of the linker histone
H1 to each nucleosome core. Such 30 nm fibers are then further condensed to form 100
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– 400 nm thick interphase fibers or the highest packaging density, found in metaphase
chromosomes.
Each core histone is composed of a structured globular domain and an unstructured N-
terminal tail. The conserved globular domain mediates histone-histone interactions
within the octamer and organizes the two wraps of DNA. The aminoterminal 20-35
residue tail is rich in basic amino acids and is believed to protrude from the surface of
the nucleosome; histone H2A is unique in having an additional 37 amino acid carboxy-
terminal domain. These histone “tails” do not contribute significantly to the structure of
nucleosomes, but probably influence the folding of nucleosomes into higher order
structures. Indeed, in vitro removal of the histone tails results in nucleosomal arrays that
cannot condense past the 10 nm fiber.
Coiling of DNA around the nucleosome is now recognized as a cornerstone of
transcriptional control (Kornberg et al., 1999; Struhl et al., 1999). Nucleosomes can
repress transcription by occluding sites of protein binding to DNA, thereby interfering
with the interaction of DNA binding proteins i.e. activator and repressor proteins,
polymerases, transcription factors and DNA-modifying enzymes. Moreover, chains of
nucleosomes can become further condensed, and this higher-order coiling can represses
transcription of entire chromosomal domains. The interaction of nucleosomes with
additional chromosomal proteins in condensed heterochromatin can repress gene
expression in a hereditary manner, while a more open, transcriptionally active state is
found in euchromatin. There are at least three principal ways by which the nucleosomes
contribute to the dynamics of chromatin. First, the composition of nucleosomes can be
modulated by replacing the major histone proteins with specialized variants
(Santisteban et al., 2000; Smith et al,. 2002; Ahmad et al., 2002). Second, ATP-
dependent chromatin-remodeling complexes can change the position of nucleosomes,
which is believed to “loosen” nucleosome arrangement and allow DNA-binding
proteins to gain access to their target (Martens et al., 2003). Finally, the histones are
subject to a rich variety of posttranslational, covalent modifications.
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1.1.2 Post-translational histone modifications
Separate lines of work on chromatin structure and gene activator proteins recently
intersected to reveal a fundamental mechanism of eukaryotic gene regulation. Proteins
previously identified as modulators of transcription were discovered to possess catalytic
activities directed at histones. Identified histone modifications include lysine
acetylation, lysine and arginine methylations, serine and threonine phosphorylations,
lysine ubiquitylation and sumoylation, as well as ribosylation. These modifications
could theoretically affect chromatin function through two distinct mechanisms. First,
nearly all modifications alter the electrostatic charge of the histone. Consequently, this
could affect the interactions between nucleosomes themselves and nucleosomes and
DNA, thereby influencing the folding dynamics of nucleosomal arrays. Although it was
observed that hyperacetylation by 6 to 12 acetates per histone does disrupt the folding
dynamics of nucleosomal arrays in vitro, there is no further evidence for this model. In
contrast, there is much evidence for a second model, where histone modifications can
create binding surfaces for protein recognition and thus recruit specific functional
complexes. Indeed, examples of such epitopal binding have been identified in the case
of the bromodomain, which can recognize acetylated lysine, and the chromodomain,
which can recognize methylated lysine (Dhalluin et al., 1999; Jacobs et al., 2002). The
discovery of these specific interactions led to the “histone code” hypothesis, which
posits that specific histone modifications recruit particular transacting factors to
accomplish specific functions (Jenuwein and Allis, 2001). Recent studies have
supported this view and shown that specific combinations of histone modifications
often dictate a particular biological outcome. Methylation of H3 K9, H3 K27, and of H4
K20 and absence of H3 and H4 acetylation is often found in transcriptionally repressed
regions of the genome (i.e. pericentric heterochromatin). Conversely, trimethylation of
H3 K4, phosphorylation of H3 S10, and acetylation of H3 K14 and H4 K8 are often
found in transcriptionally active euchromatin. Further, histone modifications not only
affect transcriptional control, but also play fundamental roles in DNA repair, during the
cell cycle, and in establishment of pericentric heterochromatin. In the case of DNA
repair, the DNA damage checkpoint kinase ATM (yeast Mec1p) is recruited to a DNA
double strand break where it phosphorylates histone H2A in yeast or H2AX in
mammals. Particular patterns of histone modifications also correlate with global
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chromatin dynamics during the cell cycle. Diacetylation of histone H4 at K4 and K12 is
associated with histone deposition at S phase, while phosphorylation of histone H2A (at
S1 and T119) and H3 (at T3, S10 and S28) are often found in condensed mitotic
chromatin. Finally, the establishment of chromatin structure surrounding mammalian
and fission yeast centromeres involves histone methylation and the RNA interference
(RNAi) machinery (Schramke et al., 2003). The low transcription of double-stranded,
noncoding RNAs from repetitive elements (retrotransposons) clustered in pericentric
heterochromatin provides substrates processed by the RNAi machinery. The resulting
21-23 nucleotide RNAs associate with several chromatin components, target Clr4
methylation at H3 K9 to pericentric regions, which subsequently recruits Swi6 (HP1)
and leads to heterochromatin formation.
The identification of histone modifying enzymes and their respective target sites has
made remarkable progress recently, and led to the definition of histone
acetyltransferase (HAT), histone deacetylases (HDAC), histone methyltransferase
(HMT) and histone kinase families.
Fig.1 (A) Structure of the nucleosome (B) Histone methyltransferases (except Rad6) and their target
sites on histone tails.
1.1.3 Histone acetyltransferases (HAT)
Acetylated histones are usually associated with transcriptionally active chromatin and
deacetylated histones with inactive chromatin. The acetylation of histone tails could
theoretically increase the access of transcription factors to DNA through structural
changes in nucleosomes. The neutralization of the basic charge of the histone tails by
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acetylation is thought to reduce their affinity for DNA and to alter histone-histone
interactions. Moreover, coactivators and transcription factors are recruited by specific
binding to acetylated histone tails. The highly conserved histone H3 lysines at amino-
terminal amino acid positions 9, 14, 18 and 23, and H4 lysines 5, 8, 12 and 16, are
frequently targeted for acetylation. As an exception to the hyperacetylation found in
transcriptionally active regions, acetylation of H3 lysine 12 is linked to transcriptional
silencing in yeast and Drosophila (Turner et al., 1992; Braunstein et al., 1996).
Strong molecular evidence for a direct link between acetylation and transcription was
provided when the conserved transcriptional regulator Gcn5 was found to have histone
acetyltransferase (HAT) activity (Brownell et al., 1996). Yeast and human Gcn5 is
usually associated with other transcriptional adaptors or gene-specific activator proteins
in multisubunit complexes (i.e. SAGA complex) that regulate its specificity and
recruitment to target promoters. Numerous other coactivator proteins have been found
to possess HAT activity, and there are currently several reported families of
acetyltransferases, comprising over twenty enzymes. In human cells, the related
proteins CBP [cAMP-responsive element-binding (CREB)-binding protein] and p300
bind to activator proteins involved in cell-cycle control, differentiation, DNA repair and
apoptosis. CBP and p300 stimulate transcription by acetylating histones and are
therefore termed ‘coactivators’. The physical association between CBP and a histone
methyltransferase activity indicates a functional cooperation of acetylation and
methylation of histones (Vandel et al., 2000).
1.1.4 Histone deacetylases (HDAC)
Specialized regions of chromatin are transcriptionally inactive and form hypoacetylated,
heterochromatin-like regions, i.e. telomeres, centomeres, and silent yeast mating-type
loci. Inhibition of histone deacetylase (HDAC) activity and inactivation of sites for
hypoacetylation in histone H4 are known to disrupt the formation of such highly
condensed domains (Ekwall et al., 1997). Furthermore, a large number of HDAC have
been identified, many of which act as corepressors of transcription. The yeast HDAC
Rpd3 is recruited by repressor proteins to promoters, thereby contributing to repression
by local deacetylation of chromatin (Wu et al., 2000). In yeast, heterochromatin
formation is mediated by the HDAC Sir2 and the Sir3 and Sir4 silencing proteins (Imai
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et al., 2000; Landry et al., 2000; Smith et al., 2000).  Interestingly, HATs and HDACs
seem to counteract the effects of each other by a constant acetylation and deacetylation.
This global, antagonizing activity maintains an equilibrium level of histone acetylation
throughout the genome. Probably, the genome-wide acetylation status of histone tails is
adaptable to certain requirements of chromatin dynamic during the cell cycle.
1.1.5 Histone kinases
Histone phosphorylation contributes to processes such as transcription, DNA repair, and
chromosome condensation. Gene activation in mammalian cells and during the heat
shock response in Drosophila has been shown to correlate with phosphorylation on
serine 10 of histone H3. Epidermal growth factor (EGF) treatment of fibroblasts leads to
rapid phosphorylation of serine 10 by Rsk-2 and simultaneously induces the induction
of early response genes such as c-fos. The mechanism by which phosphorylation
contributes to transcriptional activation is not well understood. However, it has been
shown that several HATs have increased activity on phosphorylated substrates. Thus,
the transcriptional activation by histone kinases could be mediated by phosphorylation-
dependent recruitment of acetylating co-activators. Phosphorylation of H2A is
correlated with mitotic chromosome condensation. In yeast, the induction of DNA
damage rapidly induces phosphorylation of   H2A at serine 139 by the Mec1 kinase.
The requirement of this histone modification for efficient non-homologous end-joining
repair of DNA suggest the formation of a chromatin structure that facilitates the repair,
or the surface-dependent recruitment of DNA repair proteins.
1.1.6 Histone methyltransferases (HMT)
 Acetylations and phosphorylations of histones occur with a relatively high turnover and
are therefore considered as short-term signals of the ‘histone code’. By contrast, histone
methylation has been regarded as a more long-term epigenetic mark, consistent with the
relatively low turnover of the methyl group. Histone methylation occurs on lysine
residues 4, 9, 27, and 36 in H3, and on position 20 in H4. In addition, lysine
methylation is present in the highly variable N-terminus of the linker histone H1 and in
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non-histone proteins. Each lysine can accept up to three methyl groups, adding another
level of complexity to the ‘histone code’. Suv(var)3-9 was the first identified
mammalian HMT, which specifically methylates H3 at lysine 9 (Rea et al., 2000). The
methyltransferase activity of Suv(var)3-9 lies within one invariant protein motif named
the SET domain. The SET domain was initially identified as a 130-residue motif present
in Drosophila SU(VAR)3-9, the Polycomb-group protein Enhancer of zeste [E(z)] and
in the trithorax-group protein Trithorax (TRX). There are more than 70 gene sequences
containing the SET domain in mammals, but only seven SET-domain gene sequences
(named Set1 to Set7) in the budding yeast S. cerevisiae. Furthermore, budding yeast,
unlike fission yeast, does not undergo H3 lysine 9 methylation. Comparison of the SET
domains found in mammals led to their classification into four subfamilies.
The SUV39 subfamily includes the founding member, Drosophila Su(var)3-9, closely
related to yeast Clr4. In mice, there are two orthologues named Suv39h1 and Suv39h2.
Methylation by Suv39 at lysine 9 of H3 creates a binding site recognized by the
heterochromatin protein HP1 [yeast Swi6] (Bannister et al., 2001; Lachner et al., 2001).
Interestingly, Suv39 associates with HP1 and therefore creates its own binding site, a
mechanism that allows the spreading of the methyl mark for repressive
heterochromatin. Another member is G9a, which is closely related to Suv39 and
represents a ‘dual’ HMT that methylates K9 and K27 of histone H3. Interestingly,
methylation specific antibodies have revealed that G9a mono-methylates lysine 9, while
Suv39 di- and tri-methylates lysine 9. Finally, ESET methylates lysine 9 on H3 in vitro,
recent observations however suggest that the in vivo target of this HMT is the p53
protein.
The SET2 subfamily is defined by the SET domain of the founding member from
Saccharomyces cerevisiae SET2, which methylates K36 on histone H3 (Strahl et al.,
2002). Included in this subfamily are the three highly related members NSD1, NSD2
and NSD3. NSD1 binds hormone receptors such as retinoic acid receptors and thyroid
hormone receptors. Thus, it is possible that NSD1 is a co-regulator of hormonally
regulated gene transcription through specific interaction with nuclear receptors. The
Drosophila ASH1 gene has a bromodomain, a Phd finger domain and a SET domain
that suggests its classification within the SET2 subgroup. In addition, ASH1 is a TRX
group gene homologue that also belongs to the trxG3 subgroup, which includes
Trithorax, ASH1 and ASH2. The multiple methylation specificities towards H3 K4, H3
K9 and H4 K36 of ASH1are intriguing but may be artifacts of the in vitro assays.
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The third group is the RIZ subfamily, which includes the proteins RIZ, MDS-EVI1,
MDL1, BLIMP1, PFM1 and MEL1. None of the RIZ proteins has been shown to
possess methyltransferase activity. However, a mutation in the SET domain of RIZ1
identical to a mutation that abolishes the methyltransferase activity of Suv39
(Cys106Thr) has a transforming effect. The fact that this mutation is found in tumors
suggests that the RIZ1 protein might possess an enzymatic activity, impairment of
which promotes oncogenesis.
The SET1 subfamily includes yeast SET1 that has the capacity to methylate lysine 4 on
histone H3 (Roguev et al., 2001). In mice, there are two orthologues named SET1a and
SET1b. This family includes the polycomb group (PcG) proteins EZH1 and EZH2, and
the trithorax group (TrxG) proteins MLL (TRX1/HRX/ALL1), MLL2 (TRX2/HRX2),
MLL3 and the related protein ALR. Finally, this family includes SET7 (SET9),
whichmethylates H3 K4 and H4 K20. A defining structural feature of this family is a
SET domain, at the very carboxyl terminus of the protein, which is mostly followed by
a POST-SET domain. The two proteins that do not fit this definition are EZH1 and
EZH2, which methylate H3 K27, while all other members are likely to methylate H3
K4. Therefore EZH1 and EZH2 may represent a subset of this family.
Set1 is the exclusive H3 K4 methyltransferase in the yeast genome, which does not
contain homologues of the TrxG genes MLL and MLL2. The Set1 complex purified
from S. cerevisiae comprises eight members (Roguev). Interestingly, two separate
polypeptides, Bre2, containing a SPRY domain, and Spp1, containing a PhD finger,
appear to be the homolgue of Ash2, which contains both conserved motifs. Subsequent
purifications of the 3 mammalian Set1, Mll and Mll2 complexes revealed a remarkable
similarity in composition (Wysoka et al., 2003; Yokoyama et al., 2004; Hughes et al.,
2004). All three complexes contain mammalian ASH2L (Drosophila Ash2 and yeast
Bre2/Spp1), and the highly conserved WD40 repeat-containing proteins WDR5 and/or
RBBP5 (yeast Swd2/3 and Swd1, respectively). In addition, the tumor suppressor menin
associates with both MLL and MLL2 complexes and is required for the
methyltransferase activity. The similar composition of the mammalian SET1, MLL and
MLL2 complexes and the yeast SET1 complex could indicate an ancient and conserved
biochemical machinery for histone H3 lysine 4 methylation.
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1.1.7 Epigenetic regulation of cellular memory by the Polycomb and Trithorax
group proteins
The maintenance of differential gene-expression patterns of specific cell types during
DNA replication and at mitosis is believed to be accomplished by epigenetic
mechanisms. In Drosophila, the antagonizing Polycomb group (PcG) and Trithorax
group (TrxG) proteins are required to maintain gene expression patterns of important
developmental regulators like the Hox genes during cellular proliferation. The
molecular mechanism of this regulation is poorly understood. However, recent work has
shown that at least part of the silencing function of the PcG complex ESC-E(Z) is
mediated by its intrinsic activity for methylating histone H3 on lysine 27. Several
studies have indicated that histone tail methylation can affect chromatin-based gene
regulation and lead to the proposition that patterns of covalent modifications serve as an
epigenetic code for transcriptionally active or silenced chromatin. Previous studies have
shown that PcG mediated gene repression mediated by histone methylation can be
propagated through DNA replication and mitosis, thereby guaranteeing the inheritance
of silenced chromatin states. In contrast, much less is known about inheritance of the
active state, which leads to the question:
Are there epigenetic mechanisms in mammals based on inheritance of active chromatin
states?
It is unclear, if and how ‘active’ chromatin states are propagated and inherited through
cell divisions, but mammalian SET1-like complexes are likely to contribute to these
mechanisms. The goal of this thesis was a functional analysis of Mll2, a SET1-like
histone methyltransferase, and to gain insights to mammalian mechanisms of
inheritance of active chromatin states. For reasons that are discussed in section 1.2, this
study used the mouse as model organism.
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1.2 Manipulating the mouse genome
The availability of totipotent mouse embryonic stem (ES) cells and near-complete DNA
sequence of the mouse genome(s) has greatly simplified the generation of transgenic
mouse mutants. One reason for the use of the mouse relative to other model genetic
organisms is that it is the closest genetically tractable organism. Indeed, despite the
facility with which other model organisms can be dissected genetically (e.g. D.
melanogaster and C. elegans), the mouse is valued for its relatively unique applicability
to the genetic study of immunology, cancer, behavior, and mammalian development. At
present, it represents the premier genetic model organism for the study of human
disease and development.
The development of new methods for manipulating the mouse genome, including
transgenic and embryonic stem (ES) cell knockout technology, combined with greatly
improved genetic and physical maps for mouse has revolutionized our ability to
generate new mouse models to study gene function.
1.2.1 Mammalian multipurpose allele
Hundreds of genes have been mutated by targeted mutagenesis in the mouse, and the
field of biomedical research has benefited significantly from the study of these mutant
mice. Despite the power of the targeted mutation technology, this approach has
limitations. The creation of targeted mutations is still costly, labor-intensive and time
consuming. Moreover, while the basic gene targeting experiment yields a null allele, it
is often the case that more subtle mutations provide more information about gene
function. These mutations can be gain-of-function alleles, hypomorphic alleles or
hypermorphic alleles. In addition, recently developed technologies include conditional
tissue-specific and/or inducible mutagenesis and protein complex purification using
targeted insertion of protein tags. Instead of creating several mouse lines with different
allelic variations for a single gene, an elegant enhancement is to combine more than one
of those features in one multipurpose allele. A paradigm for such a multivalent
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approach is a null allele that is convertible to a conditional allele in vivo b y
recombeneering the genome with site-specific recombinases (SSR).
1.2.2 Recombeneering the mouse genome with site-specific recombinases
Regulated somatic mutagenesis is essential for the analysis of gene function during
development and in the adult organism. In mice transgenesis through oocyte injection or
DNA recombination in embryonic stem (ES) cells allows mutations to be introduced
into the germ line. However, the earliest phenotype of the introduced mutation can
eclipse later effects and circumvent studies of gene function during subsequent
development. A solution to this problem is temporally and/or spatially regulated
somatic mutagenesis.
Recent work on somatic mutagenesis has focused on the use of site-specific
recombination (Kilby et al., 1993; Rossant et al., 1995; Bedell et al., 1997). Two site-
specific recombinases (SSRs), Cre recombinase from the Eschericha coli phage P1 and
FLP recombinase from the 2µ circle of Saccharomyces cerevisiae, have been shown to
possess the properties required for genomic manipulations in a wide range of living
systems including mice. Genomic manipulations with SSRs require expression of an
SSR protein and introduction of at least two recombination target sites at chosen
positions in the genome. The type of recombination event mediated by the SSR depends
on the disposition of the recombination target sites, with deletions, inversions,
translocations and integrations being possible (Kilby et al., 1993).
In addition, it was shown that the ligand-dependent characteristics of steroid hormone
receptors could be imposed on SSRs by expressing recombinase-steroid receptor fusion
proteins (Logie et al., 1995; Metzger et al., 1995). These fusion recombinases are
inactive in the absence of a cognate steroid hormone, but respond rapidly to hormone
administration, allowing regulation of their enzyme activities by administration of the
appropriate ligand. In the absence of ligand, the hormone receptor domain interacts with
the ubiquitous heat shock protein 90 (HSP90) and traps the recombinase fusion protein
in an inactive complex. Upon ligand binding, the fusion protein is released from this
complex and can now bind the target sites, were it catalyses the recombination reaction.
Thus SSR-steroid receptor fusion proteins present an experimentally convenient way to
determine the time of recombination by ligand administration.
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Fig. 2  Temporal regulation of site-specific recombinase.
The expressed protein is a fusion of Cre recombinase and the ligand binding domain (LBD) of the human
estrogen receptor. The fusion protein is inactive because the LBD interacts with the ubiquitous Hsp90
complex. The fusion protein is released from the inactive state upon ligand binding by the LBD, allowing
recombination between loxP sites in the genome. The LBD is mutated and does not bind to the
endogenous hormone estrogen, instead activation is achieved with binding of the synthetic ligand
tamoxifen.
Somatic mutagenesis in mice using SSRs requires, for precision, a near complete
absence of background recombination. This is accomplished by expressing a fusion
protein with a mutant estrogen receptor ligand-binding domain (EBD) that is insensitive
to endogenous hormone ß-estradiol but still responsive to the synthetic estrogen
antagonist 4-OH-tamoxifen (Feil et al., 1997).
1.2.3 The Mll2 multipurpose allele
The mll2 allele used in this study serves three purposes of valuable merit. It is a null
allele and a reporter for mll2 expression in its original configuration, but convertible to
a conditional allele.
The strategy for the null allele is trapping of the endogenous transcript by a strong
splice acceptor at the 5’ end of the cassette (see section 2.2.1 for more detail). In the
transcribed pre-mRNA exon 1 is spliced to the cassette instead to exon 2. The cassette
comprises an IRES-LacZneo sequence that leads to expression of a LacZneo fusion
protein under the promoter of mll2. A polyadenylation signal at the end of the cassette
truncates the trapped transcript from which no mll2 protein is translated.
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A null allele based on RNA splicing rather than genomic destruction of the gene gives
an additional option, the creation of a conditional allele. For this purpose the cassette
flanked by FRT sites is removed by the site-specific recombinase (SSR), Flp, which
converts the null allele back to wild type. By using a second SSR, cre, a small genomic
sequence including exon 2 can be deleted. By consequence, exon1 is spliced to exon3 in
the pre-mRNA, creating a frame-shift mutation. The frame shifted mRNA has several
stop codons and presumably does not produce full-length Mll2 protein. While the
original allele is a constitutive null, the Flp recombined allele is a conditional that can
be induced selectively to a null in a tissue and temporal specific manner by the cre
recombinase.
            
Fig. 3  The mll2 multipurpose allele.
Shown is the mll2wt allele from exon 1 to exon 3.  The mll2- allele was created by insertion of a
synthetic exon, including IRES-LacZneo, a STOP codon and a polyadenylation signal, to intron 1. Mll2-
is a null allele by trapping and truncation of endogenous mRNA and a reporter for mll2 expression by
LacZ expression. By Flp mediated recombination, the null allele can be converted to the mll2F allele,
which is similar to wild type. The conditional allele mll2F (Flp recombined) can be mutated by Cre
recombinase, which removes exon 2 and creates the frame shifted allele mll2FC (Flp & Cre recombined).
In the processed mRNA transcribed from the mll2FC allele, exon1 is spliced to exon 3. This creates a
frame shift and a STOP codon, which prevents Mll2 protein translation.
- 21 -
1.2.4 Recombinogenic DNA engineering in E.coli
Section 1.2.1 described the benefits of multipurpose alleles in functional genomics.
DNA engineering of these alleles often requires complex assembly of several elements
creating very large molecules. Moreover, Escherichia coli vectors that contain large
inserts, such as bacterial artificial chromosomes (BACs), offer several advantages for
functional genomics. They can carry sufficient DNA to encompass most eukaryotic
genes in a single molecule and are a valuable source for production of targeting
constructs. However, DNA engineering by conventional cloning methods relies on the
use of restriction enzymes, which precludes engineering of large molecules, as suitable
restriction sites are often absent. Novel DNA engineering strategies that rely on
homologous recombination in vivo in E. coli alleviate this limitation and allow a wide
range of modifications of DNA molecules at any chosen position (Muyrers et al., 2001).
Homologous recombination allows the exchange of genetic information between two
DNA molecules in a precise, specific and faithful manner. These qualities are optimal
for engineering of a DNA molecule regardless of its size. Homologous recombination
occurs through homology regions, which are stretches of DNA shared by the two
molecules that recombine. Because the sequence of the homology regions can be
chosen freely, any position on a target molecule can be specifically altered, and virtually
any DNA alteration can be achieved.
Recombinogenic engineering can be accomplished using ET recombination™ where
recombination is mediated by phage-derived protein pairs, either RecE/RecT from the
Rac phage or Redα/Redβ, from γ phage (Zhang et al., 1998; Muyrers et al., 1999). RecE
and Redα are 5’-3’ exonucleases, and RecT and Redβ are DNA annealing proteins
(Kolodner et al., 1994). Redγ, another protein from the  γ  phage, is used to inactivate
endogenous E. coli exonuclease RecBCD for protection of introduced linear targeting
molecules. All three proteins can be applied to and induced in any E. coli  host by
transient transformation of an expression plasmid (Zhang et al., 1998).
With ET recombination, as illustrated in Fig. 4, a linear targeting DNA carrying short
homology regions flanking a selectable gene (sm) is integrated into a circular target
DNA. The length of homology required for efficient recombination is 35 – 60
nucleotides, and thus short enough to be made by oligonucleotide synthesis. In a very
convenient application, the synthesized oligonucleotides also include polymerase chain
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reaction (PCR) primers for amplification of the selectable gene. In the second variation
represented in Fig. 4, the linear targeting molecule is a PCR-amplified plasmid
backbone that contains a selectable gene and an origin of replication. The
oligonucleotides used for PCR also contain homology regions that are chosen to define
the exact boundaries of the DNA region to be cloned or subcloned. The advantage of
this strategy is that the subcloned DNA is not PCR amplified, excluding the risk of PCR
generated mutagenesis and allowing manipulation of DNA fragments of up to 40
kilobases.
       
Fig.4  Two variations for recombinocenic DNA engineering.
A linear DNA is created (e.g. by PCR amplification) to include two regions, A and B, homologous to the
regions in the targeting molecule, and a selectable marker gene (sm). The simplest exercise (left) involves
insertion, by homologous recombination, of the linear targeting DNA into the target.
In a second variation (right), a DNA sequence is subcloned from a donor molecule (e.g. BAC). The linear
DNA is a PCR amplified vector backbone, and includes an origin of replication (ori), a selectable marker
(sm), and the homologie arms A and B. With this strategy, the subcloned DNA is not PCR amplified,
excluding the risk of PCR generated mutagenesis and allowing manipulation of DNA fragments of up to
40 kilobases. (Muyrers et al., 2001)
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2. Results
2.1 The Mll2 mouse line
Frank van der Hoeven generated this mouse line at EMBL in Heidelberg. My contribution
to this work started with the analysis of the mouse line. Although I was not involved, I will
briefly describe the production of the line in sections 2.1.1, 2.1.2 and 2.1.3.
2.1.1 Mapping of the mll2 gene.
Pierre-Olivier Angrand mapped the mll2 gene that spans approximately 35 kb of genomic
sequence on chromosome 7. Three murine cDNA fragments named CF 28, CF 3.7, and
CF14, were cloned and sequenced. The CF28 3.5 kb insert included incomplete exon1 and
the missing sequence up to the initiating ATG was added by PCR. CF28 and CF3.7 had 2
kb overlapping sequence and were combined to a 5.5 kb sequence.  The CF14 1.4 kb
fragment confirmed exons 26 to 29 that were predicted by homology to the sequence of the
murine homologue MLL. Mihail Sarov cloned the 3’ end of the Mll2 cDNA including the
SET domain.
2.1.2 Cloning of the mll2 targeting construct
A phage clone with genomic sequence of mll2 named X 2.2 was identified by
hybridization to the murine mll2 cDNA CF28. A 6.1 kb HindIII fragment of X 2.2 was
subcloned into pKS-bluescript and served as backbone for a targeting construct.
Next, a single loxP site was introduced in intron 2 of mll2. First, we inserted a loxP flanked
PGK-neo cassette by Red/ET recombination. The two loxP sites were recombined by
transient expression of Cre recombinase in E. coli. This removed the cassette and left a
single loxP site in the plasmid. In the final step, a sA-IRES-lacZ-neo cassette flanked by
FRT sites and a single loxP on the 3’ end was introduced to intron 1 by Red/ET
recombination. The final targeting construct had a 5’ homology arm of 4.5 kb and a 3’
homology arm of 1.6 kb. The 3’ homology arm included one 35 bp loxP site, reducing the
3’ flanking homologous sequence to 880 bp..
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2.1.3 Targeting of ES cells by homologous recombination
The targeting vector was linearized by NotI/SalI and the insert fragment purified. ES
cells were electroporated with purified DNA and G418 resistant colonies were picked
and expanded.
Fig.6  Targeted disruption of the mouse mll2 gene.
Shown are the mouse mll2 cDNA sequence, the genomic mll2 wild type locus, the targeting vector, and
the disrupted mll2- allele. The cDNA (8.5 kb) encodes several protein domains including four PhD
fingers (PHD), ATA domains 1 and 2, the SET domain, and a sequence homologous to DNA
methyltransferase (MTase). The mll2 gene spans a genomic region of approximately 18 kb and has a CpG
island at the transcription start site. The targeting construct was linerized with NotI/SalI and replaced 6.1
kb of endogenous sequence by homologous recombination. KpnI/NcoI-digested ES cells DNA was used
for Southern analysis with probe C to screen for homologous recombinant clones. The probe hybridized
to 4 kb and 2.6 kb restriction fragments generated from the wild type and the mutated allele, respectively.
Fig. 5  Cloning of the mll2 allele.
The selectable marker neomycin (neo),
flanked by loxP sites, was introduced to
intron 1 by Red/ET recombination. By
transient expression of Cre recombinase in
E.coli, the sm was removed, leaving a single
loxP site in intron 2. Next, the cassette
including sA-IRES-βgeok(LacZneo), two
flanking FRT sites and a single loxP site,
were integrated in intron 1 by Red/ET
recombination.
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The southern strategy used by Frank to identify homologous recombined clones is not
known, but later Southern blotting with probe C of KpnI/NcoI digested tail DNA from
wt and mll2 +/- mice confirmed the successful targeting (fig. 7).
2.1.4 Strains, crosses and genotypes of mice
The mll2 line was created by injecting targeted 129/ola ES cells into C57BL/6
blastocysts. Chimeric offspring was crossed to wild type C57BL/6 mice that gave birth
to mll2 +/- mice with mixed background. Southern blotting of digested tail DNA
confirmed correct targeting of Mll2 and excluded additional non-homologous insertions
of the targeting construct. Intercrosses of heterozygote F1 mice did not yield
homozygote offspring, indicating an embryonic lethal phenotype of Mll2 mutants. The
line was kept in a heterozygote state with 5 consecutive crosses to C57BL/6 mice
producing an inbreed background of 99 %. The genotyping of the Mll2 line was
performed by PCR with sense primer 34 annealing in the neo gene and antisense primer
36 annealing in intron 2. This primer pair produces a 1.6 kb product from the targeted
allele and no product from the wt allele.
Recombination of loxP sites flanking exon 2 was tested by crossing the mll2 line to the
transgenic mouse strain PGK-Crem (Lallemand et al., 1998). In this strain, Cre is driven
by the early acting PGK-1 promoter, but, probably due to cis effects at the integration
site, the recombinase is under dominant maternal control. Consequently, when Cre is
transmitted by PGK-Crem females, even offspring that do not inherit PGK-Cre
recombine loxP sites. In the PGK-Crem female, cre activity commences in the diploid
phase of oogenesis and is maternally inherited by the zygote. Thus, recombination
occurs soon before the first cell division and is transmitted to replicating daughter cells.
By coincidence, this transgenic line is X-linked (the Pgk-1 gene is located on the X
chromosome). Advantageous for mouse colony management, males transmit the
transgene to all their male offspring.
The mll2 null allele after cre recombination is still a null allele and was named mll2C
(Cre recombined). As expected, no difference was observed between mll2+/- and
mll2C/+ mice. Successful recombination of loxP sites could be confirmed with primer
pair 34/36, which produced a 800 bp smaller PCR product compared to the product
from the unrecombined allele.
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Fig.7 Genotyping of mice by PCR (A, B, C, D, E) and Southern blot (F). (A) Flpe-specific PCR for
genotyping of the hATPC-Flpe line. Homozygote Flpe mice were identified by matings to wild type
mice, in which they produced  100% transgenic offspring. (B) Cre-specific PCR for genotyping of the
PGK-Crem and Rosa26-CreER(T2) line. Homozygous Rosa26-CreER(T2) mice where identified by PCR
(C) with a primer pair flanking the insertion point of the targeting in the Rosa locus. (D) Genomic PCR
for genotyping of the mll2 mouse line. The amplified PCR products are 1.6 kb and 0.8 kb from the mll2-
allele and the cre recombined mll2C allele, respectively. (E) PCR to distinguish the Flp recombined allele
mll2F from the mll2 wild type allele. The PCR product amplified from mll2F is 105 bp longer due to two
loxP sites and a single FRT site. (F) Southern blotting of KpnI/NcoI digested tail DNA. Probe C
hybridized to 4 kb and 2.6 kb restriction fragments generated from the wild type and the mutated alleles,
respectively.
Fig. 8 Genotyping of mll2 alleles by PCR.
The primer pair 34/36 was used to identify
the mll2- and mll2C alleles and produced a
1.6 kb and a 0.8 kb PCR product,
respectively.
The primer pair 70/36 was used to identify
the mll2F allele. The amplified PCR
product was 1.5 kb, and could be
distinguished from the 1.4 kb product of
the wild type allele. Moreover, this
primerpair was used to distinguish mll2-/-
from mll2+/- embryos, as it amplified a 1.4
kb product from the wild type allele of
heterozygotes. In contrast, the mutant
embryos did not yield a PCR product, as
the theoretical 7.9 kb product from the
mll2- allele is not amplified.
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We generated a conditional mll2 line by crossing the original line to 2 different lines.
First, we crossed mll2+/- mice to the transgenic line hATPC-Flpe (Rodriguez et al.,
2000). This line expresses the improved version of the Flp recombinase selected to
recombine efficiently at 37ºC and referred to as Flpe. The F1 offspring had only
partially recombined FRT sites due to a lower efficiency of the enzyme compared to
Cre, and a rather long distance of 6.5 kb between the target sites. However, an
additional cross to hATPC-Flpe mice produced heterozygous Flp recombined offspring.
We named the modified allele without the IRES-LacZneo cassette mll2F (F lp
recombined). In contrast to the null allele, the mll2F allele is similar to wild type and
was successfully breed to homozygosity. For genotyping, we used sense primer 70
annealing in exon 1 and antisense primer 36 annealing in intron 2 that produces a 1.5 kb
PCR product from the wt allele. The PCR product from the mll2F allele is 102 bp
longer due to the presence of one FRT site and two loxP sites.
Next, we crossed the mll2F line to the Rosa26-CreER(T2) line (Seibler et al., 2003).
This line was created by targeting an inducible cre recombinase to the Rosa26 locus.
The fusion protein is ubiquitously expressed and inducible by tamoxifen.  Offspring
heterozygous for mll2F and creER(T2) were crossed to mll2F homozygote and
genotyped by PCR for both alleles. In addition, we crossed mll2C/+ mice to Rosa26-
creER(T2) mice . Finally, we crossed mll2 F/F cre/+ mice to mll2C/+ and obtained
mll2C/F:cre/cre mice. These mice have presumably the ideal genotype to efficiently
induce loss of Mll2. First, the mll2C allele is already a null, leaving a single allele to be
destroyed to create a k.o. Furthermore, homozygosity of the creER(T2) allele should
favor efficient recombination due to higher concentrations of the protein. Mice were
genotyped by PCR with cre specific primers 19 and 20. Homozygote cre allele was
determined with primer pair rosa26 flanking the insertion point of the cre construct and
producing a PCR product only in wild type and heterozygote mice.
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Fig. 9 Matings of the mll2 mouse line. Shown on top is the original mll2+/- line, which was obtained from
matings of chimeric mice generated by blastocyst injections. Intercrosses of mll2 +/- mice did not yield
homozygous offspring, which indicated an embryonic lethal phenotype of homozygous embryos.
Crossing the mll2 line to three different lines generated a conditional mll2 line. First, heterozygous mll2
mice where crossed with PGK-Crem ((Lallemand et al., 1998) and produced mll2 C/+ mice. Due to
partial Flp recombination, mll2 +/- mice where mated twice with hATPC-Flpe mice (Rodriguez et al.,
2000) to generate mll2 F/+ mice. The conditional mll2F allele is functional, and could therefore be
intercrossed to homozygosity. Homozygous mll2F mice (and mll2C/+ mice) where mated to the
ubiquitous, inducible Cre line Rosa26-CreER(T2) (Seibler et al., 2003). The F4 offspring from these
matings where backcrossed to mll2F mice, yielding offspring without wild type mll2 allele and
heterozygous for Rosa26-CreER(T2). Intercrosses of this F5 offsprings yielded mice with one null and
one conditional mll2 allele, and two Rosa26-CreER(T2) alleles.
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The genetic background of the Flpe line was 75% C57BL/6 and 25% 129/ola when
crossed to the mll2 line that had 87% C57BL/6 and 13% 129/ola backgrounds. The
additional crossing of the partially recombined offspring to the Flpe line and subsequent
crossing to Rosa26-creER(T2) with inbred 129/ola background produced conditional
mice with a 39% to 61% C57BL/6 and 129/ola background, respectively.
Later, we crossed mll2F mice twice to C57B6 (wild type and Rosa26-creER(T2) to
produce conditional mll2 mice with an inbred C57BL/6 background of 94%. With these
mice the conditional genetic alteration was maintained on a standard background, a
feature important for obtaining reproducible results and genetically defined controls.
Fig.10 Genetic backgrounds of the mll2 mice. The mll2 line was obtained in a mixed 129ola/C57BL/6
background. An inbreed strain was obtained by 6 to 7 crosses to C57BL/6 mice. The conditional line
mllF/Rosa26-CreER(T2) was generated twice, once with a mixed background (39 to 61), and once with a
more inbreed background (94 to 6)  of C57BL/6 and 129/ola.
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2.2 Constitutive mutagenesis of Mll2
The absence of Mll2 -/- mice from heterozygote crosses indicated an embryonic lethal
phenotype of mutants and argued for an essential role of Mll2 during embryonic
development. The goal of this study was to describe the embryonic phenotype and to
gain insight into the roles of Mll2 in mouse development.
2.2.1 Validation of the null/reporter allele on RNA level
As described in section 1.2.3, the mll2 null allele leaves the genomic structure of the
gene intact, but relies on trapping and truncation of the RNA transcript. The trap
cassette is made of 1.8 kb of genomic sequence from the homeobox protein engrailed-2
(En2, ENSMUST00000036177/chromosome 5, BAC clone RP23-358F24) inserted
between FRT and IRES of FRT-IRES-LacZneo-Stop-pA-FRT-loxP. The genomic
sequence includes 1.65 kb of intron 1 and 158 bp of exon 2 of the En-2 gene and serves
as splice acceptor (interestingly the En2 splice site is not properly predicted by the
splice site detection software from www.cbs.dtu.dk/services/NatGene2/, therefore splice
site prediction appears unfaithful). The null/reporter allele produces a polycistronic
transcript from which 2 proteins are translated; First, a protein including 121 aa of mll2
(coded by exon1) fused to 40 frame shift mutated aa of En-2 (coded by a part of exon
2). Second, a LacZneo fusion protein is translated from the IRES sequence.
Such an allele design requires careful validation to exclude alternative splicing events
that would ruin the strategy. Therefore, we wanted to confirm absolute trapping of mll2
transcript by the inserted trap cassette and efficient truncation at the newly introduced
polyA site. If this was the case, no transcript spanning exon 2 to 37 should be detectable
in mutant embryos.
We dissected E 8.5 embryos from mll2+/- intercrosses. Genotyping by yolk sac PCR
with primer pair 34/36 determined that 3/4 of each litter was carrying the null allele, and
therefore potentially heterozygote or homozygote. A second PCR with primer pair
31/36, which flank the insertion point of the LacZneo cassette, detected 1/4 of embryos
as homozygotes. These primers amplify a 720 bp product from the wt allele of
heterozygotes, but not the theoretical 7.2 kb product from both null alleles of mutants.
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This result indicated that the embryonic lethality occurs at later stages than E 8.5 in
mll2 mutants.
We extracted RNA from individual embryos and transcribed cDNA to perform RT-
PCRs. The mll2 specific primer pair 78/79 annealing to exons 26 and 29 did not amplify
a product from cDNA of mll2 mutants. However, the 1.6 kb product was amplified
from mll2+/- and mll2+/+ cDNAs with approximately twice the amount of product in
the wild type. As control we used LacZ specific primers that amplified a product from
mll2+/- and mll2-/- but not mll2+/+. A third PCR with actin specific primers
demonstrated the use of equal amounts of PCR template.
Fig.11 The mll2 – allele is a null allele. (A) Expression of mll2 at E8.5. The expression is ubiquitous in
the ωιλδ τψπε embryo and absent in the homozygous embryo. (B) RT-PCR analysis of E 8.5 embryos.
An mll2 specific primer pair amplified a reaction product from mll2+/- and mll2+/+ embryos, but not
from an mll2-/- embryo. (C) Western blot analysis of wild type and mll2-/- ES cells probed with an
antibody that recognizes the N-terminus of Mll2 (amino acids 168 – 288). A strong band was detected in
ωιλδ τψπε extract probably corresponding to the predicted proteolytic 225 kDa Mll2 fragment processed
by taspase1 (Hsieh et al.). The weaker band in wild type extract could correspond to the predicted 284
kDa unprocessed Mll2 fragment. No bands were detected in extracts from mll2 -/- cells.
Furthermore, we used whole mount in situ hybridization on embryos, with an mll2
cDNA probe amplified by the RT-PCR primers 78/79. We observed ubiquitous
expression of mll2 in wild type embryos at E 8.5 d.p.c. Moreover, no signal could be
detected in mll2-/- embryos, further substantiating that no alternate splicing bypassed
the synthetic exon.
Finally, we provided evidence that the null allele causes complete absence of Mll2
protein by using an mll2 specific antibody and mll2-/- ES cells. Julia Schaft generated
the Mll2 antibody serum by immunization of two rabbits with synthetic peptide (aa 754
to 925). Julia Schaft generated mll2 -/- cells by targeting the second allele of mll2+/-
cells with a sA-IRES-LacZneo-hygromycin cassette. In a western blot we observed
complete absence of Mll2 protein in double-targeted ES cells. An antibody specific for
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CBP (Santa Cruz), a protein with similar size than Mll2, was hybridized to the stripped
membrane to confirm loading of equal amounts of extract.
Next we wanted to compare the mll2 null/reporter and the induced conditional mll2
allele during embryonic development. If the design is correct, both alleles should give
an identical embryonic phenotype. This experiment was a first validation of the
conditional mll2 allele, and a more detailed validation is described in sections 2.3.3,
2.3.4, and 2.3.5. We crossed the Mll2F line, where the mll2 allele is flp recombined, to
PGK-Crem (section 2.1.4; Lallemand et al., 1998). Offspring of these crosses with one
(cre recombined) mll2FC allele were crossed to mll2+/- mice. Embryos from pregnant
mothers where dissected and genotyped at various time points and phenotypes of
mll2FC/- embryos were compared to mll2-/- embryos from previous dissections. Both
alleles produced an identical embryonic phenotype, which confirmed that the frame
shifted mll2 allele is identical to the null allele. Genotypes from all dissections are
summarized in table 2 in section 2.2.3.
2.2.2 Embryonic expression pattern of Mll2
We dissected various litters from mll2+/- intercrosses at developmental stages E 6.5 to
E 12.5 d.p.c. and performed LacZ staining for genotyping and expression pattern
analysis. Results of β-Galactosidase stainings were confirmed by whole mount in situ
hybridization of wild type embryos with an mll2 specific probe described in section
2.1.1.
Fig. 12 Mll2-/- embryos and
mll2FC/FC embryos have an
identical embryonic lethal
phenotype. This validates the
design of both alleles to be
null alleles.
mll2FC/+ intercross mll2+/_ intercross
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At gastrulation mll2 expression was detected in the epiblast and visceral endoderm, but
absent or weak in the trophectoderm. The almost ubiquitous expression pattern was
found at all stages that we dissected and may persist throughout development. At E 9.5
mll2 was detected in the ectoderm (surface ectoderm, neural tube, neural crest),
endoderm (branchial arches) and mesoderm (mesenchyme and somites).
2.2.3 Phenotype of Mll2 mutant embryos
Embryos from E 6.5 and 7.5 were genotyped by lacZ staining, with mutants staining
more strongly than the heterozygotes due to the presence of two copies of the β-
galactosidase gene. Embryos from later stages came from mll2+/- to mll2C/+ crosses
and were genotyped by yolk sac PCR. Due to the size difference of the PCR products
amplified from the two different null alleles, primer pair 34/36 produced a double band
in mutants (section 2.1.4).
          
At gastrulation (E 6.5) no obvious difference was observed between all 3 genotypes.
However, at E 7.5 some mutants were retarded in development. While heterozygotes
developed normally, the retardation was observed in all mutants at E 8.5. During further
development the retardation of mutants compared to their wild type and heterozygote
Table1. Genotype of mice resulting
from mll2 heterozygous intercrosses
in C57BL/6J inbreed mice
Table2. Genotype of mice resulting
from mll2FC heterozygous intercrosses
in outbreed (C57BL/6 and 129/ola)
mice. Both alleles produce an identical
phenotype during embryogenesis.
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littermates increased gradually. Interestingly, retarded mutant embryos still developed
normally until E 9.5 and were morphologically identical to earlier stages of wild type
embryos. However, from E 9.5 mutants had morphological abnormalities although they
were still viable and continued developing. We observed widespread abnormalities
rather than specific defects, e.g. anterior misshaping of the forehead but also posterior
irregularities. An increase of resorbtions to 10% at this stage indicates the earliest
occurrence of lethality in mutants. Nevertheless, most mutants continue to develop and
rarely turn between E 9.5 and E 10.5. Despite proper neurulation and closure of the
head fold, the neural tube appears to be kinked, which is often a characteristic of lack of
paraxial mesoderm. Indeed, while somites are visible at early stages, somite
development is lacking in mutants at later stages. All mutants are hemorrhagic and dead
by E 11.5 and fully resorbed by E 12.5.
Fig. 13 Mll2-/- embryos exhibit developmental delay and morphological abnormalities. Mutant embryos
from litters shown in A, B, C, and D where identified by a strong LacZ staining due to two mll2 null
alleles. Individual embryos from litters C, D, E, and F were genotyped by yolk sac PCR and confirmed
the LacZ results. (A) At 6.5 dpc, mll2 mutants were identical compared to littermates (mll2+/- and
mll2+/+). (B) The phenotype became first evident at 7.5 dpc when some mutants were retarded in
development. (C) At 8.5 dpc, mutant embryos exhibited developmental delay but no morphological
abnormalities. (D, E, F) Normal 9.5 dpc, 10.5 dpc, and 11.5 dpc embryos (mll2+/- and mll2+/+)
compared with mutant mll2-/- littermates. Mll2-/- mutants had morphological abnormalities from 9.5 dpc
and lethality occurred between 9.5 and 11.5 dpc.
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Table 3 & 4. Developmental retardation of mll2-/- embryos. Table 3 summarizes typical somite numbers
during developmental stages 8 to 9 dpc. Table 4 indicates the developmental stage of mll2-/- embryos
based on morphology and somite numbers. The developmental retardation was first obvious at 7.5 dpc
and gradually increased until lethality occurred.
2.2.4 Histological analysis of Mll2 mutant embryos
We embedded embryos in paraffin and performed saggital and transverse sections.
Apoptotic cells and proliferating cells were labeled using terminal
desoxyribotransferase (TdT) and an antibody recognizing Ki-67, respectably. No
specific region of mutant embryos was apoptotic; instead we found an evenly
distributed increase of apoptotic cells throughout the whole embryo compared to wild
type controls. In contrast, the number of proliferating cells was similar in mutants
compared to controls (data not shown). The increased ubiquitous apoptosis could
explain the retardation of mutants, as more proliferation events would have to occur in
those embryos to reach required cell numbers for progression in development.
Table 4 Retardation of Mll2-/- mutants
Table 3 Typical somite numbers in wild type
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Fig.14  Analysis of apoptosis in mll2 mutant embryos. TUNEL stained paraffin section of a E9.5 mll2-/-
embryo and a E9.5 mll2+/+ embryo. Positive cells are indicated by arrow. (B) For E9.5 and E10.5
embryos, apoptotic cells divided by the total number of cells yield the apoptotic index.
2.2.5 Molecular characterization of the Mll2 embryonic phenotype
We used an extensive array of markers to analyze defects in mll2 null mutant embryos.
To account for the retardation observed in mutants we used ωιλδ τψπε embryos from
different litters at suitable developmental stages as controls. As summarized in table 4,
mutant embryos from litters dissected at E 9.5 are generally at a developmental stage
corresponding to E 8.5. We therefore compared their gene expression patterns to
wild type embryos from litters of this stage, rather than to their heterozygote and
wild type littermates.
Defective longitudinal extension of paraxial mesoderm is the most likely cause of the
kinky and compressed shape of the neural tubes in the mutant embryos. To establish
whether the defects observed in somite development originate from defects in the
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morphogenesis of the primitive streak, Brachyury (T) expression was assessed. In wild
type embryos at E 7.5, T marks the entire proximodistal axis of the streak and nascent
mesoderm (Wilkinson et al., 1990), and an identical expression was detected in mll2
null mutants. At later stages, T expression was detected in the notochord and posterior
(tail) mesoderm cells of both wild type E 8.5 and mutant E 9.5 embryos.
We then used the somite marker mox1 and observed normal expression in paraxial
mesoderm in wild type and mutants during early somitogenesis. However, mox 1
expression was lost in mutant embryos at later stages. While mutants expressed mox1
from the 1 to 8 somite stage, all mutants at later stages had lost expression.
Interestingly, some mutants at the 10 somite stage showed a loss of mox1 expression in
anterior somites, while newly formed posterior somites still expressed mox 1. The
somitogenesis of the mouse embryo is controlled by a cyclic biological clock, which
leads to the formation of a new pair of somites every 2 hours. Thus, we could conclude
that the loss of mox 1 expression at the 10 somites stage had occurred 20 hours after
formation of the affected somite. Moreover, mll2 function was not required to
determine the initial expression of mox1, but was soon required to maintain it.
Despite the abnormal development of the anterior region of mll2-/- embryos, expression
of the prospective forebrain and midbrain marker otx2 (Ang et al. 1993) was
appropriately detected although weaker in some mutants. However, expression of six3,
a homeobox gene that is normally expressed in the forebrain (Oliver et al. 1995) was
not detected in mll2-/- embryos. Previous studies have shown that otx2 activity in the
anterior neuroectoderm is not essential for initiation of six3 expression but is required
for maintenance of Six3 expression (Acampora et al. 1998; Kimura et al.,2000).
Because Otx2 expression was detected in mutants, the absence of six3 expression seems
to be directly related to mll2 function. Previous studies have indicated that Otx2
regulates Wnt1 positively (Rhinn et al., 1999). In agreement with this observation, wnt1
expression was detected as two sharp transverse rings immediately next to each other at
the midbrain-hindbrain border by E 9.5 and E10.5 in wild type and mutants,
respectively. We next examined the expression of Hoxb1, which is normally expressed
in rhombomere 4, lateral mesoderm and posterior neuectoderm at E9.5. In mll2-/-
mutants hoxb1 expression was properly initiated at E8.5 but completely absent at E9.5.
Thus, Mll2 function is not required for initial expression of Hoxb1 but for maintenance
of expression.
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Taken together, these data demonstrate that Mll2 is a maintenance factor of specific
homeotic transcription factors. While initial expression of mox1 and hoxb1 was not
affected, a role for maintenance of expression for these genes was observed. Moreover,
no expression of the forebrain marker six3 was observed, either because of a lack of
forebrain development or a specific role of Mll2 for six3 expression.
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Fig. 15 In situ hybridization analysis of T (A, D), wnt1 (B, E), and otx2 (C, F). The expression of these
markers was not affected in mll2-/- embryos (D, E, F) compared to mll2+/+ embryos (A, B, C). (D) In
E9.5 mll2-/- mutant embryo, brachyury (T) expression in the streak and notochord was similar to the
expression detected in wild type (A) E8.5 embryo. A normal expression pattern of wnt1 was observed in
E9.5 mll2-/- mutant (E) compared to E10.5 wild type (B) embryo. The forebrain/midbrain marker otx2
was normally expressed in E9.5 mll2-/- mutant embryo (F). Compared to the wild type (C) E10.5
embryo, the mutant had an abnormally shaped head.
Fig.16 In situ hybridization
analysis of six3 (A.C) and
hoxb1 (B, D) indicated a
defect in expression
maintenance of these genes
in mll2-/- mutant embryos.
E9.5 Mll2-/- embryos (C,
D) where compared to E8.5
mll2+/+ embryos (A, B).
Six3 was detected in wild
type (A) E8.5 embryo, but
not in E9.5 mll2-/- mutant
embryo (C). Hoxb1 was
detected in E8.5 wild type
(B) embryo. In mll2-/-
mutants ,  h o x b 1  was
expressed from E7.5 to
E8.5, but not at E9.5 (D).
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Fig. 17 In situ hybridization analysis of the paraxial mesoderm marker mox1 indicated a defect in
expression maintenance in mll2-/- mutant embryos. Whole-mount embryos (A-D) and transverse sections
(E-G) are depicted. (A) In a E8.4 wild type embryo (8 somites), mox1 is expressed in the presomitic
mesoderm and in somites. (B) In a E9.0 mll2-/- embryo with 8 somites, mox1 expression is normal. (C)
In a E9.5 mll2-/- embryo with 10 somites, mox1 expression is lost in the 2 anterior somites. (D) In a
E9.75 mll2-/- embryo, no mox1 expression is detected. Defective longitudinal extension of paraxial
mesoderm is the most likely cause of the kinky and compressed shape of the neural tube in mutant
embryos at this stage. (E) Transverse section of the E8.4 wild type embryo displayed in (A) shows mox1
expression in paraxial mesoderm. (F) TUNEL stained transverse section of the E9.5 mll2-/- embryo
displayed in (C). Black apoptotic nuclei appear throughout the section. Mox1 signal (arrow) is not
decreasing because of apoptosis of paraxial mesoderm. (G) TUNEL stained transverse section of a E10.5
mll2-/- embryo. Whole embryo section is positively stained with the highest amount of apoptotic cells in
the paraxial mesoderm (arrow).
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2.3 Conditional mutagenesis of Mll2
We used the conditional mll2F allele to perform induced mutagenesis in adult mice and
cell culture. Mutagenesis is achieved by deletion of 815 bp of Mll2 genomic sequence
by cre recombinase. The deletion includes exon 2 and creates a frame shift in the
processed mRNA (section 1.2.1).
The goal of this study was ubiquitous mutagenesis of Mll2 in all tissues of embryos and
mice. We therefore planned to generate an ubiquitous, inducible cre deleter line by
targeting a ligand-regulated recombinase to the housekeeping gene topoisomerase I.
This work is described in section 2.4.
As this work was ongoing, we obtained the similar cre deleter line Rosa26-CreER(T2).
By targeting CreER(T2) to the Rosa26 locus, Seibler and colleagues created a line in
which inducible cre recombinase is expressed in all tissues in vivo  (Seibler et al., 2003).
As this suited our purpose, we used this Cre line for all experiments described in section
2.3.
2.3.1 Induction of the conditional Mll2 allele in vitro
A homogenic cell population produced by in vitro cell culture is sometimes more
beneficial for experiments than a heterogenic cell population extracted from in vivo.
Organs are complex structures composed of blood vessels and many different cell types,
which by consequence may produce high variations in the outcome of an experiment. In
contrast, cells grown in tissue culture usually produce reproducible, robust results.
Different cell lines were generated from Mll2F/creER(T2) mice under the supervision
of Konstantinos Anastassiadis. First, we obtained embryonic fibroblast (MEFs) by
dissecting 6 embryos at E 13.5. All embryos had creER(T2); Embryos heterozygous for
Mll2F gave rise to a control cell line and embryos homozygous for Mll2F the inducible
mll2 null line. Second, we cloned ES cells from blastocysts. Five independent clones
homozygous for Mll2F and creER(T2) were obtained.
In vitro mutagenesis of Mll2 was induced by adding 100 nM (10-7 M) 4-
hydroxytamoxifen to the culture medium.
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2.3.2 Induction of the conditional Mll2 allele in utero and in vivo
For in vivo and in utero inductions two protocols for administration of tamoxifen to
mice were tested; We fed a tamoxifen/oil solution orally by gavage or injected (i.p.) 4-
hydroxytamoxifen dissolved in oil. In agreement with previous studies (Kuehbandner et
al., 2000), both protocols gave identical recombination efficiencies. We preferred the
gavage protocol, as the LD50 of tamoxifen in mice is 15-fold higher via the oral route
than by i.p. injection (200mg versus 5g/kg, Seibler et al., 2003). In addition, orally
administrated tamoxifen is probably efficiently metabolized to 4-hydroxytamoxifen in
the liver of the mouse. We could therefore restrict the use of costlier 4-
hydroxytamoxifen to in vitro inductions. The recombination efficiencies obtained with
different concentrations of tamoxifen are described in section 2.5.3.
As an alternative induction protocol, we tested injections (i.p.) of tamoxifen dissolved
in 15% EtOH. The partial cre recombination achieved with this protocol was probably
due to incomplete dissolving of tamoxifen in 15% EtOH. Increasing the EtOH
concentration to 40% resulted in better dissolving, but was not used for injections, as
this concentration would be toxic for the mice. However, the partial recombination
achieved with injections of tamoxifen in 15% EtOH was beneficial for an experiment
described in section 2.5.8.
In addition to inductions of adult mice, we induced mutagenesis in embryos and
newborn pups. Inductions in embryos at different stages of development were carried
out by feeding pregnant females tamoxifen. Induction in neonates was obtained by
feeding lactating females tamoxifen, which achieved efficient transmission via the milk
(section 2.5.10).
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Fig. 18 Induced mutagenesis of mll2 in vivo. (A) Mice were tailed, induced for 5 days by gavage of a
tamoxifen/oil solution, and retailed 7 days after the last feeding. (B) The gavage is performed by applying
5mg tamoxifen dissolved in 50µl oil, which was heated to 37ºC and fed with a feeding syringe.  (C)
Southern blot of PstI-digested tail DNA before (1) and after (2) induction. In three mice homozygous for
the conditional allele mll2F (ID 614, 767, and 764), almost complete recombination after induction was
observed. Hybridization with probe C detected a 3.4 kb fragment for unrecombined mll2F and a 2.6 kb
fragment for recombined mll2FC.
2.3.3 Validation of the induced allele on DNA level
We analyzed the recombination rates of the conditional mll2 allele using different
concentrations of tamoxifen with the goal to achieve the highest possible rate in all
tissues. Recombination was determined by PCR and southern blotting of PstI digested
DNA from various organs and hybridization to probe C. A dose-response experiment
indicated that the extent of recombination is highly dependent on the amount of
tamoxifen given to the mice. A daily dose of 2.5 mg tamoxifen for 5 days resulted in
partial recombination in most tissues and no recombination in the brain. However, the
use of 4mg and 7mg yielded full recombination in all tested tissues and 30% or 50%
recombination in the brain, respectively. The limited degree of recombination in the
brain may reflect a lower local concentration of ligand due to the blood-brain barrier
rather than a reduced expression level of CreER(T2) (Seibler et al., 2003). For further
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induction experiments, we administrated 5 mg tamoxifen for 5 days, a treatment that
caused no side effects on 28 tested wild type mice.
A background activity of CreER(T2) in untreated mice was detected in tail DNA of
15% of genotyped mice. The leakiness of CreER(T2) was only observed in some mice,
with a recombination rate of up to 20% in the tail, while in most animals no background
activity was detected. The mice with background activity were excluded from
experiments.
Fig. 19 Recombination efficiencies obtained with different induction protocols. (A, B, C) Southern blot
with DNA from various tissues of three mice (mll2F/F; RosaCreER(T2)+/-) induced with different
protocols. (A) Gavage with 2.5 mg tamoxifen in oil yielded incomplete recombination in some tissues.
(B) Gavage with 4 mg tamoxifen in oil yielded complete recombination in all tissues except the brain.
Heterozygosity for Cre is sufficient to obtain complete recombination; indeed the tamoxifen
concentration is the rate-limiting step during the induction. (C) Injection (i.p.) of 1 mg tamoxifen
dissolved in 15% EtOH yielded partial recombination in all tissues. The partial recombination obtained
with this protocol was used in an experiment described in section 2.5.8.
Fig. 20 Induction of breast feeded pups by gavage of lactating mothers with 5x 5mg tamoxifen.
- 45 -
2.3.4 Validation of the induced allele on RNA level
The induced Cre recombination of the conditional mll2 allele removes exon 2 (73 bp)
and presumably results in splicing of exon 1 to exon 3 in the pre-mRNA. This abnormal
splicing would create a frame shift and a nonsense codon in exon 3 that circumvents
full-length mll2 protein translation. Instead, a putative peptide of 140 amino acids could
be translated from the frame shifted mll2 mRNA, including 121 amino acids of wild
type sequence coded by exon 1 and 19 amino acids of mutated sequence coded by exon
3. This hypothetical protein has a predicted low compositional complexity (SMART
database), as it does not include any protein domain. Indeed, the most N-terminal
protein domain of Mll2 is an AT hook coded by aa 149 to 159.
Fig. 21 Analysis of the mRNA expressed from the frame shifted mll2FC allele. RT-PCR was performed on
several tissues of induced mice with a primer pair annealing in mll2 exon 1 and exon 3. Sequencing of the
PCR product confirmed the expected splicing of exon 1 to exon 3 in absence of exon 2. The created
nonsense mutation in exon 3 and the hypothetically translated protein of 140 amino acids are indicated.
We analyzed the RNA produced from the induced conditional mll2 allele by Northern
blot and RT-PCR. Total RNA from various organs of induced mice was extracted 2
weeks after tamoxifen treatment. Mutant mice were heterozygous for CreER(T2) and
homozygous for the conditional mll2 allele, while control mice were heterozygous for
CreER(T2) and the conditional mll2 allele. Control mice were therefore exposed to
tamoxifen treatment, activated cre recombinase activity and recombination of loxP sites,
but retained one wt mll2 allele after recombination.
We expected complete absence of mll2 mRNA in induced mutants due to nonsense-
mediated mRNA decay (NMD), which is triggered by premature translation
termination. Surprisingly, we did not observe a marked reduction of mll2 mRNA in
induced mutants. However, due to the minimal size difference of 73 bp between the wt
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and the frame shifted mll2 mRNA, we could not conclude if the signal detected in
mutants was frame shifted mRNA that resisted NMD or unrecombined mRNA
transcribed before the induction.
Fig. 22 Northern blot analysis of various tissues from induced mice. The mutant mouse
(mll2F/F;RosaCreER(T2)+/-) and the control mouse (mll2+/+) were induced with 5 mg tamoxifen and
sacrificed after 7 days for RNA extraction. Hybridization with probe CF14 detected the 8.5 kb mll2
transcript in all tissues of both mice. Due to the minimal size difference of 73 bp between the wt and the
frame shifted mll2 mRNA, we could not conclude if the signal detected in mutants was frame shifted
mRNA that resisted NMD, or unfecombined mRNA transcribed before the induction.
We therefore used quantitative RT-PCR on tissue culture, mouse embryonic fibroblasts
and ES cells, with primer pairs 145/146 and 145/147, which distinguish the wild type
from the recombined allele, respectively. Both primer pairs were tested on serial
dilutions of template to evaluate the PCR efficiencies. A similar slope of –3.4 for both
assays in a Ct vs. concentration graph (data not shown) indicated a PCR efficiency of 95
%.
A PCR reaction is described by:
Xn = Xo (1+E)
n Xn = concentration at cycle n
E =PCR efficiency: 0≤ E ≤1
With E = 0.95 and n = -∆∆Ct we used (1.95) -∆∆Ct to calculate the expression levels of wt
(unrecombined although induced) and frame shifted Mll2 mRNA after induction
compared to normal expression levels of Mll2 in untreated cells.
After 2 - 4 days of treatment with 4-hydroxytamoxifen the wild type Mll2 mRNA was
detected at 0.3% and 0.7% compared to the expression level in untreated Mefs and ES
cells, respectively. The residual unrecombined allele detected in ES cells could be a
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contamination of wt feeder cells on which the ES cells were grown before they were
selected for 3 passages to grow without feeder cells.
In agreement with the northern result with mouse tissues, the frame shifted mll2 mRNA
was detectable in induced Mefs and ES cells. While the frame shifted mRNA was
reduced to 23% compared to the expression of mll2 in uninduced Mefs, the reduction in
ES cells was 82%.
Taken together these results demonstrate that the induction of the conditional Mll2
allele results in a reduction of wild type mll2 mRNA levels below the detection limit of
1%. The frame shifted mRNA is still transcribed and present in the cells after induction
although at reduced levels.
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Fig. 23 Quantitative RT-PCR analysis to distinguish unrecombined mll2F RNA from recombined mll2FC
RNA. The primer pair 145/146 was specific for unrecombined mll2F template and produced a 104 bp
product. This assay was used to estimate if unrecombined mll2F allele was detectable after induction. The
second primer pair 145/147 amplified products from both alleles, which could be distinguished by size
difference. This assay was used to estimate if the frame shifted mll2FC RNA was detectable after
induction. Both assays had identical amplification efficiencies and produced identical Ct values when
used on wild type template (date not shown).
Table 5: Mll2 RNA levels in tamoxifen induced mouse embryonic fibroblasts (MEF). While the wt RNA
is detectable at 0.3%, the frame shifted RNA is detected at 23% compared to normal mll2 expression
level in untreated cells.
Table 6: Mll2 RNA levels in tamoxifen induced ES cells. While the wt RNA is detectable at 0.7 %, the
frame shifted RNA is detected at 82% compared to normal mll2 expression level in untreated cells.
Table 5
Table 6
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2.3.5 Validation of the induced allele on protein level
The essential validation of the conditional mll2 knockout allele was to demonstrate that
the induced frame shift mutation leads to a complete absence of Mll2 protein. Therefore
the goal was to induce the frame shift by Cre recombination in (mll2F/F) ES cells and
perform western blots with the Mll2 antibody. We used mll2-/- ES cells that had been
Flp recombined by Sandra Lubitz, creating ES cells homozygous for the conditional
mll2F allele. The cells were electroporated with a newly engineered Cre expression
plasmid (pCAGs-iCreIRESpuro) that confers puromycin drug resistance upon
transformed cells. After growing cells for 2 days in selection medium (1µg/ml
puromycin), approximately 300 resistant colonies from 3 independent experiments were
picked and expanded. Cre recombination of loxP sites could be detected in all clones by
amplification of a 716 bp PCR product with primer pair 145/147.
However, primer pair 145/146 detected a double band indicating unrecombined mll2F
allele; because ES cells were grown on wild type feeders, a 1.1 kb product was
amplified from the wild type allele. In addition, a second 1.17 kb PCR product indicated
unrecombined mll2F allele in all clones. An XhoI digest of the PCR products
ascertained the presence of unrecombined mll2F and produced two smaller fragments.
This is due to the Xho site in the spacer of the FRT site that is not in the PCR product
amplified from the wild type allele.
These unexpected PCR results indicated that Cre recombination had occurred in all
clones and proved functionality of the newly engineered Cre expression construct.
However, as unrecombined allele was also detectable in all clones, this lead to the
conclusion that only one of both mll2F alleles had recombined. This is considered to be
a very unlikely event, as one would expect recombination of both loxP pairs if
molecules of the recombinase were present in the cell. The mll2-/- cells from Julia
Schaft had indicated that the protein is not essential in ES cells. This excluded the
possibility of a lethal counter selection of double recombined clones. We therefore
suspected a mutation in the loxP site(s) of the second mll2 allele that was targeted with
sA-IRESLacZneo-hygro. This targeting construct was cloned from sA-IRESLacZneo,
which has functional loxP sites (section 2.1.2). It is possible that the insertion of
hygromycin gene by Red/ET recombination introduced a mutated loxP site with the
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oligonucleotide. However, sequencing of the hygro targeting plasmid revealed no
mutation in the loxP sites (sequencing by Jun Fu). Therefore, we assume that the 3’
loxP site did not integrate during the targeting of the second mll2 allele with the hygro
construct.
Fig. 24 Cre recombination of the conditional allele in mll2F/F ES cells. (A) Shown are 10 clones that
where puromycin resistant after electroporation of pCAGs-hCre-IRESpuromycin. Primer pair 145/147
detected Cre recombination in all clones. However, unrecombined mll2F allele was also detectable by
amplification of a 1.18 kb PCR product in all clones with the indicated primer pair. The PCR products
were digested with XbaI, which yielded two smaller fragments in all clones (gel). As the XbaI site is in
the spacer of the FRT site, this indicated that the PCR product originated from mll2F and not from the
wild type mll2 allele from feeder cells. None of the > 300 resistant clones was recombined at both mll2F
alleles. We concluded that the mll2 -/- ES cells where generated with a mutation in the loxP site during
the second round of targeting with the construct FRT-sA-lacZneo-hygro-FRT-loxP.
(B) Cloned eukaryotic Cre expression construct. The plasmid is functional for puromycin selection and
Cre recombination.
Konstantinos Anastassiadis solved the problem by cloning ES cells from blastocysts of
intercrossed mice homozygous for mll2F and CreER(T2). Cre recombinase was induced
in these ES cells by adding 10-7 M 4-OHtamoxifen to the medium, and complete
recombination of loxP sites was detected by southern blot and PCR (data not shown).
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Fig. 25 The frame shifted mll2FC allele is a null allele. Western blot analysis of ES cells (A) and mouse
tissue (B) probed with an antibody that recognizes the N-terminus of Mll2 (amino acids 168 – 288).
(A) A strong band was detected in wild type ES cells. Specificity of the antibody was demonstrated by
absence of the signal in mll2-/- ES cells. In conditional ES cells (mll2F/F; RosaCreER(T2)-/-), mll2 was
detected before but not after induction with tamoxifen. (B) Mll2 is detected in testis and brain of induced
wild type mouse. In contrast, mll2 is absent in testis of induced mll2F/F; Rosa26CreER(T2) mouse. In the
brain, low levels of mll2 are detected, which corresponds to the incomplete recombination observed in the
brain.
Protein extracts from Mll2+/+, Mll2-/-, and Mll2F/cre (induced and uninduced) ES cells
were used in western blots with the Mll2 antibody. Mll2 was detected in wild type and
uninduced Mll2F cells, but absent in induced Mll2FC cells. The absence of a signal in
Mll2-/- extracts proved the specificity of the Mll2 antibody.
In parallel, we have done western blots with protein extracts from various organs of wt
and induced Mll2FC/creER(T2) mice. Mll2 protein was detected in testis and brain
extracts of wild type mice, but absent in testis extract from induced Mll2FC mice.
However, low levels of Mll2 were detected in brain extracts of induced mutants. This is
in agreement with the incomplete DNA recombination observed in the brain, probably
due to low penetration of tamoxifen into the organ.
Taken together, these results demonstrate that the induced frame shift of the conditional
Mll2 allele leads to complete absence of the protein. By Cre recombination, Mll2
protein is efficiently knocked out in ES cells and most organs of the mouse, except for
the brain.
mll2 mll2
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2.3.6 Severe diarrhea in induced Rosa26-CreER(T2) mice
We induced 201 mice with 5x 5 mg tamoxifen per day administered by gavage. Of
these, 127 mice were “mutants” homozygous for mll2F and homozygous or
heterozygous for Rosa26-CreER(T2). As controls, we used 29 wild type mice
(C57BL/6) to assess possible side effects of the tamoxifen dose. Furthermore, we used
35 mice of the Rosa26-creER(T2) line (C57BL/6 and 129/ola) as controls for possible
side effects of cre recombinase activity on the genome in the absence of loxP sites. As
control for possible side effects of cre recombinase activity in the presence of one pair
of loxP sites, we used 10 mice heterozygous for Mll2F and Rosa26-creER(T2) where
recombination occurred on one of both Mll2 alleles.
Gavages where well tolerated by 28 of 29 wild type mice (grey), which showed no
abnormal behavior. One mouse had symptoms of adynamia on the 1st day of induction
due to suffocation (blue tongue) caused by oil that had accidentally penetrated the lung.
Dissection of the lung confirmed this diagnosis and proved the critical illness to come
from improper handling of the feeding needle. With more practice, the experimenter
never produced such a case again.
In contrast to the wild type mice, we observed a high rate of illness and lethality in all
other mice. Due to the close observation after induction, only a few of the mice were
found dead. In most cases, mice with symptoms of illness were sacrificed to avoid
extended periods of suffering. The illness occurred between the 5th and the 15th day after
induction, with most cases from day 8 to day 10. The first symptoms of illness were
reduced motility and constant weight loss that indicated pronounced dehydration.
During progression of the illness, mice sustained severe diarrhea observable at the anus
of animals. Dissections of sick mice revealed that the entire intestine was filled with
liquid. The gall bladder and stomach were distended and the gastric content of sick mice
had on average twice the weight as in wild type mice.
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Fig. 26  Toxicity of the Rosa26-CreER(T2) line. Summarized are all tamoxifen induced mice grouped by
genotypes. Possible side effects of the tamoxifen treatment where excluded with 29 wild type mice
(grey). Lethality occurred in the Rosa26-CreER(T2) line that was wild type for mll2 (blue). The lethality
of the cre strain is not significantly influenced by the strain (C57BL/6 or 129/ola), but strongly influenced
by the number of Rosa26-CreER(T2) allele(s). For this allele, we observed a lethality of
18 % in heterozygous mice and 72 – 100 % in homozygous mice (blue and yellow).
Fig. 27 Illness and body weight of the Rosa26-CreER(T2) line. Mice received tamoxifen gavage from the
1st to the 5th day. Illness and lethality occurred between the 5th and the 18th day with most cases from day8
to day 10. Sick mice showed abnormal weight loss [       ] and reduced motility. When symptoms of
illness where observed, mice were sacrificed to avoid extended periods of suffering.
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Surprisingly, the gastrointestinal phenotype was not caused by mutagenesis of Mll2, as
it also occurred in mice of the Rosa26-CreER(T2) line. In fact, the lethality seemed to
originate from activated CreER(T2) protein. This conclusion is substantiated by the
observation that the diarrhea occurred in 18% of mice heterozygous for Rosa26-
CreER(T2), but in 76 % of all homozygous mice. The 2 different strains that were used,
C57BL/6 or 129/ola, did not produce a significant difference in disease. Furthermore,
the oil was not the cause of the diarrhea; pups with Rosa26-CreER(T2) that did not
receive oil but were induced by lactating mothers had an identical phenotype.
     
We assumed that the diarrhea caused by the fusion protein is an effect of activated
ER(T2) rather than an effect of cre activity. Several ubiquitous cre lines with no
apparent phenotype exist; in contrast, the Rosa26-CreER(T2) is the first line that
expresses the triple mutated ER in all tissues.  It is unknown whether differently
mutated versions of EBD, e.g. ER(T1), would be deleterious or whether other ER
versions would be more valuable for applications in the mouse.
Fig. 28  Gastrointestinal phenotype of the Rosa26CreER(T2)
line. Dissections and comparison of sick mice (A) to wild type
controls (B). (A) Diarrhea is clearly visible at the anus of the
mouse. Dissection revealed that the entire intestine was filled
with liquid. The gall bladder (arrows) and stomach of sick
Rosa26CreER(T2) mice were distended and the gastric content
(stomach) had on average twice the weight as in wild type mice
(box). (C) TUNEL staining of paraffin-sectioned intestine from
sick mice did not reveal increased rates of apoptosis as a cause
of the diarrhea.
A B
C
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2.3.7 Phenotype of Mll2 mutant embryos
The temporal flexibility of the conditional system allowed an extended analysis of the
function of Mll2 during embryogenesis. As previously described in section 2.2.3,
constitutive knock out of the protein results in a failure of gestation between E9.5 and
E11. We induced mutagenesis at various stages of development to further define the
period were Mll2 function is essential. Inductions of pregnant females by one to two
daily doses of 5 mg tamoxifen at E4.5, E8.5 and E11 yielded complete recombination.
In contrast, inductions of pregnant females by one dose of 5 mg tamoxifen at E17
resulted in incomplete recombination.
Interestingly, embryos induced at E4.5 and E5.5 recapitulated the phenotype of null
embryos when dissected at E10.5. Previous tamoxifen inductions of ES cells had
revealed that the recombination on DNA level is complete after 24 hours, which lead to
absence of protein 72 hours later. Therefore, we assume that inductions in utereo at
E4.5 lead to absence of Mll2 protein at 6.5. The absence of protein from gastrulation is
sufficient to recapitulate the phenotype of null embryos, which indirectly indicates that
mll2 function is dispensible before.
In contrast, induction at E 8.5, which presumably leads to absence of protein at E 11.5,
did not have any effect on embryos dissected at E13. Moreover, induction at E11, which
presumably leads to absence of protein at E 14, did not have any effect on embryos
dissected at E16. It cannot be concluded that Mll2 is dispensable from E11, as this
would only be proven if inductions at E8.5 yielded viable pups. However, the normal
morphological appearance of embryos induced at this stage strongly supports that
conclusion.
Fig. 29  Crossed genotypes for embryo inductions. Induced embryos where cre/+ to avoid the toxicity
observed in adult mice homozygous for Cre. Moreover, induced females did not have Cre.
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Fig. 30 Mutant embryos (Mll2F/F;cre/+) induced at
E4.5 and dissected at E 10.5 recapitulate the
phenotype of Mll2 null embryos.
Fig. 32 Mutant embryos (Mll2F/F;cre/+) induced
at E8.5 and dissected at E13.5 are morphological
identical to induced control embryos (Mll2F/+ ;
cre/+)
Fig. 31 Control embryos (Mll2F/+;cre/+) induced
at E8.5 and dissected at E13.5 served as control to
exclude possible side effects of tamoxifen.
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2.3.8 Phenotype of Mll2 mutant mice
Except for the diarrhea, which is an artifact of the Rosa26-CreER(T2) line, the Mll2
mutant mice showed no conspicuous abnormalities compared to control mice. We
monitored the health state of all induced mice by weekly hematological examination.
The hematological profile generated with HEMAVET™ included:
Leukocytes (total count/differential count of the five types of white blood cells:
 lymphocytes, monocytes, neutrophils, eosinophils, basophils).
Erythrocytes
Hemoglobin
Haematocrit
Average cell volume
Average Hb content of erythrocytes
Fig. 33 & 34 Control (top) and mutant
(Bottom) embryos induced at E11.5 and
dissected at E16 are morphologically
identical. Minor hemorrhage (top panel) was
observed in control embryos.
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Reticulocytes
Platelets
Average platelet volume
All values of mutants were in the normal range and showed no significant variation with
induction, except the white blood cell counts. This value multiplied by 1000x represents
the total number of leukocytes in a microliter of blood. In the C57BL/6 strain the white
blood cell count (WBC) is usually between 2 and 18 (Russell et al., 1951), thus more
variable than in adult humans where the average WBC is 4.5 to 10.
The WBC of our 12 control (wild type) mice did not vary significantly with induction.
The average value was 4 before induction with a small standard deviation of +/- 2.
During tamoxifen treatment we observed a minor increase to 6, but similar values as
before induction in the second and the third week. In contrast, the average WBC of
mutants decreased with induction. The average WBC of mutants was 11 before
induction and, although much higher than in control mice, still within the normal range
of 2 – 18. However, this value dropped to 4 during induction and to 2 in the first week
after. Whereas some mutants had only a slight decrease of WBC, some mutants dropped
below 2 and had values that placed them at risk for a fatal infection.
Fig. 35 White blood cell counts (WBC) are significantly reduced with induced mutagenesis of mll2.
The total number of white blood cells of mammals is highly dynamic and depends on
physiological conditions. In response to an acute infection, trauma, or inflammation,
white blood cells release a substance called colony-stimulating factor (CSF). CSF
stimulates the bone marrow to increase white blood cell production. In a person with a
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normal functioning bone marrow, the numbers of white blood cells can double within
hours if needed. In contrast, while the average lifespan of white blood cells range from
13 to 20 days, they can be rapidly eliminated by apoptosis after an infection.
An increase in the number of circulating leukocytes is rarely due to an increase of white
blood cell production. When this occurs, it is most often due to dehydration and
hemoconcentration. Intriguingly, we observed a decrease of WBC in most mutants
including mice that showed signs of dehydration from diarrhea. A possible explanation
is that white blood cells are efficiently recruited to the gastrointestinal tissue in mutants
with diarrhea, which in consequence caused a reduction in the peripheral blood system.
Another hypothesis was that the loss of Mll2 triggered apoptosis in white blood cells.
However, southern blotting with DNA from blood cells of induced mutants revealed
complete recombination of the conditional allele (data not shown). This indicated that
Mll2 is not essential in Leukocytes. Furthermore, recombination was complete in
haematopoietic stem cells (HSC) that achieved steady-state hematopoiesis in absence of
Mll2. These observations indicate that Mll2, unlike its orthologue MLL, is not essential
in haematopoietic cell lineages.
The reduction of WBC occurred only in a fraction of induced mutants; therefore these
observations are not conclusive. Furthermore, we do not know if this effect is due to
mutagenesis of Mll2 or the toxicity of CreER(T2), as our control mice did not have
CreER(T2). In contrast to the polymorphic effect on leukocytes, we did observe sterility
uniformly in all induced mutants. Furthermore, the infertility did not happen in control
mice with CreER(T2). The infertility of mutant females (2.3.9) and mutant males
(2.3.10) is described in the following sections.
2.3.9 Infertility of mutant females
In order to analyze the infertility of Mll2 mutant females, we have to be familiar with
the major cell types of the murine ovary. Thus, this section starts with a brief review of
the origin of female germ cells and their maturation during oogenesis and
folliculogenesis.
The formation of the ovary commences with the migration of the primordial germ cells
(PGC) from the yolk sac into the intermediate mesoderm of the gonadal ridge. Although
PGC may be found as early as day 8, they arrive at the gonadal ridge about gestation
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day 11 to 11.5 (Baker, 1972). As the sex cords proliferate to form the ovary proper, the
germ cells also proliferate via mitotic divisions and form “oogonia” beginning on
gestation day 13. Subsequently, oogonia begin synchronized meiotic divisions and are
then referred to as “primary oocytes”. Meiotic prophase is divided into the leptotene
stage (condensation of chromosomes), which occurs on or about day 14 of gestation, the
zygotene stage (synatptonemal complex) between days 14 - 17, the pachytene stage
(crossing-over) between days 15 - 19, and the diplotene division from day 17 of
gestation to day 5 postpartum. In contrast to male meiosis where a diploid germ cell
(4n) yields 4 haploid spermatozoa (1n), the female meiosis yields a single oocyte (1n)
and the redundant chromosome sets are eliminated during both meiotic divisions by
formation of 2-3 polar bodies. In the first week after birth, the mouse ovary contains
about 7500 to 10 000 oocytes, which are arrested at the diplotene stage of meiosis I.
Stromal cells surround the oocytes to form follicles, a process starting at E18 and
referred to as “folliculogenesis”. Concomitant with the growth of oocytes, the
granulosa cells transform to acquire a cuboidal shape, forming primary follicles.
Follicles are composed of an oocyte surrounded by granulosa cells, a basement
membrane, and a concentric layer of thecal cells admixed with fibroblasts and
myoblasts. Although vessels do not penetrate the basement membrane, blood-borne
products (e.g. applied tamoxifen) freely diffuse across it to reach the granulosa cells and
oocyte. After birth, cohorts of primordial follicles are periodically recruited to enter into
a 3-week growth phase. The proliferation of granulosa cells results in pre-antral follicles
composed of multilayer of granulosa cells surrounding the oocyte within the follicular
basement membrane. Concurrent with the development of follicles, there is marked and
continuous loss of oocytes, and by puberty, the mouse ovary contains about 2500 to
5000 primordial follicles. It is believed that these primordial follicles in the newborn
mouse ovary represent the entire complement of germ cells available for reproduction,
however this issue has recently been challenged (Johnson et al., 2004).
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Fig. 36 Maturation of female germ cells during oogenesis and folliculogenesis. Migrating primordial
germ cells enter the gonadal ridge at E11 and become mitotic oogonia. At E14, oogonia begin
synchronized meiotic divisions and are then referred to as primary oocytes. Stromal cells surround the
oocytes to form follicles, a process starting at E18 and referred to as “folliculogenesis. At birth, the
mouse ovary contains about 7500 to 10 000 oocytes, which are arrested at the diplotene stage of meiosis
I. Concurrent with the development of follicles, there is marked and continuous loss of oocytes, and by
puberty, the mouse ovary contains about 2500 to 5000 primordial follicles. In the mature mouse (5-6
weeks), the ovaries enter the estrous cycle with ovulation of oocytes every 4 days, which corresponds to
the menstrual cycle of 28 days in humans. Within a cycle, meiosis I is resumed before ovulation. Arrest in
meiosis II followed by ovulation marks the end of folliculogenesis. Fertilization of the secondary oocyte
triggers completion of the second meiotic division.
After puberty, further growth of follicles is accelerated by gonadotrophins, namely
FSH, leading to the formation of antral follicles (Kumar et al., 1997). Although oocytes
within large antral follicles are competent for maturation, they remain arrested due to
their interaction with the surrounding granulosa cells (Bornslaeger et al., 1986). In the
mature mouse (5-6 weeks) the ovaries reflect a cycling reproductive status with
ovulation of oocytes every 4 days, which corresponds to the menstrual cycle of 28 days
in humans. Within a cycle, a preovulatory LH surge affects the maturation of the
oocyte. This allows meiosis, held in abeyance since entering prophase weeks before, to
resume approximately 24 hours before ovulation. In response to this LH surge, fully
grown oocytes complete the first meiotic division, extrude the first polar body
containing a set of chromosomes, and become arrested at metaphase II (Richards et al.,
2002). With occurrence of meiosis II the oocyte is now referred to as a secondary
oocyte. The LH surge is responsible for ovulation of the oocyte marking the end of
folliculogenesis (Lee et al., 1996). While meiosis I is completed before ovulation,
meiosis II does not continue into the second cell division until the occurrence of
fertilization. If a sperm penetrates the oocyte, the fertilization triggers completion of the
second meiotic division and formation of a second polar body.
- 62 -
        
Fig. 37 Folliculogenesis. (1) Diagrammatic representation of follicular growth and ovulation (From
Baker, 1972, Reproduction in mammals, Cambridge Univ. Press). (2) Photomicrographs of early stages
of human prenatal folliculogenesis. A) Primordial follicle; arrow, squamous granulosa cell. B)
Recruitment showing the primordial-to-primary transition; arrow, cuboidal granulosa cell. C) Primary
follicle with multiple cuboidal granulosa cells. D) Fully grown primary follicle at the primary-to
secondary transition stage; arrow, formation of a secondary layer of granulosa cells. All photos are 40x
and were found on the web at www.endotext.org. (3) Multiple cross regulations occur between the oocyte
and the granulosa cells.
Since the majority of follicles (approximately 80%) that are recruited for growth in any
given cycle degenerate rather than ovulate, cell death is a common and normal
histological feature of the ovary. The process of follicular degeneration is referred to as
“follicular atresia” and is characterized by granulosa cell death, which is
morphologically and biochemically comparable to apoptosis (Hughes and Gorspe,
1991; Hsueh, 1994; Richards, 1980; Hirshfield, 1989). It is unclear, what determines
which follicles will be ovulated and which will undergo atresia.
We used 10 females homozygous for the conditional Mll2 allele and heterozygous for
Rosa26-CreER(T2) and 3 control females heterozygous for the conditional Mll2 allele
and Rosa26-CreER(T2). All females were bred with wild type males prior to induction
and produced offspring. After induced mutagenesis of Mll2 by tamoxifen gavage,
mating to the previously used wild type males assessed the fertility of females.
1 2
3
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Moreover, we included a wild type female in all matings to verify the virility of males.
Although these control females became pregnant in the first week of breeding, all
tamoxifen treated mice (mutants and controls) did not during 3 - 4 weeks after
induction. This temporal infertility is probably caused by the antagonistic effect of
tamoxifen on the estrogen receptor and not due to the absence of Mll2, as it was also
observed in the 3 heterozygous Mll2F females. However, these control females
recovered from infertility and became pregnant in the 3rd and the 4th week after
induction, while the 10 mutant females never produced any offspring over a period of 8
months. We concluded that the absence of Mll2 protein caused sterility of the females.
The adult ovary at the time of induction includes primary follicles that contain oocytes
arrested in meiosis I, which periodically mature by resuming the 1st meiotic division
with subsequent ovulation and arrest in metaphase II. The sterility of mutants indicated
that Mll2 is involved in this process.
To further characterize the phenotype, we induced 4 mutant females with a different
tamoxifen induction protocol that yielded incomplete recombination. Instead of oral
feeding of 5 mg tamoxifen, these mice received i.p. injections of 1 mg tamoxifen
dissolved in 20 % ethanol. Southern blotting with DNA from various organs of these
females revealed that recombination had occurred in only approximately 50 % of the
cells (fig. 19 C). This was probably due to a rapid precipitation upon injection and
therefore poor metabolism of tamoxifen dissolved in an aqueous solution, as i.p.
injections of 1 mg tamoxifen dissolved in oil performed in other mice yielded complete
recombination. Interestingly, the partially recombined females were still fertile and
produced offspring during 4 months of subsequent breeding. We genotyped the
offspring and observed that the induced females had transmitted the recombined
haplotype mll2FC. This indicated that primary oocytes that had recombined proceeded
through meiotic telophase I and ovulated in the absence of Mll2. It is theoretically
possible that a diploid primary oocyte recombined only one of both conditional Mll2
alleles. With meiotic division this could yield a recombined haploid secondary oocyte
and a polar body with the unrecombined allele. As most of the cytosol is distributed to
the oocyte while the polar body contains only one set of chromosomes, the recombined
oocyte would probably contain sufficient levels of Mll2 until fertilization and
transcription from the male genome. Moreover, it is possible that Mll2 protein
translated in the oocyte before the recombination is very stable for extended periods,
therefore our results do not provide final evidence that Mll2 is dispensable in oocytes.
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However, it is possible that chimeric recombination obtained with the partial induction
protocol produced primary follicles with few unrecombined granulosa cells. Although the
oocyte recombined, there could possibly have been enough unrecombined granulosa cells to
exert an essential, Mll2 dependent function on the oocyte. An experiment to test this
hypothesis should use cell type-specific Cre recombination of the conditional mll2 allele. This
could be achieved by crossing the Mll2F line to oocyte specific Cre lines, [GDF-9-iCre,
Zp3cre, or Msx2Cre (Lan et al., 2004)], or a granulosa cell specific Cre line [AMH-Cre
(Lecureuil et al., 2002)]. These experiments are currently being discussed.
2.3.10 Infertility of mutant males
Before description of the infertility observed in induced Mll2 mutants, this section will start
with a short introduction to the male germ line (Cooke et al., 2002). In both man and mouse,
the adult testis carries out two essential functions: it produces mature, haploid spermatozoa
and it secretes steroid hormones, the most important of which is the androgen testosterone.
Spermatogenesis, that is, the development of mature spermatozoa from diploid
spermagogonial cells, takes 35 days in the mouse (fig. 40 A). Normal spermatogenesis and
therefore fertility depends on interaction between the somatic cells (Sertoli, Leydig, and
peritubular) and the germ cells, and also on hormonal support from the pituitary gland. Germ
cells mature in the testis in the seminiferous tubules, highly organized structures that contain
germ cells at all stages of maturation, with the most mature cells lying closest to the central
lumen. Each Sertoli cell exists in close association with germ cells at multiple stages of their
development (fig. 38 B). Maturation of germ cells is usually subdivided into three phases:
mitotic proliferation of spermatogonia, meiotic division of spermatocytes, and differentiation
of spermatids during spermiogenesis, which culminates in the release of mature spermatozoa
(spermiation). In contrast to female germ cells, which proliferate exclusively during fetal
development, the male germ cells are mitotically active in adults.
Two classes of spermatogonia have been identified by functional criteria: spermatogonial
stem cells (Asingle or As), which can colonize a recipient testis after germ cell transplantation,
and differentiated spermatogonia (type A or B), which are not able to colonize the testis (De
Rooij, D.G. 2001). These differentiated diploid spermatogonia undergo several mitotic
divisions before they leave the stem cell niche, a compartment defined by tight junctions
between Sertoli cells. During a lengthy meiotic prophase divided into the leptotene, zygotene
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and pachytene phases, they are now referred to as spermatocytes. At the end of meiotic
prophase, they undergo the final meiotic divisions to form haploid spermatids. Thereafter, the
spermatids undergo spermiogenesis, during which the nucleus of the germ cell is remodeled
and compacted into the form that is found in the mature spermatozoa. Spermatogenesis
culminates in spermiation, when the mature spermatozoa are released from the Sertoli cell
into the lumen of the seminiferous epithelium.
Fig. 38 Organization of the testis. (A) A diagrammatic cross-section through testicular tubules, showing
the germ cells (green) at different stages of maturation developing embedded in somatic Sertoli cells
(each Sertoli cell is outlined in red). Leydig cells, where testosterone is synthesized, are present in the
interstitium. Shown in the box is a single Sertoli cell with its associated germ cell. Spermatogenesis
comprises mitotic proliferation of spermatogonia, meiotic division of spermatocytes, and differentiation
of spermatids. PTM, peritubular myoid cell. (B) Male germ cell niches. Germ cells are represented in
yellow. The stem cell (spermatogonia), also known as Asingle (As) cell, is shown in red and constitutes a
minority of the basal germ cells in contact with the basement membrane. Note that tight junctions
between Sertoli cells (green) define two compartments: the stem cells and the pre-meiotic cells
(spermatogonia) are found on one side of the junction, whereas the meiotic (spermatocytes) and the post-
meiotic (round and elongating spermatids) cells are found organized in strict order of maturation towards
the lumen. Figures A and B are published in Saunders et al. (2002) and Spradling et al. (2001).
A
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For a fertility experiment, we used 11 males homozygous for mll2F and heterozygous
for Rosa26-CreER(T2) and 9 control males heterozygous for mll2F and Rosa26-
CreER(T2), which were successfully mated to females before induction. Induction was
performed by gavage of 5 mg per day tamoxifen for 5 consecutive days (see section
2.3.2). As described previously, mutant mice showed no exterior distinctive features
compared to control mice. However, we had observed infertility of males (and females)
in a previous experiment. Therefore, we mated 11 mutant and 9 control mice to 2 wild
type females each after induction to assess fertility. Furthermore, we replaced the
females with new females once per week for 8 weeks to determine a time lapse of the
infertility.
Fig 39  Fertility of induced control and mutant mice. Fertility was evaluated by weekly breeding of males
to 2 females for a period of 8 weeks after induction. Fertility was temporally reduced in mutants and
controls during 2 weeks after the tamoxifen treatment. Mutants and controls recovered fertility in the 3rd
week, but mutants only became permanently infertile from the 7th week.
Similar to what we observed in induced females, there was temporary infertility in both
mutant and control mice, which was probably a side effect of the tamoxifen treatment.
Control mice recovered fertility gradually with 56% in the 3rd week, 78% in the 4th
week, and 100% of individuals being fertile in the 5th week after induction. While older
mice (3 - 4 months) recovered fertility in the 3rd week, younger mice (2 months)
recovered more slowly. This could have been due to the lower body weight of the
younger mice, which in consequence received a higher relative tamoxifen dose, as all
mice were induced with 5 mg tamoxifen.
Of the mutants, 18% were fertile in the 2nd, 64% in the 3rd, 55% in the 4th, and 64% in
the 5th week after induction, producing similar rates of recovery as in control mice.
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However, not all mutants recovered fertility as controls did. Furthermore, there was
subsequently a dramatic loss of fertility with 1/11 male fertile in the 6th week and all
males sterile from the 7th week. We determined the transmitted mll2 haplotype by
genotyping the offspring from mutant crosses. Offspring derived from fertilizations
during the 2nd and the 3rd week (day 7 to 22) after induction had the unrecombined
mll2F allele, while offspring conceived during the 5th, 6th, and 7th week had the
recombined mll2FC allele. This observation allowed determination of recombination
success during tamoxifen treatment in different germ cell types. While spermatogonia
and primary spermatocytes of early prophase I (leptotene to pachytene) did recombine,
later stages of primary spermatocytes, secondary spermatocytes and spermatids did not.
We assumed that Rosa26-CreER(T2) was not expressed at the cell stages where no
recombination was obtained. Alternatively, the particular conformation of the DNA in
these cells could explain the absence of recombined mll2FC allele. The formation of
synaptonemal complexes and chiasmata during meiosis I could inhibit
intrachromosomal recombination. Interchromosomal recombination, which could be the
favored recombination event due to close pairing of homologous chromosomes, would
not create the mll2FC allele. However, the existence of spermotocyte-specific and
spermatid-specific Cre deleter lines (Pgk2-Cre, Ando et al., 2000; Sycp1-Cre, Vidal et
al., 1998 & Chung et al., 2004; Protamine1-Cre, O’Gorman et al., 1997) argues against
this possibility. Furthermore, Cre recombination is obtained in primary oocytes of adult
females, which are arrested at the diplotene stage of meiosis I.
The induced mutants lost fertility between days 35 and 42 after induction, which
corresponds exactly to a complete cycle of spermatogenesis. This indicated that the
earliest phase of spermatogenesis was disturbed by mutagenesis of Mll2, as it required a
full cycle to become striking. Moreover, offspring conceived in the 5th and the 6th week
originated from germ cells that were spermatogonia A or B at the time of induction.
Although these cells recombined, they underwent meiotic division, which indicated that
Mll2 is not required during meiosis and subsequent spermiogenesis.
- 68 -
Fig. 40 Stages of spermatogenesis. (A) Spermatogenesis is a highly organized cyclic process with distinct
phases: mitosis (purple), meiosis (red and orange), and spermiogenesis (grey). The time course shown
indicates the duration of the maturation phases. (B) Fertility and transmitted haplotype of induced
mll2FC/FC mice. Infertility in the first week after induction is also observed in control mice and a side
effect of tamoxifen. The unrecombined mll2F allele is transmitted in the 2nd and 3rd week after induction,
indicating that no cre recombination occurred in spermatocytes beyond the pachytene stage and
spermatids. The recombined mll2FC allele is transmitted in the 4th to the 6th week after induction,
indicating that cre recombination had occurred in spermatogonia and spermatocytes of the leptotene and
zygotene stage. Mll2 was not required for meiosis and spermiogenesis, as recombined spermatogonia
succeeded in maturation and fertilized oocytes. The infertility of mutant males after 7 weeks indicated an
essential function of mll2 in spermatogonia.
Even though we determined the infertility to be related to spermatogonia, we could not
conclude whether the cause was a defect intrinsic to the
germ cells or a defect in Sertoli cells. A model for
defective Sertoli cell function is observed in the sterile
mouse mutant Steel, which has mutated SCF/c-kit
ligand. In contrast, the mouse mutant Kit has a mutated
c-kit receptor, a defect of the germ cell that disrupts the
same pathway and provokes an identical phenotype
(Ogawa et al., 2000; Chabot et al., 1988; Geissler et al.,
1988; Sorrentino et al., 1991; Flanagan et al., 1991).
Whether Mll2 function is required in Sertoli cells
and/or spermatogonia could be addressed by the use of
cell type specific cre recombinases. Therefore we are
currently crossing the mll2F line with the inducible,
germ cell specific Cre line PrP-CreER(T2) (Weber et
al., 2003).
A
B
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2.3.11 Histological analysis of testis
None of the eleven mll2FC/FC males produced any offspring 7 weeks after induction.
To define the infertility phenotype, the histology of the testes from the induced males
was examined. Testes of the mutants were atrophic and histological examination
revealed smaller seminiferous tubules compared with controls. Spermatocytes where
present in mutant testis but their number appeared reduced. Some seminiferous tubules
were completely devoid of germ cells and contained only Sertoli cells, suggesting that
the germ cells were undergoing rapid degeneration. In contrast, the Leydig cells in
mutant testis appeared to be normal.
Fig. 41 Histology of testes. Testis sections were stained with haematoxylin and eosin. (A) In wild type
control males (no tamoxifen) all stages of germ cells can be identified in the seminiferous epithelium. (B)
Sections from tamoxifen treated heterozygous control mice (mll2FC/+; Rosa26CreER(T2)+/-) were
similar to wild type contols. (C) In testis sections from mutant males (mll2FC/FC; Rosa26CreER(T2)+/-)
5 months after tamoxifen induction seminiferous tubules are completely devoid of germ cells. The
interstitial Leydig cells surrounding the tubules appear to be increased in number, probably because of the
decrease in the number of germ cells.
To determine if the loss of germ cells from seminiferous tubules was associated with
cell death, the TdT-mediated fluorescein-dUTP nick-end-labeling (TUNEL) assay was
used to detect the single and double strand DNA breaks that occur during apoptosis.
Although very few apoptotic germ cells were seen in control testes, a large number of
apoptotic germ cells were detected in mutant testes. Apoptotic cells were located
exclusively in the peripheral region near the base of seminiferous tubules and therefore
confined to spermatogonia. We induced several mutant mll2F males and examined the
histology and extent of apoptosis in testis at several time points after induction. 
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meiotic and post-meiotic germ cells appeared normal after induction, but the overall
number of germ cells decreased with time because of the degeneration of
spermatogonia. Increased apoptosis of spermatogonia was first observed 6 days after the
beginning of tamoxifen treatment and was most prominent from the 15th to the 30th day.
We immunostained testis sections with Ki-67 antibody, a marker for mitotically active
spermatogonia. The positively stained cells in wild type sections were identified by
their relative location in the seminiferous tubules to be spermatogonia of all stages.
These include the self-renewing spermatogonia Asingle, which differentiate to form
spermatogonia Apaired, divide to form 4, 8, or 16 spermatogonia Aaligned, then
differentiate to spermatogonia A1, resume division to form spermatogonia A1 to A4,
divide to form intermediate spermatogonia (In) and finally divide to form
spermatogonia type B. In testis sections of mutant males, no positive cells were detected
5 months after tamoxifen induction. These results confirmed the conclusions that the
timing of infertility indicated a disruption of the earliest, mitotic phase of
spermatogenesis in mutant mice. Furthermore, the complete lack of Ki-67 positive cells
demonstrated a decay of the germinal stem cell (Asingle cell) in the absence of Mll2.
Fig. 42 Defective spermatogenesis in Mll2FC/FC males. (A) Shown are 2 control testis of a wild type
male (no tamoxifen) and a heterozygous male (mll2FC/+:cre/+, with tamoxifen). Only the testis of the
mutant male (mll2FC/FC:cre/+, with tamoxifen) is atrophic. Testis section of wild type (B,D) and mutant
(C,E-F) males. (B,C) Ki-67 immunostaining in tubules 5 month after tamoxifen induction.
(D-H) TUNEL staining 6 days (D,E), 15 days (F), 25 days (G) and 5 months after tamoxifen induction.
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2.3.12 Molecular characterization of the male infertility
To gain further insight in the infertility phenotype of Mll2-/- males, we analyzed the
expression of both mll and mll2 in the testis by LacZ staining and in situ hybridization.
LacZ stained cryosections of testis from mll2+/- mice indicated expression of β-
galactosidase in all germ cell stages, but not in Leydig cells. In situ hybridizations on
wild type testis with probes specific for mll2 and the close homologue mll were
performed by collaborators (K. Loveland, Monash, Melbourne). Sense transcripts were
used as controls and indicated low background for both probes. Antisense mll2 cRNA
signal was present in spermatogonia and spermatocytes, but absent in post-meiotic germ
cells or somatic cells, including Sertoli cells. In contrast, the antisense MLL cRNA
probe exhibited a strong signal in the pachytene spermatocytes, and a fainter signal in
the round and early elongated spermatids. This partial exclusive expression pattern of
both homologues in the testis could explain the restriction of the adult mll2 phenotype
to germ cell. Indeed, the rather surprising absence of abnormalities in other tissues of
Mll2FC/FC mice could be due to functional and spatial redundancy to mll. To
substantiate this hypothesis, it remains to be excluded that mll is expressed in
spermatogonia. Therefore, we are currently planning to isolate type A spermatogonia
using the STAPUT method, which utilizes gravity sedimentation on a bovine serum
albumin (BSA) gradient. RT-PCR analysis on a purified cell population will determine
if mll is expressed in spermatogonia.
   
Fig. 43 Expression of Mll and Mll2
in the testis evaluated by in situ
hybridization on paraffin section
and LacZ staining of Mll2+/- testis
cryosect ion.  The s t rongest
hybridization signal with the Mll2
probe is observed in mitotic germ
cells, while the strongest signal
obtained with the Mll probe is
detected in meiotic germ cells.
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Next, we wanted to investigate if the infertility of mutant males is caused by a
disturbance of the hormonal regulation of spermatogenesis. Testicular function is
influenced both by endocrine (extra-testicular) and paracrine (intra-testicular) factors.
The gonadotrophins luteinizing hormone (LH) and follicle-stimulating hormone (FSH),
which are the main endocrine hormones, are secreted by the pituitary gland and signal
through receptors (LHR and FSHR) expressed by Leydig and Sertoli cells, respectively.
The paracrine regulation of spermatogenesis is thought to be provided by steroids, such
as testosterone and oestradiol, which are both synthesized by Leydig cells, and by
proteins, such as inhibin and activin, which are synthesized by the Sertoli cells. Several
studies have indicated that deprived endocrine and paracrine support of the testis leads
to reduction of testosterone concentration and complete infertility.
We tested testosterone levels of serum from 6 mutant mice and 2 control mice before,
and at several time points after tamoxifen induction (experiments performed by
Konstantinos Anastassiadis and Stefan Glaser in collaboration with Rattenberger).
Blood samples were taken at a fixed time (11 a.m.) and plasma was collected by
centrifugation. Testosterone concentrations where determined by a solid-phase 125I-
radioimmunoassay in 0.1 ml of plasma. The testosterone concentrations of induced
mice were similar to the concentrations (2 to 5 ng/ml) previously measured in the
C57BL/6 strain (Sayegh J.F. et al., 1990, Hampl et al., 1971). No difference in
testosterone concentration was observed between induced mutant and control mice for
up to one year after tamoxifen treatment. Thus, a perturbation of endocrine and/or
paracrine signaling was not the cause of infertility in mll2FC/FC mice. Due to the
incomplete recombination of the conditional mll2 allele in the brain of induced mutants,
a defective signaling of the pituitary gland was very unlikely. However, the normal
testosterone levels indicated undisturbed paracrine signaling in the testis and functional
Leydig cells in the absence of mll2.
Fig. 44 Normal testosterone
levels in mll2 mutant mice.
Blood samples where collected
at different time points and
testosterone levels [ng/ml]
where determined from 100 µl
serum. A control sample from a
female yielded a value below
0,4 ng/ml
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As mll2 is strongly expressed in spermatogonia but absent in Sertoli cells, the infertility
of mll2 mutants is probably caused by an intrinsic defect in spermatogonia. Thus, these
data indicated an essential function for mll2 in spermatogonia. We wanted to determine
if mll2 is also essential in the fetal precursors of spermatogonia, the primordial germ
cells (PGC). In the mouse, PGC arise early in embryogenesis, first becoming visible at
E 7.5 in the extraembryonic mesoderm, posterior to the primitive streak. They
subsequently become incorporated into the epithelium of the hindgut, from which they
emigrate (E 9.5) and move first into the dorsal mesentery (E 10.5), and then into the
genital ridges that lie on the dorsal body wall (E 11.5) (Gomperts et al., 1994).
Simultaneous with the migration, PGC enter a period of proliferation from E 8.5 to E
13.5. After this time, PGCs in the male gonad undergo cell cycle arrest until a few days
after birth, whereas in the female gonad, PGCs enter meiosis and arrest in prophase of
meiosis I (McLaren, 2000). The high content of tissue non-specific alkaline phosphatase
(TNAP) in PGC can be used as a rough marker to trace their development, however the
widespread expression of another alkaline phosphatase gene in the embryo limits this
application. Studies based on the detection of alkaline phosphatase (ALP)-positive cells
detected about 8 cells at E7.0, 50 to 80 cells at the end of gastrulation, and about 125
cells at E8.0 (Ginsburg et al., 1990). Other studies detecting PGCs by alkaline
phosphatase assays detected 50 cells at E 8.5 and 180 – 200 cells at E 9.5. PGC at later
stages were detected using anti-PECAM antibody (Schmahl et al., 2000; Yao et al.,
2002) and detected 2000 cells at E11.5, 5000 cells at E12.5, and 7000 cells at E13.5
(Atchison et al., 2003).
Interestingly, mll2 seems to be dispensable in PGC, as (ALP)-positive cells were
detected in E9.5 and E10.5 mll2-/- embryos. However, fewer PGCs were seen in mll2-
deficient male embryos. No abnormal or ectopic PGC migration was noted in mll2-/-
embryos, indicating that the PGC number did not decrease as a result of defective
migration. The observed reduction of PGC number supports the concept that the
absence of mll2 increases apoptosis in various cell types and tissues including ES cells
(Sandra Lubitz, unpublished results), developing embryos (section 2.2.3), and
spermatogonia (section 2.3.11)
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Fig. 45 Alkaline phosphatase staining of Mll2 -/- embryos revealed a decreased number of migrating
primordial germ cells compared to wild type embryos.
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2.4 Generation of an ubiquitous, inducible Cre mouse line
The goal of this project was the generation of a mouse line expressing an inducible
SSR-steroid receptor fusion protein in all tissues. To achieve ubiquitous expression we
decided to introduce the recombinase gene by DNA recombination into ES cells. A
precise insertion by targeting an endogenous, ubiquitously expressed gene of the mouse
would increase the chance of achieving omnipresent expression and be preferable to
random integration of transgenes.
Fig. 46 Targeting to create an ubiquitous, inducible Cre line. By targeting IRES-ER(T2)-Cre-ER(T2)-
hygro to the 3’UTR of topoisomerase I (topI), the homologous recombined locus expresses a
polycistronic transcript (topI and cre) under the promoter of a house keeping gene.
Topoisomerase I belongs to the group of housekeeping genes, which are expressed in all
nucleated cells. We designed a strategy for targeting a construct into the 3’ UTR of this
gene, thereby creating an allele for a polycistronic mRNA. By translation of both
proteins, topoisomerase I and the CreER(T2), ubiquitous expression of the inducible
recombinase would be achieved. Furthermore, the polycistronic approach would
presumably not disturb expression of the targeted gene and the line could be maintained
in a homozygous state.
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2.4.1 Cloning of the targeting construct Topoisomerase I-ER(T2)-Cre-ER(T2)
The goal of this cloning was a construct with the coding sequence of Cre recombinase
fused to two N- and C-terminal ER(T2)s. ER(T2) is a modified version of the estrogen
receptor sequence with three amino acid substitutions (G400V/M543A/L544A). These
substitutions render the ligand-binding domain insensitive to endogenous hormone ß-
estradiol but still responsive to the synthetic estrogen antagonist 4-OH-tamoxifen (Feil
et al., 1997). An IRES was placed before the promoterless ORF to ensure its translation.
For screening of ES cells by drug resistance the selectable marker hygromycin was
placed at the 3’ end of the construct. Flanking FRT sites allow removal by the site-
specific recombinase Flp. Between all elements of the construct are one or two rare
cutters, so that new variations of different alleles can be generated easily from this
construct.
We generated ER(T1) and ER(T2) based on EBD (G400V) by a triple PCR strategy.
The first reaction introduced the mutations L539A/L540A for T1 and M543A/L544A
for T2 in the antisense primer, while the second PCR reaction carried the mutations in
the sense primer. In the third reaction, both templates were used with the sense primer
of the1st and antisense primer of the 2nd reaction to generate the fused product.
Fig. 47 Engineering of ER(T2) based on ER(G400V) by PCR. Two mutations (M543A and L544A) where
introduced with primers in two separate PCRs. In a third PCR, a fusion of these two templates was
generated by using sense primer of the 1st PCR and antisense primer of the 2nd PCR.
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Next we introduced two ER(T2) into pBKC-iCreGBD (gift from Michael Huebner).
This plasmid provided the improved Cre gene (iCre), where mammalian codon usage
was applied to the prokaryotic coding sequence (Shimshek et al., 2002). First we
replaced GBD by a BsiWI/EcoRI digest with one C-terminal ER(T2). Second, an
additional N-terminal ER-T2 was cloned BstXI/EcoRV. This sequence coding a fusion
protein with two ligand-binding domains is possibly less prone to leakiness.
In parallel we used Red/ET recombination to insert a PCR amplified chloramphenicol
gene flanked by SgfI and AscI/PacI into pIRES-EGFP (Clontech). In a second Red/ET
recombination we introduced this reamplified Cm-IRES sequence into pBKC-ER(T2)-
hCre-ER(T2) setting the right frame between both elements.
In a third Red/ET reaction we introduced a PCR amplified hygromycin gene flanked by
FRT sites and the restriction sites PmeI/NotI and FseI/SbfI. This selectable marker has a
dual promoter for both prokaryotic and eukaryotic expression. Next we introduced 200
bp of PCR amplified sequence homologous to genomic topoisomerase I by restriction
digest cloning using AscI/PacI on the 5’ end and FseI/SbfI on the 3’ end. This two-step
conventional cloning was necessary because the construct was too large to be amplified
in one PCR to introduce flanking homologous sequence. The final step was integration
of the construct into a plasmid with genomic sequence of topoisomerase I by Red/ET
recombination, creating a targeting construct with flanking genomic sequence for
targeting in ES cells.
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Fig. 48 Cloning of the targeting construct Topoisomerase I –ER(T2)-Cre-ER(T2). (1a) Insertion of Cm
into pIRES-EGFP by Red/ET recombination. (1b) Insertion of N-terminal and C-terminal ER(T2) in
pBKC-hCreGBD by restriction digest cloning. (2) Insertion of Cm-IRES in pBKC-ER(T2)hCreER(T2)
by Red/ET recombination. (3) Insertion of FRT-hygro-FRT into pBKC-IRES-ER(T2)hCreER(T2) by
Red/ET recombination. (4) Insertion of two topoisomerase I homologie arms by restriction digest cloning.
(5) Insertion of the construct into a cosmid with genomic topoisomerase I sequence by Red/ET
recombination. (6) Subcloning of a targeting construct with suitable homologie arms for targeting in ES
cells by Red/ET recombination.
2.4.2 Cloning of genomic topoisomerase I sequence
The goal was to obtain a clone with genomic sequence of topoisomerase I that would
serve as a backbone to create a targeting construct for a TopoI-ER(T2)CreER(T2) allele.
This work was done in the year 2000 before release of the mouse genome sequence
therefore we did not have any sequence information on topoisomerase I. For more
recent targeting projects we used sequenced BAC clones from the RCPI library, but at
the time this work was done, those were not yet available. Instead, we used a 750 bp
probe of topoisomerase I 3’UTR (from Julia Schaft) to screen 11 filters of a mouse
129/ola cosmid library. This screen identified 4 cosmids:
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Cosmid 1: MPMGc121G19773Q2
filter: 78-2-249
coord. : 28 210, 26 208
Cosmid 2: MPMGc121E12757Q2
filter: 78-2-249
coord. : 61139, 64 138
Cosmid 3: MPMGc121H03498Q2
filter: 78-5-154
coord. : 228 124, 229 122
Cosmid 4: MPMGc121I04703Q2
filter: 78-2-219
coord.: 105 118, 102 117
Library 129/ola mouse cosmid
Library No: 121
Creator: Carola Burgtorf, Annette Poch, Michael Wiles
Source: Spleen
Vector: Lawrist 7 (not Lorist)
Host: DH5 alpha (E.coli)
Growth conditions: 37˚C, kanamycin
The 4 clones were analyzed by restriction digest (EcoRI/SapI) and hybridized to the
3’UTR Topoisomerase I probe used for the screen. The probe hybridized to a 1.75 kb
fragment in cosmids 1, 2 and 3 but not cosmid 4. The 1.75 kb EcoRI/SapI fragment
could also be detected on the same blot from mouse tail genomic DNA. Therefore
cosmids 1, 2 and 3 were identified as positive clones, while cosmid 4 was negative.
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Fig. 49 Genomic topoisomerase I DNA. (A) Southern blotting of PstI digested mouse tail DNA
hybridized with a 750 bp topoisomerase I 3'UTR probe detected a single 4.3 kb fragment. This probe was
used for screening of a cosmid library containing mouse genomic sequence. (B)
Next we wanted to do an approximate mapping of the cosmids 1/2/3. In our design the
final construct for ES cell targeting had a minimum of 3 – 5 kb of homology arms to
achieve a high rate of homologous recombination. We were therefore searching for an
adequate clone with a minimum of 3-5 kb of genomic sequence flanking the 3’UTR of
topoI, which was our chosen integration locus for the ER(T2)Cre-ER(T2) construct.
The size of the cosmid backbone (Lawrist 7) was 5 kb with one XhoI site and two SfiI
sites flanking the insert. We used these enzymes and southern blotting with the 3’UTR
topoI probe for mapping. An XhoI digest of cosmid1 gave 4 fragments of 23, 12, 9.5
and 7 kb, and the probe hybridized to the largest fragment. To find out where in this 20
kb fragment the TopoI 3’UTR was located, we introduced the ER(T2)-Cre-ER(T2)
construct into the cosmid by Red/ET recombination. The size of the construct is 6 kb
with a single XhoI site. Hybridizing an XhoI digest of this modified cosmid with a
probe of the construct detected two fragments, of 18.5 and 8 kb. These two fragments
together correspond to the 20 kb fragment, to which 6 kb (construct) and an XhoI site
were added.  We could therefore identify the insertion point of the construct at 5.5 kb of
the 20 kb fragment, giving sufficient sequence on both sides of the construct. Next we
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wanted to exclude the possibility that the 5.5 kb at the 5’end included the 5 kb backbone
of the cosmid, reducing the genomic sequence to 0.5 kb. An XhoI/SfiI digest produced
a 5 kb band (backbone) but the 8 kb fragment to which the construct probe hybridized
was unaltered. From this we concluded that the construct was flanked by at least 5.5 kb
at the 5’ and 15 kb at the 3’ end.
Fig. 50 Mapping of the cosmid containing genomic topoisomerase I sequence.
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In the final cloning step we wanted to subclone the construct with suitable homology
arms from the cosmid into a p15 origin plasmid by Red/ET recombination. This
targeting construct would have homology arms according to the design of the southern
strategy to screen for homologously recombined ES cell clones.
To perform this cloning we needed sequence information from the external ends of the
cloning insert to create the 50 bp homology arms of the PCR primers. To obtain the
sequence from the 5’ end, we subcloned the 8 kb XhoI fragment from the modified
cosmid into the pCI plasmid for end sequencing. Since this 8.5 kb fragment included
2.5 kb of inserted mll2 construct, by end sequencing the insert we obtained sequence
information from the region 5 to 6 kb from the start of the construct. At the 3’ end, we
performed 3 rounds of primer walking sequencing to create a homology arm of 3 kb.
The cloning of the targeting construct was performed by transformation of
pBADαβγAmp into the DH5α cells with the modified cosmid. The PCR amplified
backbone of pACYC184-kanamycin including two 50 bp homology arms was
transformed after inducing Red protein expression, and 10 kanamycin resistant colonies
were analyzed and showed the expected restriction digest pattern.
Fig. 51 Final targeting construct for the TopI-ER(T2)-Cre-ER(T2) allele
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2.4.3 Repair of a point mutation in the TopI-CreER(T2) targeting construct
During the cloning of the targeting construct most intermediate cloning products were
verified by sequencing. Nonetheless, a final sequencing of the whole construct before
electroporation of ES cells revealed a point mutation in the IRES sequence (G to A). It
turned out that this sequence, which was PCR amplified in the first cloning step, had
never been sequenced before. We decided to repair the mutation in a two-step Red/ET
recombination by first inserting a streptamycin/chloramphenicol cassette. In the second
step we generated two final variations of the construct: (i) by reintroducing only a 150
bp IRES fragment we removed the N-terminal ER(T2) (ii) by reintroducing a 1.1 kb
IRES-ER(T2) fragment we obtained the original construct design with N- and C-
terminal ER(T2). As the recombinase fusion protein with two ERs could have
disadvantageous induction properties (E. Cassanova, personal communication), we
wanted to compare the two versions.
Fig. 52 Two-step Red/ET recombination used to repair the point mutation (A) in the IRES sequence.
First, a counter selection cassette (Streptomycin/Chloramphenicol) is introduced. The second step was
performed in two variations in order two obtain a cre fusion with a single ligand binding domain or  two
ligand binding domains. Shown in the box  is the most probable recombination event (red arrow), which
is the undesired recombination between the homologous ER(T2) sequences (1 kb). However, the correct
recombination was obtained at a frequency of > 1%.
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2.4.4 Targeting of ES cells by homologous recombination
The 2 final targeting constructs, IRES-ER(T2)-Cre-ER(T2) and IRES-CreER(T2) were
linearized by SfiI digest separating inserts from plasmid backbones, purified from an
agarose gel and extracted with phenol/chloroform. ES cells were eletroporated and
grown in selective medium with 200 µg/ml hygromycin. Although the experiment was
repeated twice no drug resistant colonies survived the selection.
This failure is probably caused by a stretch of 35 bp missing in the promoter of the
hygromycin gene and thus creating a hypomorphic allele. Sequencing identified the
missing nucleotides, but since the original PCR template, pGK-P-hygro, had never been
sequenced, we assumed the plasmid file to be incorrect. After failing to obtain resistant
ES colonies, we sequenced pGK-P-hygro and realized that the gap had occurred during
the PCR amplification in our cloning of the hygro cassette. Comparisons with the
murine Pgk-1 promoter, from which this promoter for hygro is derived, revealed that
the gap mutation is 49 bp upstream of the transcription start. This could indeed be a
plausible explanation for a hypomorphic allele that did not confer drug resistance under
the selection conditions used.
The repair of the presumed defective hygromycin promoter can be easily achieved in a
single cloning step by replacing a 1 kb NotI/SgfI fragment from the targeting constructs
with the same fragment from pGK-P-hygro.
We did not continue this project at this stage because we did receive an inducible cre
deleter mouse line from colleagues, which had targeted CreER(T2) to the Rosa26 locus.
This locus is known to give ubiquitous expression therefore this mouse line would
presumably fulfill our requirements.
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Fig. 53 Deletion in the hygromycin promoter of the TopI-CreER(T2) targeting construct probably
responsible for the unsuccessful targeting in ES cells. The repair of the defective hygromycin promoter
can be achieved in a single cloning step by replacing a 1 kb NotI/SgfI fragment from the targeting
constructs with the same fragment from pGK-P-hygro.
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3. Discussion
3.1 The Mll2 multipurpose allele
The mll2 allele used in this study is versatile in its application. It is a null allele and a
reporter for mll2 expression in its original configuration and convertible to a
conditional allele. The inclusion of multiple features within one (i.e. multipurpose)
allele is achieved by (i) leaving the genomic organization of the locus intact, (ii)
insertion of a trap/reporter cassette that creates a null/reporter allele based on RNA
splicing, (iii) removal of the trap/reporter cassette by site-specific recombinase to
restore functionality of the allele, (iiii) conditional excision of an exon catalyzed by site-
specific recombinase to create a frame shifted allele. The incontestable merit of a
multipurpose allele is that the engineering of one targeted mutation can address several
allelic purposes. However, a null allele based on RNA splicing rather than destruction
of the genomic structure of the gene can comprise unforeseeable drawbacks. It is
impossible to reliably predict the splicing events that are going to occur from a locus
where a trap cassette has been inserted. In our targeting construct, we used 1.8 kb
genomic sequence of the homeobox gene engrailed 2 as splice acceptor, which included
the entire intron 1 and 158 nucleotides of exon 2. Although this sequence should
provide a strong splice acceptor, it could not be excluded that the splicing of exon1 of
mll2 to the trap cassette would be partial. An incomplete trapping of the transcript due
to alternative splicing bypassing the trap cassette could result in production of the full
length mRNA and therefore impede the creation of a null allele. However, no such
transcript could be detected in mll2 -/- embryos and ES cells, indicating that the splicing
of exon 1 to the trap cassette was complete. Interestingly, RNA splicing is not only
sequence specific but appears to be influenced by the position of the trap cassette
(probably dependent on mRNA secondary structure). While a trap cassette inserted in
the 5’ end of a gene often results in complete trapping, insertions in the 3’ end of genes
often produce incomplete trapping (German gene trap consortium, unpublished
communication). Therefore, our approach to introduce the trap cassette in intron 1 of
mll2 and having previously excluded alternative splicing of exon1 presumably
contributed substantially to the successful creation of the null allele.
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The mll2 conditional allele was created by Flpe mediated excision of the trap cassette.
This was achieved by breeding mll2+/- mice to hATPC:Flpe mice (Rodriguez et al.,
2000). Flpe recombination was partial in the F1 offspring, probably due to a rather long
distance (6.5 kb) between the FRT sites. However, an additional cross to hATPC-Flpe
mice produced heterozygous Flpe recombined offspring. In contrast to the null allele,
the mll2F (Flpe recombined) allele is similar to wild type and could be bred to
homozygosity.
Conditional mutagenesis of mll2 in vivo and in vitro was induced by Cre mediated
excision of loxP flanked exon 2. The presumed splicing of exon 1 to exon 3 in the
mll2FC transcript (Flpe & Cre recombined) would create a frame shift and a nonsense
mutation in exon 3. Cloning and sequencing of an RT-PCR product confirmed the
exclusive splicing of exon 1 to exon 3. Surprisingly, the frame shifted mll2 transcript
was still detectable at reduced levels by Northern blot and RT-PCR and not fully
eliminated by nonsense-mediated mRNA decay. This raised the issue if N-terminally
truncated mll2 protein could still be translated from the mutated transcript. The
initiation of translation occurs by assembly of ribosomes at the 5’ end of an mRNA.
Subsequently, the ribosomes “scan” the mRNA to find the initiating AUG triplet. In this
process, it is not always the most 5’ AUG that is preferred as translation start site, but
usually the triplet embedded in what most resembles a Kozac consensus sequence
(ccA/Gcc AUG G ). In the mll2 transcript, the 3rd methionine-coding triplet (position
948), which is downstream of the created stop codon, corresponds to a Kozac consensus
sequence. In an adversarial scenario, ribosomes would assemble at the 7’cap, skip the
created stop codon and start in frame translation at the 3rd AUG triplet, which would
yield a negligibly shorter protein (Δ 316 aa). However, this possibility was excluded by
demonstrating complete absence of Mll2 protein by western blot in tissue of induced
mice (except brain see section 2.3.3) and ES cells.
The null allele and the frame shifted allele are identical in the sense that both are null
alleles. However, the mechanisms behind the two alleles are quite different. While the
mll2- allele relies on trapping and truncation of the endogenous transcript, the mll2FC
allele relies on frame shifting of the transcript. We compared the two alleles by breeding
them to homozygosity in mice. The observed embryonic lethal phenotype was identical
and additionally proved both alleles to be equivalent.
As described in section 2.2.1 the transcript of the null allele produces two proteins; The
LacZneo fusion protein is translated from the IRES while a presumed 161 aa protein is
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translated from the endogenous translation start site. This protein consists of 121 aa of
Mll2 coded by exon 1 and 40 mutated aa coded by frame shifted exon 2 of the engrailed
2 gene that served as splice acceptor for the trap cassette. It is unlikely that this new
protein has a gain of function effect and influences the phenotype, as it does not include
any conserved protein domain. Moreover, mll2+/- embryos that produce this truncated
protein from one null allele did not show any abnormality. However, a dosage
dependent effect of the 161 aa protein cannot be fully excluded. Indeed, a similar
protein consisting of 121 aa coded by exon 1 of mll2 and 19 mutated aa coded by frame
shifted exon 3 is translated from the mll2FC transcript. The similarity of both alleles in
embryogenesis could therefore not exclude the possibility of an influence of the
proteolytic side products of both alleles.
We conclude that the multipurpose mll2 allele successfully accomplished three different
purposes. Its design therefore represents a valuable enhancement to currently applied
strategies in mouse genetics.
3.2 The Rosa26-CreER(T2) allele
The embryonic lethal phenotype of mll2 -/- embryos between E8.5 and E11 obliged us
to apply a conditional knockout strategy to study the function of the gene at later time
points. We used the ability of the Cre recombinase to catalyze the excision of DNA
flanked by loxP recognition sequences to mutate Mll2. Temporal control of Flp- and
Cre-mediated recombination has been achieved with a recombinase fused to the
hormone-binding domain of the mutated estrogen receptor (Logie et al., 1995; Metzger
et al., 1995 and section 1.2.2). The fusion protein becomes active upon administration
of the synthetic ligand tamoxifen, but not in the presence of the natural ligand
17β−estradiol (Feil, 1996). For this analysis, we have used the mouse strain Rosa26-
CreER(T2) (Seibler et al., 2003) that utilizes a triple mutated ligand binding domain
ER(T2) with approximately 10 fold higher binding affinity to tamoxifen than the single
mutated ER(T) domain used for the Rosa26-CreER(T) line (Vooijs et al., 2001). The
ubiquitous expression of Cre-ER(T2) from the Rosa26 locus allowed induced
mutagenesis of Mll2 in all tissues of embryos, neonates and adult mice.
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Partial Cre recombination without administration of the ligand was detected in tail DNA
of approximately 15% of mice with the conditional mll2F and the Rosa26-CreER(T2)
allele. Thus, the leakiness of ligand regulated Cre occurred only individually and is not
a general feature of the system, as is the case for the tetracycline inducible system tet-on
(Gossen et al., 1995). The observed ligand-independent Cre activity may be a
consequence of inappropriate nuclear transport or proteolysis of the Cre fusion protein,
sufficient to catalyze a low level of recombination. The leakiness could be fully
eliminated from the analysis by excluding the partially recombined mice.
We have cultured mouse embryonic fibroblasts (MEFs) and ES cells homozygous for
the mll2F and the Rosa26-CreER(T2) alleles and tested the in vitro induction of the Cre
recombinase by using serial dilutions of 4-hydroxytamoxifen (4-OHT). The
recombination of the mll2F allele in ES cells was over 97% after 24 hours treatment
with 100 nM 4-OHT (data not shown, see diploma thesis of Daniela Röllig). By using
an Mll2 specific antibody that was validated using mll2-/- ES cells (see thesis of Julia
Schaft), we observed complete absence of the protein after 5 days of 4-OHT treatment.
A more detailed analysis of Mll2 protein levels at earlier time points of induction
indicated that the protein is lost after 72 hours of 4-OHT treatment. Thus, the
approximate half-life of Mll2 protein in ES cells is 48 hours (diploma thesis Daniela
Röllig).
For induction of the mll2F allele in vivo two protocols for administration of tamoxifen
to mice were tested; Oral feeding of a tamoxifen/oil solution (gavage) or injection (i.p.)
of 4-hydroxytamoxifen dissolved in oil. In agreement with previous studies
(Kuehbandner et al., 2000), both protocols gave identical recombination efficiencies.
We preferred the gavage protocol, as the LD50 of tamoxifen in mice is 15-fold higher
via the oral route than by i.p. injection (200mg versus 5g/kg, Seibler et al., 2003). In
addition, orally administrated tamoxifen is probably efficiently metabolized to 4-
hydroxytamoxifen in the liver of the mouse. We could therefore restrict the use of
costlier 4-hydroxytamoxifen to in vitro inductions. We analyzed the recombination rates
of the conditional mll2F allele using different concentrations of tamoxifen with the goal
of achieving the highest possible rate in all tissues. A dose-response experiment
indicated that the extent of recombination is highly dependent on the amount of
tamoxifen given to the mice. A daily dose of 2.5 mg tamoxifen for 5 days resulted in
incomplete recombination in most tissues and no recombination in the brain. However,
the use of 4mg and 7mg yielded full recombination in all tested tissues and 30% or 50%
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recombination in the brain, respectively. The limited degree of recombination in the
brain may reflect a lower local concentration of ligand due to the blood-brain barrier
rather than a reduced expression level of CreER(T2) (Seibler et al., 2003). The standard
protocol for all further induction experiments was gavage of 5 mg tamoxifen per day for
5 consecutive days, a treatment that caused no side effects on 28 tested ωιλδ τψπε
mice.
In addition to induction of adults, we induced recombination in embryos and neonates
by feeding pregnant or lactating females tamoxifen, respectively. Previous studies
describe the induction of a ligand regulated Cre-ERT M in utero by a single,
intraperitoneal injection of tamoxifen into a pregnant mouse at E8.5 postcoitum
(Danielian et al., 1998; Hayashi et al., 2002). The transgenic CAGGCre-ERTM line used
displayed dose-dependent recombination (0.5 to 9 mg i.p.), with higher doses giving
more LacZ reporter activity (50 to 95 %). However, injections of tamoxifen doses
above 3 mg at E8.5 caused pregnancies to fail after E 13.5, presumably due to the anti-
estrogenic properties of tamoxifen (Jordan et al., 1990). The cytotoxic effect of
tamoxifen on pregnancy was not observed in inductions at later developmental stages (E
11.5 and 14.5). The limitation of that study is the high concentration of ligand required
to activate the CreERTM, which is quite close to the tamoxifen concentration that
interferes with the maintenance of early pregnancy. Moreover, the obtained
recombination was variable and incomplete.
Due to the higher binding affinity of the ER(T2) for ligand, we obtained complete
recombination in embryos at various stages using two daily gavage doses of 5 mg
tamoxifen. Interestingly, mll2F embryos induced at early stages (E4.5 and E5.5)
recapitulated the embryonic phenotype of mll2 null mutants at E 10.5, which further
validated the effectiveness of the system. We are currently testing if two oral doses of 5
mg tamoxifen are tolerated by the females of early stages (E0.5 to E11.5) and permit
pregnancy to develop to term.
Finally, we have tested induction in neonates by feeding lactating mothers tamoxifen,
assuming that the milk would efficiently transmit the ligand. With 5 daily doses of 5 mg
tamoxifen to the mother during postnatal period P5 to P9, the recombination was
complete in all tissues and 30 to 50% in the brains of pups dissected at P13 to P15.
The superiority of RosaCreER(T2) mice for producing induced recombination is
diminished by a serious side effect of CreER(T2) expression. Clearly, we observed a
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high rate of illness and lethality in mMll2F/F;Rosa26CreER(T2) mice (74/172). Illness
occurred between the 5th and the 15th day after induction, with most cases from day 8 to
day 10. In contrast, the tamoxifen caused no side effect on wild type mice (0/28). The
first symptoms of illness were reduced mobility and constant weight loss that indicated
pronounced dehydration. During progression of the illness, mice sustained severe
diarrhea observable at the anus of animals. Dissections of sick mice revealed that the
entire intestine was filled with liquid. The gall bladder and stomach were distended and
the gastric content of sick mice had on average twice the weight as in wild type mice.
Surprisingly, the gastrointestinal phenotype was not caused by mutagenesis of mll2, as
it also occurred in control mice of the Rosa26-CreER(T2) line. In fact, the morbidity
seemed to originate from activated CreER(T2) protein. This conclusion is substantiated
by the observation that the diarrhea occurred in only 16% (13/82) of mice heterozygous
for Rosa26-CreER(T2), but in 76% (61/80) of homozygous mice. The 2 different strains
that were used, C57BL/6 or 129/ola, did not differ significantly the incidence of this
disease. Furthermore, the oil was not the cause of the diarrhea; pups homozygous for
Rosa26-CreER(T2) that did not receive oil but were induced by lactating mothers
developed an identical phenotype. Finally, as most inductions were performed outside
the Specific Pathogen Free (SPF) laboratory, we also induced mice inside the colony
under pathogen free conditions and observed a similar rate of illness. This excluded the
possibility that the diarrhea was a result of severe infection (i.e. as observed in INF-γ
k.o. mice), which could have implied an immunodeficiency triggered by the induction.
We assume that the diarrhea is caused by activated ER(T2) and not an effect of cre
activity. Several Cre lines including some with ubiquitous expression have proven that
constitutive recombinase activity does not produce such a severe phenotype (Schwenk
et al., 1995; Schmidt et al., 2000). In contrast, the Rosa26-CreER(T2) is the first line
that expresses the triple mutated ER-T2 (G400V/M543A/L544A) in all tissues. Indeed,
a tissue specific mouse line that expresses CreER(T2) only in germ cells does not
develop the illness (Weber et al., 2002). Therefore, we speculate that the diarrhea of
Rosa26-CreER(T2) mice is caused by the effect of activated fusion protein in one
specific tissue. Being aware of this tissue would leave the CreER(T2) sequence to be
applicable in lines specific for all other tissues. We have not identified the tissue
responsible for the phenotype, but we suspect that the gastrointestinal phenotype is
caused by a defect in the pancreas, as the pancreas of ill mice often looked brownish
compared to healthy mice.
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Further, no phenotype was reported from two previous ubiquitous CreER lines (Hayashi
et al., 2002; Vooijs et al., 2001). However, the authors apparently did not breed their
lines to homozygosity, which could have increased the chances of noticing a possible
phenotype. One of these lines, Rosa26-CreER(T), has an identical expression pattern of
the fusion protein but a different ER (G521R). This raises the issue as to whether only
the ER(T2) has a toxic effect, while other mutated ER versions (e.g. ER-T1 [G400V/
L539A/L540A]) produce no side effects and are more valuable for applications in the
mouse.
3.3 The Mll2 gene
Analyses of mice lacking Mll2 function have demonstrated that the gene is dispensable
in adults but essential during development. Mll2 -/- embryos failed in gestation between
E 8.5 and E11. The growth and differentiation of most tissues until mid-gestation was
retarded but not prevented in the absence of Mll2 function. However, completion of
embryogenesis is dependent on the activity of the gene. The phenotype is first
noticeable at E7.5 by a growth retardation of the mll2 -/- embryos compared to their
wild type and heterozygote littermates. During further development the retardation of
mutants increased gradually. Interestingly, the retarded mutant embryos still developed
normally until E 9.5 and were morphologically identical to E8.5 wild type embryos.
However, from E 9.5 mutants had widespread morphological abnormalities that affected
the entire body structure. Despite proper neurulation and closure of the head fold, the
neural tube appeared to be kinked, which is often a characteristic of a lack of paraxial
mesoderm. Indeed, while somites were visible in mutants at early stages, somite
development was clearly lacking at later stages. While the overall number of
proliferating cells is normal in mll2-/- embryos, there is a significant increase of
apoptosis throughout the whole embryo. In average, 20% of all cells where apoptotic in
Mll2 mutants, while less than 1% where apoptotic in wild type embryos. The elevated
apoptosis rate could account for the retarded phenotype without specific defects of early
mutants. Due to the increased elimination of cells, more proliferation events are
necessary to reach a critical cell number that could be required for progression in
development. The mechanism by which the absence of Mll2 leads to increased
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apoptosis is unclear. Possibly, Mll2 is directly involved as an inhibitor in the regulation
of apoptosis. If that was the case, overexpression of Mll2 should theoretically render
cells more resistant to apoptotic stimuli i.e. UV radiation, chemical insult, or serum
deprivation (possible future experiments). Alternatively, a widespread misregulation of
gene expression in cells lacking Mll2 function could initiate the cellular suicide
program. Indeed, we detected a misregulation of specific genes during embryogenesis;
Hoxb1, mox1 and six3 expression was absent in mll2-/- embryos at E9.5. Moreover,
normal expression of wnt1, brachyury, Shh, and otx2 in mutants at E10.5 indicated that
the absence of hoxb1, mox1 and six3 was specific and not due to a global failure of
transcription as could occur in a dying embryo. Further, expression of hoxb1 and mox1
was normal in mutants of earlier stages (E8.5). Mll2 mutants expressed mox1 from the
1 to 8 somite stage (E7.7 to E8.4), while all mutants at later stages had lost expression.
Interestingly, some mutants at the 10 somite stage showed a loss of mox1 expression in
anterior somites, while newly formed posterior somites still expressed mox 1. During
somitogenesis, a cyclic biological clock leads to formation of a new pair of somites
every 2 hours. Consequently, we conclude that the loss of mox 1 expression at the 10
somite stage occurred 20 hours after formation of the first somite pair. Therefore, Mll2
function is not required for initial expression of mox1 but is soon required to maintain
it. The role of Mll2 to sustain expression of specific homeotic transcription factors
supports the model of epigenetic maintenance. According to this model, the expression
of certain genes can be divided in two different phases. First, the establishment phase
produces the specific expression pattern of a gene, which is in part initiated by the
presence of transcription factors and DNA binding proteins. Second, the maintenance
phase epigenetically “locks” the active state of the gene and preserves the specific gene
expression. The maintenance of expression therefore becomes independent of the
initiating factors, which are often transiently available. The mechanism of maintenance
is not well understood, but probably involves alteration of methyl marks on histone
tails, which subsequently recruit activators of transcription and modify chromatin
towards an “active state”.  Mll2 methylates histones and is probably a major component
in a conserved pathway to maintain Hox expression, presumably by counterbalancing
the heterochromatic effects of the Pc-G genes.
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Fig. 54 (A) The “establishment phase” produces the specific expression pattern of a gene, which is in part
initiated by the presence of transcription factors and DNA binding proteins at the promoter and
recruitment of the basal transcription machinery. (B) The “maintenance phase” is characterized by
recruitment of epigenetic regulators like Trx2/Mll2 that subsequently “locks” the active state of the gene.
Due to this mechanism, the established expression pattern is preserved even in absence of the initiating
factors. The mechanism of maintenance is not well understood, but probably involves alteration of methyl
marks on histone tails, and/or recruitment of activators of transcription i.e. the histone acetyltransferases
CBP/p300.
During embryogenesis, Hoxb1 expression starts at E7.5 and is subsequently lost in Mll2
mutants at E9.5. As this is when morphological abnormalities are first observed, it is
likely that they are an effect of the loss of expression of this and several other potential
target genes. However, it is not clear whether the embryonic lethality is a consequence
of the specific defect in maintenance of homeotic genes. Alternatively, the increased
apoptosis could perturb unspecifically and cause a lagging of development, which
culminates in lethality. We tested this possibility by induced mutagenesis of mll2 in
conditional embryos. Pregnant females were induced at various stages (E4.5 to E 19) by
tamoxifen gavage, which produced recombination efficiencies in embryos of up to
100%. Consequently, we obtained litters where all embryos were mutants (6-12
embryos) as opposed to the conventional approach where intercrosses of heterozygous
mice yield 25% mutants per litter (1-3 embryos). We propose that a variation of this
approach where induction is performed at fertilization (if possible) could greatly
facilitate the analysis of any embryonic lethal phenotype. The earliest time of induction
in our analysis was E4.5, which presumably results in full recombination at E5.5 and
complete absence of mll2 protein between E6.5 and E7.5. Induced embryos dissected at
E10.5 fully recapitulated the mll2 null allele phenotype. Consequently, the absence of
Mll2 from E6.5 is sufficient to recapitulate the null phenotype and indirectly indicates
that the protein is dispensable until gastrulation. Moreover, the delayed removal of mll2
protein in induced embryos did not change their phenotype compared to null embryos.
A B
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Clearly, this excluded a nonspecific, cumulative deficiency and indicated a specific
requirement for mll2 function between E7.5 and E11. As mll2 is dispensible in adults,
we performed further inductions at E7.5, E12.5 and E16.5 and dissected embryos 5 days
later. Surprisingly, none of the induced conditional mutants had any morphological
abnormalities. The induction at E7.5 presumably leads to absence of the protein
between E9.5 to E10.5, therefore the essential Mll2 function could be restricted to the
period from E7.5 to E10.5. However, it remains to be investigated if embryos induced at
E7.5, which are viable at E11.5, develop to term and are born as healthy pups.
Fig. 55 Presence of Mll2 protein during embryogenesis of null mutants and induced mutants. E4_10:
Tamoxifen gavage of pregnant females at E4 results in absence of mll2 protein at E6. Dissections at E 10
revealed an identical phenotype as null mutants (red cross). Inductions at E8 and E 11 result in absence of
mll2 protein at E12 and E16, respectively. Dissections of these embryos 5 days after induction revealed
no abnormalities compared to cotrol embryos (green cross).
In adults, mutagenesis of mll2 did not cause any detectable abnormalities during their
lifetime. Therefore, Mll2 function is dispensable in most tissues. However, both males
and females were sterile after induction. The infertility of males was caused by
apoptosis of spermatogonia, which indicated an essential function of Mll2 in this cell
type. Other unipotent stem cells located in the gut epithelium, skin and bone marrow
were not affected. Circulating WBC were fully recombined and therefore originated
from mll2-/- haematopoietic stem cells. Furthermore, histological analysis of the gut
epithelium revealed no increased apoptosis after induction. The relatively mild
phenotype could be a result of functional compensation from other epigenetic regulators
or might indicate the presence of different parallel regulatory pathways, which for Mll2
would most likely be the close homologue Mll.
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Fig. 56 Mll2 phenotype in ES cells, mouse embryonic fibroblasts (MEF), embryonic development an
adult mouse.
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4. Methods
4.1 DNA methods
4.1.1 Restriction enzyme digestion
DNA fragments are cleaved with commercially available restriction enzyme. For
calculation of the amount of enzyme, the following rule is applied: 1 unit of restriction
enzyme cuts 1 µg DNA within 1 hour.
Every enzyme is used with its corresponding buffer in 1x concentration. The optimal
temperature and further information about conditions for every digest is gathered from
the New England Biolabs (NEB) catalogue. Incubation is at least 1 hour.
x µl DNA (1 – 10 µg)
2 µl NEB buffer
1 µl restriction enzyme
add to 20 µl with sterile water
4.1.2 Ligation
DNA ligations were set up by mixing vector and insert DNA (insert in three fold molar
excess to vector) in a volume of 10 µl with one unit DNA T4 ligase and the buffer
suggested by the supplier. The reaction was incubated at 16°C for 1 hour or o/n. The
ligation is ATP dependent, which is supplied in the 10x buffer. 10x buffer was stored at
– 20ºC and replaced by a fresh vial after 1-2 years.
x µl fragment DNA
y µl vector DNA
add to 8 µl with sterile water
1 µl 10x buffer
1 µl T4 Ligase
4.1.3 Transformation of chemical competent E.coli cells
• Thaw competent cells on ice.
• Add about 10ng DNA in 5 µl H2O.
• Leave 15 min on ice.
• Heat shock 100s at 42°C.
• Leave the tubes for 4 min on ice then add 800µl LB-media
• For Ampicilin:  0 to 30 min at 37°C shaking at 12000 rpm
• For Kanamycin: 60 min at 37º C shaking at 12000 rpm
• Spin down 4000 rpm for 4 min at RT.
• Take off 850µl, resuspend cell pellet in the remaining 150µl and plate on
agarose plates containing the appropriate selection marker.
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4.1.4 Preparation of chemical competent E. coli cells
• Grow cells on agar plate (e.g. XL-1 blue on tet)
• start from single colony
• grow a 5 ml o/n culture
• inoculate 4 ml into 200 ml LB medium [30 µg/ml] Tet
• Grow to OD600 = 0.35
• spin 10 min. at 3000 rpm at 4ºC (e.g. 4 x 50 ml Falcon tubes )
• resuspend pellet in 40 ml icecold buffer ( 4 x 10 ml per tube )
• 2nd spin 10 min. at 3000 rpm at 4ºC
• resuspend in 20 ml icecold buffer + 800 µl DMSO ( 4 x 5 ml per tube)
• divide into 200 µl aliquots and snap freeze in liquid N2
100 ml 2x Zout
12 ml 1M CaCl2 (147 g/mol)
  8 ml 1M KAc ( 98 g/mol) Potassium acetate
30 g Sucrose
Adjust pH with acidic acid to 5.6 – 5.9 ( 2 drops of 1M)
Filter sterile and keep at –20ºC
Buffer (prepare fresh)
30 ml 2x Zout
5.4 ml 0.5M MnCl2
0.72 g RbCl (Rubidium chloride)
24.6 ml water
4.1.5 Mini preparation of plasmid DNA
• Transfer 1 ml of o/n culture into an Eppendorf tube.
• Spin 2 min at 16,000 x g at RT, remove supernatant and resuspend the bacterial
pellet in 200 µl P1 buffer.
• Add 200 µl P2 buffer, mix by inverting.
• Add 200 µl P3 buffer, mix by inverting.
• Leave 15 min at RT to let the RNAse in P1 work, then cool 5 min on ice.
• Spin at 16,000 x g for 3 min.
• Transfer supernatant, containing plasmid DNA, into a 2- ml Eppendorf tube.
• Add 30 µl (5% vol.) P3 for precipitation
• Precipitate DNA to remove residual salt by adding 900 µl isopropanol, invert
• Spin 10 min at 16,000 x g at RT
• Wash pellet with 70% ethanol
• Dry pellet for 5 min
• Resuspend in 50 µl water or TE and use 10 µl for analytic restriction digests.
P1 buffer:
50mM Tris-HCl, pH 8
10mM EDTA
100 µg/ml RNAse A
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P2 buffer:
200mM NaOH
 1% SDS
 
 P3 buffer:
 3 M potassium acetate
4.1.6 Maxi preparation of plasmid DNA
The principle of this method is based on alkaline lysis of the bacterial cell, followed by
binding of the plasmid DNA to an anion-exchange resin under appropriate low-salt and
pH conditions. RNA, proteins and low-molecular-weight-impurities are removed by a
medium salt wash. Plasmid DNA is eluted by a high salt buffer, and then concentrated
and desalted by isopropanol precipitation.
• Inoculate a starter culture of 200 ml LB medium, containing the appropriate
selective antibiotic, and grow o/n at 37˚C, shaking 300rpm.
• Harvest the bacterial cells by centrifugation 6,000 x g for 10 min at 4˚C
(Beckman JLA 16.250 250 ml)
• Resuspend the pellet in 10 ml buffer P1.
• Add 10 ml buffer P2, mix gently by inverting, then incubate at RT for 5 min
• Add 10 ml buffer P3. Mix immediately by inverting, then incubate on ice for 20
min
• Separate aqueous phase from precipitate by pouring through a filter (Falcon)
funnel.
• Equilibrate the QIAGEN-tip 500 by applying 10 ml QBT buffer (1/3 of
column), and allow the column to empty by gravity flow.
• Apply the supernatant to the column and let it enter by gravity flow
• Wash twice with 30 ml QC buffer (1 column vol.), then elute DNA with 15 ml
buffer QF.
• Precipitate DNA by adding 10.5 ml (= 0,7 volumes) isopropanol to the eluted
DNA.
• Mix and spin 30 min at 15,000 x g at 4˚C
(Beckman JS 13.1 30ml Corex glass tubes with adaptor)
• Wash pellet with 70% ethanol, and spin at 10,000 x g for 10 min.
• Dry the pellet and dissolve the DNA in 300 µl TE, adjust to [1 µg/µl]
 QBT buffer:
 750mM NaCl
 50mM MOPS
 15% isopropanol
 0.15% triton X-100
 
 QC buffer:
 1 M NaCl
 50mM MOPS
 15% isopropanol
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 QF buffer:
 1.25 M NaCl
 50mM Tris, pH 8.5
 15% isopropanol
 
4.1.7 Maxi preparation of BAC DNA
For purification of large amounts of BAC (Bacterial artificial chromosomes), a
modified version of the protocol described in section 4.1.6 was used. The amount of
buffers P1, P2 and P3 where duplicated (20ml instead of 10ml each). The elution buffer
QF was heated to 65ºC before elution of DNA. For cloning purposes, this method
yielded BAC DNA of sufficient quality. However, is BAC DNA is used for ES cell
electroporation (targetings and stable lines), a purification by CsCl centrifugation is
highly recommended.
4.1.8 DNA precipitation
• Add sodium acetate to a final concentration of 0.3M, mix by inverting.
• Add to a final concentration of 70% ethanol, mix by inverting.
• Spin 15 min at 16,000 x g 4°C
• Decant the supernatant and wash pellet with 70% ethanol.
• Spin 15 min at 16,000 x g at 4°C , decant supernatant.
• Dry the pellet and resuspend in an appropriate volume of H2O or TE.
4.1.9 Phenol-Chloroform extraction
 To remove proteins from your DNA mix, the sample has to be phenol extracted. After
adding phenol/chloroform and mixing, proteins will enter the organic phase, while
DNA will stay in the aqueous phase.
 
• Add 1 volume phenol/chloroform/isoamylalkohol (25:24:1) and vortex for 10s.
• Spin 5 min at 16,000 x g at RT
• Transfer upper water-layer into new tube and ethanol-precipitate.
4.1.10 Agarose gel electrophoresis
 DNA molecules become orientated in an electric field and migrate through a gel matrix
(in this case agarose) at rates that are inversely proportional to the size of the linear
fragment. Larger molecules migrate more slowly because of greater frictional drag and
because they find their way through the pores of the gel less efficiently than smaller
molecules.
The gels used contained 0.4% to 3 % agarose. Low agarose concentrations are suitable
for separation of large fragment sizes, while higher concentrations where used for small
fragments. Higher agarose concentrations yield sharper bands and are preferable if
small size differences have to be resolved.
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Linear fragment size % agarose
30 kb to 15 kb        0.4 %
15 kb to 1 kb      1 %
2.5 kb to 0.1 kb      2 %
< 100 bp      3 %
DNA samples were mixed with 1x DNA loading buffer, gels were run at 100 Volts
(5 –10 V/cm). DNA was visualized by 20ng/ml ethidium bromide.
For small gel electrophoresis, 1xTBE (Tris-borate) was used as running buffer. Gel
volume was 50 ml and running buffer volume 200 ml.
For large gel electrophoresis, 1xTAE (Tris-acetate) was used as running buffer. Gel
volume was 350 ml and running buffer volume 2 liters.
10x DNA loading buffer:
25% Ficoll
100mM EDTA
BFB and XCFF
TBE (0.5x): 5x TBE:
0.45 MTris 54 g Tris
0.45 Mboric acid 27.5 g boric acid
1mM EDTA (pH8) 20 ml 0.5M EDTA (pH 8)
add to 1 liter
TAE (1x): 50x TAE:
40 mM Tris242 g Tris
1 mM EDTA 57 ml glacial acetic acid
100 ml 0.5M EDTA (pH 8)
add to 1 liter
4.1.11 Polymerase Chain Reaction (PCR)
 The PCR reaction is divided into 3 steps:
1. Denaturation of the DNA template
2. Primer annealing
3. Polymerisation
 All steps were performed in consecutive cycles in a Stratagene Robocycler PCR
machine. The PCR product is a double stranded DNA, consisting of the region of the
complementary strain between the flanking primers. For establishment of difficult
genomic PCR reactions, MgCl concentration where varied and DMSO was added. Used
DNA concentrations are crucial, as genomic PCR reactions are inhibited when too
much template is used. Moreover, Phenol extraction of DNA prior to PCR improved
results.
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PCR mix:
5 µl 10x PCR reaction buffer
2.5 µl 1.2 mM dNTP
(stock 25mM ; 4x 10 µl [100mM] A/C/T/G in 360 µl water)
(2.5 µl) (optional 5% DMSO)
0.5 µl 1µM antisense/sense primer  (stock [100 pmol/µl] )
x µl 10 ng – 200 ng template DNA
0.5 µl 2.5 units Taq polymerase
add to 50 µl with sterile water
Reaction conditions vary among different experiments, but are usually conformed to the
following cyclic pattern: 1 min initial denaturation at 94°C, 35 cycles consisting of 1
min denaturation at 94°C, 1 min annealing at the relevant temperatures (depending on
the primer composition) and variable times of extension at 72°C depending on the size
of the PCR product. The last cycle was 10 minutes of additional extension at 72°C.
4.1.12 PCR product purification
For extraction PCR products where loaded on an agarose gel and extracted with the
agarose gel extraction kit from QIAGEN. DNA fragments ranging from 80bp to 10 kb
binds to silica-membrane of the columns in the presence of high salt concentrations.
Short oligos (most primers), nucleotides, salts and polymerases pass through during
washing steps, while the PCR product is eluted from the column with TE or water.
• Excise the band from the gel using a UV plate and a blade. (Protect from UV
light with googles and gloves and minimize time of exposure of DNA)
• Weigth the gel piece and add 3 volumes PB buffer
• Shake 10 min at 55ºC
• Apply on column and spin 30 sec at 10,000 x g.
• 2x wash with 750 µl PE buffer, discard flow-through
• Spin once more after removal of 2nd wash
• Place QIAquick into a clean 1.5-ml eppendorff tube, add 50 µl TE, let stand for
5 min and spin 10,000 x g for 30 sec to elute DNA.
4.1.13 Cloning of PCR products and DNA fragments
Purified PCR products or DNA fragments were cloned with the TOPO-TA cloning kit
(Invitrogen) using a modified protocol provided by the supplier. The ligation reaction
was incubated for 5 min. at room temperature and transformed in E.coli cells as
described in section 4.1.3. We reduced the volume of used pCR-TOPOII vector from 1
µl to 0.2 µl per ligation reaction.
1 to 4 µl DNA
1 µl salt solution
0.2 µl pCR-TOPOII vector
add to 6 µl with water
• incubate 5 min at RT before transformation
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4.1.14 DNA extraction from ES cells
• Remove media from confluent layer of ES cells in 24-well plate. This will yield
about 30-40 µg genomic DNA.
• Add 500 µl lysis buffer and incubate o/n at 37°C.
• Take the 500 µl cell lysate and transfer into 1ml-tubes
• Add 500 µl phenol/chlorophorm/isoamylalcohol (25:24:1) and rotate 1 hour on a
rotating drum
• Spin for 10 min at 10,000 x g at RT, transfer 500 µl aqueous phase into new
tube
• Add 500 µl Chlorophorm and rotate 1 hour on a rotating drum
• Spin for 10 min at 10,000 x g at RT, transfer 500 µl aqueous phase into new
tube
• Add 25 µl P3 / 400 µl isopropanol, mix, and take of supernatant (without spin)
• Wash with 70% Ethanol and spin 5 min at 10,000 x g at RT
• Take off supernatant and let pellet dry for not longer than 2-5 min
• Add 100 µl TE and incubate for 2 hrs at 37°C with gentle shaking
• The average DNA concentration should be 0.5-1 µg/µl
Lysis buffer:
50mM Tris-HCl, pH 8
100mM EDTA
100mM NaCl
1% SDS
just before use add 0.5 mg/ml Proteinase K
Proteinase K stock:
dissolve 100 mg Proteinase K in 10 ml water, aliquot at 1 ml and store at –20 ºC.
4.1.15 DNA extractions from mouse tails
• Add 400 µl lysis buffer to the mouse-tail and incubate at 55°C o/n
• Add 400 µl phenol/chlorophorm/isoamylalcohol (25:24:1) and incubate in a
rotating wheel for one hour.
• Spin 9,300 x g for 10 min at RT.
• Transfer supernatant into new tube, add 400 µl chlorophorm and incubate again
for one hour in a rotating wheel.
• Spin 9,300 x g for 10 min at RT.
• Transfer supernatant into new tube and add 3M potassium acetate, pH5.5 to 5%.
• Mix and add isopropanol to 70-80%. Shake hard by hand to precipitate DNA
and let the DNA sink to the bottom of the tube.
• Take off supernatant and wash pellet with 70% Ethanol.
• Spin 9,300 x g for 5 min at RT.
• Discard supernatant. Remove excess liquid by pipetting and air-dry for 2-5 min.
• Resuspend DNA pellet in 200 µl TE and incubate for 2 hrs at 37°C with gentle
shaking
• The average DNA concentration from 0.5 cm tail cuts should be 50 - 200 ng/µl.
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4.1.16 Southern analysis
For southern blot analysis, restriction digested DNA is separated on a standard agarose
gel and transferred onto a nylon membrane. The membrane can be hybridisation with a
radiolabelled probe that binds a specific DNA fragment. Southern blotting was carried
out with genomic DNA to verify homologous integration of the mll2 targeting construct
into the genomic mll2 locus, and to assess cre recombination efficiencies of the
conditional mll2F allele. Furthermore, southern blotting of plasmid DNA, cosmid DNA,
or BAC DNA was used for restriction digest mapping and verification of cloning
procedures.
• Digest 7-10 µg of genomic DNA with the desired restriction enzymes o/n
x µl DNA
6 µl NEB buffer
6 µl restriction enzyme
add to 60 µl with water
• Adding 2 x 3 µl restriction enzyme (morning and evening) improves digest
efficiency. Essential for good genomic southern results is the use of ideal
restriction enzymes, which are not blocked by CpG methylation. Good enzymes
are EcoRI, PstI, KpnI, and NcoI.
• Add 1x gel running buffer and load onto a 0.7% TAE gel
(No EtBr in the agarose, EtBr may be added before loading to the marker)
• Run gel 24 hours at 20 - 40 V in 1x TAE at 4°C
• Take a picture under UV light with a ruler aligned next to the marker
• (Depurinate 20 min in HCl, often decrease quality)
• Denature gel 2x 15 min in 0.4M NaOH
• Neutralize 1x 20 min in 10x SSC
• Label nitrocellulose membrane (0.45 µm), wet in water than 10x SSC
• Blot onto a nitrocellulose membrane in 10x SSC o/n.
• Mark slots with pencil on the membrane, rinse in 6x SSC and vacuum dry for 2
hours at 80°C
Depurination solution
37% HCl 10 ml
add water to 1 liter
Denature solution
NaCl 87 g
NaOH pellets 20 g
add to 1 liter
Neutralisation solution
NaCL 87 g
Tris 121 g
37% HCl appr. 50 ml
20x SSC
NaCl 175 g
tri-Sodium citrate dihydrate 88 g
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add to 1 liter with water
Radioactive DNA probe:
• Use the random primed DNA labeling kit (Roche)
• Use 50-100 µg DNA fragment and add vol. to 11 µl with water
• Denature 10 min at 100°C and subsequent cooling on ice.
• Add 4 µl High prime (enzyme, primer, and nucleotide mix, Roche)
• Add 5 µl [α32P]dCTP (50 µCi)
• Incubate for 60 min at 37°C.
• Spin (5 min) a G-50 sephadex column inserted in a cut 2 ml Eppi in a 12 ml
Falcon
• Load 20 µl reaction volume
• Spin 5 min at 16,000 x g at RT.
• Collect flow through from Eppendorf tube and determine volume
(50 to 200 µl)
• Mesure activity of 1 µl and calculate total activity (usually 1 - 5 x 107 CpM)
• For hybridization, use about 2x107 counts per 10x10 cm membrane
 
Radioactive RNA probe:
 
 A T3 or T7 polymerase reaction with radioactive labeled dUTP is used to transcribe an
RNA-probe from a DNA fragment.
 
• Digest 5 µg plasmid DNA with the appropriate restriction enzyme
• For antisense probe use a cutting site on the 3’end and the polymerase
transcribing from the 5’ end of the insert
• Extract DNA with Phenol/Chloroform and check an aliquot on an agarose gel
Transcription-mix: 1µg linearized DNA
1x transcription buffer (Stratagene)
 1mM rATP, rGTP, rCTP
60 µCi UTP32
 5 units RNAsin
5 units T3 or T7 Polymerase
• Incubate at 37°C for 15 min.
• Add 5 units RQ-DNAse to destroy the template for transcription
• Incubate at 37°C for 15 min
• Measure activity
 
Hybridisation
• Wet the membrane in 25mM NaHPO4 and roll it into a glass tube.
• Add 10 ml Hybridisation buffer to the tube and pre-hybridise for 30 min in a
turning oven at 72˚C for RNA probes, at 64 to 67˚C for DNA probes.
• Denature the probe for 5 min. at 95ºC and add to the tube
• Hybridize o/n.
• For washing, prewarm wash buffer on heater to 55ºC (Thermometer!)
• 1st wash rinse briefly
• 2nd and 3rd wash (usually 30 min.) according to radioactive radiation
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(should be below 5 CpM similar to background count)
• Wrap membrane in saran and expose 24 hours on phosporimager plates,
2 to 14 days on Kodak MR films in a film cassette at –70ºC
1M Hybridization stock (Church)
Sodium hydrogen phosphate 71 or 89g 
(Na2HPO4)
Adjust pH to 7.2 with
Phosphoric acid (H3PO4) 2-3 ml
1x Hybridisation buffer:
250mM Na2HPO4  pH 7.2 50 ml 1M stock
7 % SDS 35 ml 20% stock
water 15 ml
1% BSA 1 g
1mM EDTA 100 µl 0.5M stock
wash buffer:
20mM NaH2PO4  pH 7.2 40 ml 1M stock
1% SDS 50 ml 20% stock
1mM EDTA 2 ml 0.5M stock
add to 1 liter with water
20% SDS:
(Wear a mask for weighting SDS powder)
Dissolve 200 g SDS o/n in 1 liter water
4.1.17 ET cloning
In E.coli, the classical homologous recombination pathway involves RecA as a strand
invasion protein and the RecBCD complex as the major cellular exonuclease. Since
RecBCD also plays a role in recognition and destruction of foreign linear DNA, it is
impossible to introduce a linear fragment of DNA for homololgous DNA engineering.
Hence homologous recombination in E.coli has proven to be a difficult process.
The alternative to the recA based pathway is ET/Red recombination developed by
Zhang et al. in 1998. Homologous recombination is initiated by either of the two
functionally equivalent protein pairs: RecE/RecT from the Rac phage and Redα/Redβ
from the λphage (Zhang et al., 1998; Muyrers et al., 1999). RecE and Redα are 5’→3’
exonucleases, while RecT and Redβ are DNA single strand annealing proteins (Muyrers
et al., 2000). They serve to circumvent both RecA and RecBCD whereas RecBCD-
strains can be used. Alternatively, Rec BCD can be inhibited by expression of the Redγ
protein so that use of linearized DNA is possible.
In the fundamental reaction, a linear DNA molecule carrying a selectable marker flaked
by 40-60 bp regions of sequence homologous to the desired integration location on a
circular DNA molecule. The recombinogenic, linear DNA fragment can be generated by
PCR with oligonucleotides containing 3’ the PCR primer sequence and 5’ the 40-60 bp
homology arm.
ET/Red recombination has proven to be successful in cloning of regular plasmids,
BACs and the E. coli chromosome with a very high efficiency rate. In this thesis ET
cloning was applied to modify the knock out cassette for Trx2 and for the creation of
the EYFP-Trx2 targeting cassette.
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PCR reaction and recipient plasmid DNA preparation
• PCR mix: 10-20 ng template DNA
1 µM 5’ primer and 3’ primer each
1x PCR reaction buffer (Roche)
0.2mM dNTP
2.5 units Taq polymerase (Roche)
fill up with dH2O to 50 µl final volume
• Perform PCR in Stratagene robocycler:
• PCR protocol: 3 min 94°C 1 min 94°C
40 sec 62°C
1 min 72°C 35 cycles
10 min 72°C
• Pool PCR products, add 400 U DpnI, 1x NEB-buffer4 and fill up with dH2O to
150 µl volume.
• Perform DpnI digest at 37°C for two hours to remove residual template DNA.
• Ethanol-precipitate digestion-mix and resuspend in 10 µl dH2O.
• For cotransformation extract recipient plasmid DNA with Phenol/Chlorophorm
and resuspend in in dH2O at 1 µg/µl.
Preparing electro-competent cells
• Prepare 10% glycerol with dH2O, and cool down for at least three hours before
usage.
• Grow  5 ml o/n cultures of DH10B-YZA cells in 5 µg/ml tetracycline.
• Make a hole in the lid of an eppendorf tube and dilute o.n culture 1:50 in 1.4 ml
fresh selective medium.
• Grow for 2 hrs at 30°C with shaking to an OD600  of 0.2.
• Add arabinose to a concentration of 0.1-0.2%.
• Transfer to 37°C and continue growing for about one hour until cells reach log
phase (OD600= 0.35-0.4).
• Spin down the cells at 11,200 x g for 30 sec at 4°C.
• Discard the supernatant, place the tube on ice and resuspend pellet in 1 ml
icecold 10% glycerol.
• Spin down the cells at 13,400 x g for 30 sec at 4°C.
• Discard the supernatant, place the tube on ice and resuspend pellet in 1 ml
icecold 10% glycerol.
• Spin down the cells at 13,400 x g for 30 sec at 4°C.
• Discard the supernatant, leaving 20-30 µl to resuspend pellet in the remaining
solution.
• Use cells immediately for best transformation efficiency or snap freeze in liquid
N and store at -80°C.
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Electro-Transformation
• Precool 1-mm-cuvettes on ice for 5 min.
• Thaw electrocompetent and arabinose-induced cells on ice (or use them straight
after preparation). Add 1 µl PCR product (corresponds to 2-3 µg/0.2-0.3 pmol)
and 1 µl recipient plasmid (corresponds to 1 µg/0.1-0.2 pmol).
• Co-Electroporate the cells at 1200 V.
• Immediately add 1 ml LB medium and transfer back into eppendorf tube.
• Incubate at 30°C for 70 min shaking at 1200rpm.
• Spin at 5000 rpm for 2 min, aspirate the supernatant, but leave 100 µl liquid.
• Resuspend the cells in the remaining liquid, plate on appropriate antibiotic and
incubate o/n at 37°C.
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4.2 RNA methods
4.2.1 Diethylpyrocarbonate (DEPC) – treated water
• Add 1 ml of DEPC to 1 liter of water (0.1% solution), use up opened aliquot
(hydrolizes quickly and can therefore not be stored)
• Let stand for 1 hour at 37ºC  or o/n at RT and autoclave 15 min at 15 psi on
liquid cycle
Glassware and plasticware should be filled with fresh 0.1% DEPC and allowed to stand
o/N at RT.
4.2.2 Total RNA extraction from cells
• Grow ES on 10-cm-dish to confluence.
• Wash once with PBS, add 1 ml TRI REAGENTTM and collect cell lysate with a
sterile cell scraper. Pass several times through a pipette to form a homogenous
lysate.
• Let samples stand for 5 min at RT.
• Add 0.2 ml chlorophorm per ml of TRI REAGENTTM
• Shake vigorously for 15 sec and allow to stand for 2-15 min at RT
• Centrifuge 15 min at 12,000 x g for at 4°C. Centrifugation separates the mixture
into 3 phases: a organic phase containing protein, an interphase containing
DNA, and a colorless upper aqueous phase containing RNA.
• Transfer the aqueous phase to a fresh tube and add 0.5 ml isopropanol per ml of
TRI REAGENTTM
• Mix and let sample stand for 10 min at 4°C.
• Centrifuge 10 min at 12,000 x g at 4°C.
• Remove the supernatant and wash the RNA pellet by adding 1 ml 75% Ethanol
per ml of TRI REAGENTTM used.
• Vortex the sample and centrifuge for 5 min at 12,000 x g at 4°C.
• Samples can be stored in ethanol up to one year at -20°C.
• Air-dry the RNA pellet for 5 min. and resuspend in 50 µl RNAse free H2O and
store at -80°C
4.2.3 Total RNA extraction from tissue
• Use 100 mg tissue and cut into little pieces with scissors
• Add 1 ml TRI REAGENTTM
• Let samples stand for 5 min at RT.
• Add 0.2 ml chlorophorm
• Shake vigorously for 15 sec and allow to stand for 2-15 min at RT
• Centrifuge 15 min at 12,000 x g for at 4°C
• Transfer the aqueous phase to a fresh tube and add 0.5 ml isopropanol
• Mix and let sample stand for 10 min at 4°C.
• Centrifuge 10 min at 12,000 x g at 4°C.
• Remove the supernatant and wash the RNA pellet with 1 ml 70% Ethanol
• Vortex the sample and centrifuge for 5 min at 12,000 x g at 4°C.
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• Air-dry the RNA pellet for 5 min. and resuspend in 50 µl RNAse free H2O and
store at -80°C
4.2.4 Northern blotting
• Pour a 1.2% agarose gel:
Use 150 ml water with 2.4 g agarose in a 600 ml beaker
boil 3 – 5 min until dissolved (water vol. will decrease)
add 40 ml 5x formaldehyde running buffer
add 35.5 ml 37% formaldehyde (6 % final)
pour gel under hood
• Use 30µg total RNA per lane:
2 µl 5x
3.5 µl formaldehyde
10 µl formamide
x µl RNA
add to 27 µl with DEPC water
• heat 15 min. at 65ºC then put on ice
2 µl RNA loading dye
1 µl EtBr [1 mg/ml] in DEPC
• Run gel in running buffer (1xMOPS) at 120 V for 2.5 hours
Let run until 2nd LD band is 8 cm before end of gel.
Do not use EtBr in lower samples if two combs are used. Alternatively stain gel
in 0.5µg/ml Ethidiumbromide for 30 min, take picture and destain in H2O for 30
min.
• Blot o/n in 300 ml 10x SSC in disposable plastic box on nitrocellulose
membrane BiodyneB.
• Rinse membrane in 2x SSC.
• Air-dry on 3mm paper then vacuum bake for 3 hrs at 80˚C
Hybridization
DNA probe on DNA: 65º C
DNA probe on RNA: 72º C
as described in section 4.1.13, or alternatively:
• Wet filter in 5x SSC and transfer to hybridization tube
• Prehybridize for 1-3 hrs at 42°C in15 ml prewarmed Hybridization mix
• Remove and add 15 ml fresh prewarmed Hybridization mix
• Add denatured random primed DNA probe.
• Hybridize o/n at 42°C in a rotating wheel.
• Wash 15 min at RT in wash buffer1, then 2x 20 min at 65°C in wash buffer 2.
• Expose to X-Ray film.
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10x MOPS:
200mM MOPS 20.9 g MOPS
50mM Na-acetate 800 ml Na-acetate (DEPC !)
10mM EDTA 20 ml 0.5M EDTA
adjust pH 7.0 with NaOH appr. 17 ml 2N NaOH (plastic pipett)
 20x SSC:
3M NaCl 175 g NaCl
 0.3M sodiumcitrat 88 g tri-Sodium citrate dihydrate
adjust with NaOH 10N  to pH 7 add. to 1 liter with water
50x Denhardt:
1% Ficoll type 400
1% BSA fraction 5 in H2O
LB stock:
10% Ficoll type 400
0.1% bromphenolblue in H2O
Hybridization mix:
50% formamid
5x SSC
50mM NaP pH 6.5
8x Denhardt
0.5 mg/ml yeast RNA
1% SDS
RNA sample buffer:
53% formamide
6.7% formaldehyde
1x MOPS
18% L.B. stock
wash buffer1:
2x SSC
1% SDS
wash buffer2:
0.2X SSC
0.1% SDS
4.2.5 Reverse Transcription of RNA (cDNA synthesis)
A typical procedure uses between 1 ng – 1 µg total RNA or 10 pg – 1 µg mRNA.
• Mix in a sterile RNase-free tube:
2 µl Oligo(dT) [≅ 1 µg]
1 µg total RNA
add to 13 µl DEPC water
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• Heat 5 min. at 70ºC, than cool 5 min. on ice
• Add to the tube:
1 µl RNase out
5 µl 5x M-MLV RT reaction buffer
5 µl 10 mM nucleotide mix (A,C,G,T)
1 µl reverse transcriptase [≅ 200 units ]
• Mix gently, spin down, and incubate 1 h at 37º to 40ºC
• Stop reaction for 15 min at 70ºC
• Add 1 µl RNase H and incubate 20 min at 37ºC
• For RT-PCR use 1 µl per reaction
4.2.6 Quantitative RT-PCR with SYBR green
The SYBR green dye detects the absolute increase of DNA concentration during a PCR
run. It is therefore essential to establish PCR assays that produce specific products, as
unspecific amplification products or “smear” will produce a signal. Primers have to be
designed according to the following priorities:
1) PCR product between 50 and 250 nucleotides
2) Identical annealing temperature (+/- 0.3º) of se and as primer (55-63ºC)
3) Exclusion of primers with duplex formation above -5 kcal/mol
4) Annealing preferably in 3’ UTR (efficiently reverse transcribed sequence)
5) Annealing in different exons to distinguish genomic DNA contamination
The amplification efficiencies (1≥ E) of individual PCR assays have to be determined
by serial dilutions of template covering at least 10-5 magnitudes (1:1 to 1:10000). If the
efficiency of an assay is close to 1, than Xn = Xo (1+E)n can be simplified to 2-∆∆Ct for
quantification of results.
PCR reactions where pipetted in triplicates in 20 µl total volume at RT and spun briefly
before the PCR run. Calibrators where assays for tubulin, GAPDH or Rpl19.
Nontemplate controls (NTC) where used to detect primer duplex products. Rox dye
served to normalize for dye degradation.
  6 µl  se/as primer (150-300 nM)
  4 µl  cDNA (1:4)
10 µl  2x SYBR green
Primer concentration: Primer stock [100 pmol/µl]
300 nM dillute 1:50
300 nmol/l mix se and as 1:1 [1pmol/µl final]
300 pmol/ml store at –20º
0.3 pmol/µl = 6 pmol/20 µl
4.2.7 DIG labeling of RNA probe (cRNA synthesis)
Transcription efficiencies vary between different enzymes; SP6 RNA polymerase
usually gives better yield than T7 or T3 RNA polymerases.
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• Linearize (o/n) 5 µg of vector containing the probe in the polylinker on the
opposite side of the RNA polymerase promoter used to transcribe as probe
(3’ – 5’)
• Add 500 µl water and 500 µl phenol:chloroform and vortex 1 min
• Centrifuge 10 min at 13 g
• Take supernatant and add 500 µl chloroform
• Centrifuge 10 min at 13 g
• Take supernatant and precipitate DNA with 25 µl P3/400µl isopropanol
• Centrifuge 10 min at 13 g
• Wash pellet in 70 % EtOH
• Resuspend in 20 µl TE
• Use 1 µg DNA for in vitro transcription:
x µl DNA (1 µg)
4 µl 5x transcription buffer
1 µl RNasin
2 µl 10x DIG mix
Add to 18 µl with DEPC water
 2 µl RNA polymerase
• Incubate 2 h at 37º C
• Add 2 µl DNaseI and incubate 15 min at 37º C
• Add 1 µl 0.5 M EDTA
• Precipitate with 5 µl 5M LiCl / 75 µl 100% EtOH at –20º C
• Centrifuge 10 min at 13 g and wash in 70% EtOH
• Resuspend big white pellet in 100 µl DEPC water + 3 µl RNasin
keep at –20ºC
(Long term storage in hybridization buffer containing formamid)
• Check aliquot on a gel, usually for in situs use 8 µl per 1ml hybridization
4.2.8 Whole mount in situ hybridization on mouse embryo
Embryos should be fixed in methanol at least o/n before being used for in situ
hybridization. All steps before hybridization with the probe should be carried out under
RNase – free conditions. The Proteinase K digest is the critical step of the protocol and
appropriate digestion times for individual probes have to be established.
• Dissect embryo rapidly in DEPC PBS/0.4 % BSA
• Fix 2 – 4 hours in 4% PFA
• 2x 5 min. PBT
• Store in 100% MeOH
• Transfer 5 min each in decreasing MeOH dillutions
100% > 75% > 50% > 25%
• 2x 5 min PBT
• ( optional 1 hour 6% hydroxen peroxide in PBT)
• 3x 5 min PBT
- 114 -
• Digest in 1:1000 Proteinase K solution (10µg/ml)
E6.5 10sec
E7.5 2 – 3 min
E8.5 5 – 7 min
E9.5 10 – 14 min
• Stop digest by transfer for 10 min in 1:10 glycine (2mg/ml)
• 2x 5min PBT
• Refix 20min PFA/glutaraldehyde (1ml PFA + 8µl GA)
• 3x 5min PBT
• 1x (1:1) Hybmix
• 1 – 3 hours in Hybmix at 65ºC
• Heat probe 8 min at 80ºC
• Hybridize o/n at 65ºC
• 2x 30min sol1 at 65ºC
• 1x 10min sol1/sol 2 at 65ºC
• 3x 5min sol2 at RT
• 1 hour at 37ºC in 1:1000 RNaseA  (stock 100mg/ml)
• 1x 5min sol 2
• 1x 5min sol 3
• 3x 5min TBST
• 1 – 1.5 hours in 1% blocking solution/2mM levamisole at 4ºC
• o/n in anti-DIG-antibody (1:1000) in 1% blocking solution/2mM levamisole
at 4ºC
• 3x 5min TBST/2mM levamisole at RT
• 5x 1 hour TBST/2mM levamisole at RT
• 3x 10min NTMT/2mM levamisole at RT
• Develop in dark in 1 ml NTMT/2mM levamisole (+ 3,5 µl NBT / 4.5 µl BCIP)
 at RT
4% PFA
Heat 200 ml PBS to 60ºC
Add 8 g PFA
Add 2 drops 2N NaOH
filter and keep aliquots at –20ºC
PBT (0.1% Tween20)
Add 500 µl Tween20 to 500 ml DEPC-PBS
Methanol (50ml)
75% 37.5 ml MeOH in 12.5 ml PBT
50% 25 ml MeOH in 25 ml PBT
25% 12.5 ml MeOH in 37.5 ml PBT
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Hydrogen peroxydase (6% in PBT)
10 ml 30% hydrogen peroxydase
40 ml PBT store at 4ºC
Proteinase K
Dilute stock [10mg/ml] 1:1000 in PBT
Glycine
Dilute stock [20 mg/ml] 1:10 in PBT
Deionized formamide
Mix formamide with Dowex XG8 mixed bed resin (BioRad AG 501-X8 Resin)
and stirr with a magnetic stirrer for 1 hour.
Filter and keep aliquots at –20C
20x SSC
NaCl 175 g
tri-Sodium citrate dihydrate 88 g
add to 1 liter with DEPC water
10% SDS
Dissolve 10g SDS in 100 ml DEPC water
Hybridization buffer
25 ml deionized formamide
12.5 ml 20x SSC
5 ml 10% SDS
500 µl tRNA yeast [stock 100 µg/ml]
500 µl heparine [stock 5 mg/ml]
6.5 ml DEPC water
Solution 1 (50 ml)
25 ml formamide
12.5 20x SSC
5 ml 10% SDS
7.5 ml sterile water
Solution 2 (50 ml)
5 ml 5M NaCl
500 µl 1M TrisHCl pH=7.5
50 µl Tween20
44 ml sterile water
Solution 3 (50 ml)
25 ml formamide
5 ml 20x SSC
20 ml sterile water
TBST (100 ml)
2.8 ml 5M NaCl
250 µl 1M KCl
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2.5 ml 1M TrisHCl pH=7.5
100 µl Tween20
93.5 ml sterile water
Blocking solution
Dissolve 1 g blocking reagent (Roche 1 096 176) in 100 ml TBST. Heat to 70ºC
and mix with a magnetic stirrer, than filter through a paper filter. Add 50 mg [2
mM] levamisole before use.
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4.3 Protein methods
4.3.1 Crude protein extracts
• Remove media from ES cell dish and wash once with PBS
• Add icecol PBS and collect cells with a sterile scraper. Wash plate once with
icecold PBS and add to the collected cells.
• Spin 5 min 1000 rpm at 4°C, remove supernatant and resuspend cell pellet in 1
ml icecold PBS. Transfer to 2ml-Eppendorff tube.
• Spin 2 min 5,900 x g, remove supernatant, shock-freeze cells in liquidN. Store at
–80°C.
• Add about 500 µl ml buffer E to frozen cell pellet (leave cells in liqid N until
use) resuspend carefully and combine cell suspensions from same cell identity.
• Transfer solution into plastic vial filled to 70% with 1-mm-glass-beads (sterile),
close lid without airbubbles
• Bead-beat for 30 sec at 5000 rpm then cool two min on ice. Repeat six times.
• Leave on ice, spin down at 16,000 x g for one min at 4°C.
• Take out 800 µl supernatant transfer to precooled polycarbonate thick wall
ultracentrifuge tubes (6.5 ml /16x64 mm/Beckmann /355647) on ice.
• Add 500 µl cold buffer E, mix, spin again and add 500 µl supernatant to the
corresponding ultracentrifuge tube.
• Ultracentrifuge 100,000 x g for 1 hour at 4°C in a MLA80 rotor.
Aliquot at 4°C and immediately shock freeze in liquid N. Store at –80°C. (Use
approximately 40 µl protein extract from 10 x 15-m-plates for one small western gel)
Buffer E :
20mM HEPES pH 8.0
350mM NaCl
10% Glycerol
0.1% Tween 20
1% Proteinase inhibitor cocktail (Sigma) add  freshly
2mM EDTA add freshly
4.3.2 Nuclear extracts
• Grow ES cell on gelatinized10 cm plate without feeders.
• Trypsinize or collect cells with a sterile cell scraper and spin down cell pellet at
1000 rpm for 5 min (Multifuge 3 S-R, rotor 6445).
• Put cells on ice and resuspend in 1 ml extraction buffer without NP40 per 2-10 x
106 cells. Add same volume NP40 buffer and mix carefully, leave on ice.
• Leave on ice for 20 min. (Clean nuclei are smooth and refract light. If nuclei are
not released from cells try (i) douncing (loose fitting pestle) and/or (ii) pipetting
up/down repeatedly through a small bore pipette)
• Spin down nuclei 1500 rpm for 5 min at 4°C.
• Remove supernatant and store nuclei pellet at -80°C.
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Nuclei extracion buffer:
15 mM Tris-HCl pH 7.5
60 mM KCl
15 mM NaCl
5 mM MgCl2
0.5 mM EGTA
300 mM Sucrose
1% NP40
add 0.5mM β-mercaptoethanol fresh before use
add 1% proteinase inhibitor cocktail fresh before use
add to 100 ml with water
4.3.3 Polyacrylamide gel electrophoresis (PAGE)
• Prepare stacking and running gel.
• Mix desired amount of protein extract with 3X PLB.
• Boil for 4-5 min at 99°C.
• Spin shortly and leave at RT until loading.
• Load protein samples onto prepared protein gel assembly with a Hamilton
pipette and run gel at 80-150V for one to three hours depending on the protein
size you wish to detect.
Stacking gel:
5% Acrylamide
125mM Tris  pH 6.8
0.1% SDS
0.1% APS
0.1% TEMED
Running gel:
5-15% Acrylamide
375mM Tris  pH 8.8
0.1% SDS
0.1% APS
0.04% TEMED
3X protein loading buffer:
250mM Tris
25% Glycerol
5% SDS
0.25% Bromphenolblue
4.3.4 Coomassie staining of protein gels
• Dissemble protein gel assembly and transfer protein gel to a box filled with
staining solution. Incubate for five hours at RT or o/n at 4°C on a rocking
platform.
• Remove staining solution wash once with H2O and add destaining solution.
Incubate for five hours at RT or o/n at 4°C on a rocking platform with
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occasional renewal of destaining solution, until the gel has reached the desired
staining intensity.
Staining solution:
45% methanol
10% glacial acetic acid
1 g/L Coomassie R250
in H2O
Destain solution:
30% methanol
10% glacial acetic acid
inH2O
4.3.5 Western analysis
For detection of standard protein-antibody detections without requirement for
extraordinary sensitivity, this basic western protocol was used. Here polyclonal
antibodies against K4-dimethylated histone H3 were bound by a secondary antibody
anti-rabbit peroxydase. The ECL mix used after the second antibody binding reacts with
the peroxydase group and produces chemiluminescence, which can be detected on a
normal Kodak film.
• If nuclei extract is the desired starting material, use nuclei pellet from one 10-
cm-dish. Add – NP40 buffer to a concentration of 105 cells/µl. Use about 5x 105
cells for loading.
• If protein extract is the desired starting material, use desired protein amounts for
loading.
• Add 3x protein loading buffer and load on a large Polyacrylamid gel.
• Run o/n 80V at 4°C (or 4 hours 175V) until the blue front is just leaving the gel.
• Blot for 45 min, 15V in a semi-dry blotter.
• Incubate in blocking buffer for two hours at RT (or o/n at 4°C).
• Add primary antibody (K4H3 1:1000, Actin 1:2000) in blocking buffer and
incubate for one hour at RT.
• Wash three times five min in PBS/0.1% Tween
• Add secondary antibody (anti rabbit 1: 2000) in blocking buffer and incubate for
one hour at RT.
• Wash once with PBS/Tween for 10 min, then three times 5 min.
• Mix ECL solutions (Amersham) 1:1 and add to cover the membrane completely.
• Incubate for 5 min, drain on a piece of tissue and expose to X-ray film for 1-20
min.
Blocking buffer : PBS/Tween :
5% milkpowder 0.1% Tween in PBS
0.1% Tween in PBS
- 120 -
4.4 Cell culture
4.4.1 Preparing Mouse Embryonic Fibroblast cells (MEFs, feeders)
All ES cell experiments were performed in feeder dependent 129 cell lines. To maintain
their pluripotency in long-term culture, these ES cell lines should be grown an
monolayers of mitotically inactivated fibroblast cells (Thomas and Capecchi, 1987;
Leighton et al., 1995). Feeder cells are derived from mouse embryonic fibroblast tissue,
expanded up to maximally 15 cell divisions and then inactivated by mitomycin
treatment to prevent further cell divisions. Feeder cells are obtained from dissections of
E 13.5 embryo
 For cultivation feeder cells are thaw onto 0.1% gelatine coated Falcon plates and
incubated at 37 °C, 5% CO2. Cells were passaged one day after they reached 100%
confluency (roughly every three days) by trypsinization. The original vial purchased by
Medicore was expanded to in total 21 15-cm-dishes before a 2-2.5 hour treatment with
10 µg/ml mitomycin. Those mitomycin treated feeder cells were frozen and upon need
plated in 100% confluency (about 106  cells) one day before seeding the ES cells.
Feeder -media:
10% Fetal Calf Serum
100 u:µl/ ml penicillin/streptomycin
2mM L-glutamine
in DMEM high glucose
 
4.4.2 Expanding MEF cells
• Thaw original feeder vial onto gelatine coated 10-cm-dish. After one day, the
plate should be 100% confluent. Change media and leave one more day in the
incubator.
• Remove media and rinse plates with 1x PBS.
• Add 1x trypsin/EDTA (2 ml on a 10-cm-dish, 7 ml on a 15-cm-dish) and leave
the plate at 37˚C for 2 min. Immediately add feeder media to inactivate the
trypsin.
• Pipet the suspension up and down to remove cell clumps.
• Transfer the suspension into a 15-ml-falcon tube containing media and spin
1000 rpm for 5 min at RT (Multifuge 3 S-R, rotor 6445).
• Aspirate supernatant and resuspend cells in media. Then split 1/3 and plate on
new gelatine coated dishes.
• Repeat this procedure until you reach 21 times confluent 15-cm-dishes.
4.4.3 Freezing MEF cells
• Trypsinize cells from a confluent 15-cm-dish as described.
• After spinning down in media, resuspend cells from one plate in 0.5 ml media
and cool down on ice for 5 min.
• Add 0.5 ml 2x freezing media and trasfer to 1-ml freezing vials then freeze at -
80˚C.
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• Transfer to liquidN the next day. This vial contains enough feeder cells to cover
five 10-cm-dishes.
2x freezing media: 1ml 4ml
25% Fetal Calf Serum 250 µl 1 ml
10% DMSO 100 µl 400 µl
in DMEM high glucose 650 µl 2.6 ml
4.4.4 Culturing mouse ES cells
Mouse embryonic stem (ES) cells are totipotent cells derived from the inner cell mass
of 3.5 day blastocysts. They can be modified and reintroduced into blastocysts, giving
rise to manipulated chimeric animals. (Thompson et al. 1989)
If they are held under certain growth conditions, they can also differentiate to various
cell types. To avoid this, LIF serum is added to the ES medium. It suppresses
differentiation, so that the silencing of genomic regions during the differentiation
process is prevented.
 For cultivation ES cells were thawn onto feeder coated 10-cm Falcon plates and
incubated at 37 °C, 5% CO2. After ES cells are thawed it is recommended to passage
them every second day by trypsinization. Reseeding should be calculated in a way that
the cells reach 100% confluency after 48 hours in culture.
 For long-term storage ES cells are kept in liquid nitrogen in a cell density of 5x 106
cells in freezing medium containing DMSO as a cryoprotectant. Since DMSO is
harmful to cells it should contact ES cells as short as possible before and after freezing.
 
 ES cell media:
 15% Fetal Calf Serum
 100 u:µl/ ml penicillin/streptomycin
 100µM non-essential amino acids
 1mM sodium acetate
 1µM β-mercaptoethanol
 2mM L-glutamine
 600 U/ml LIF “ESGRO”
 in DMEM high glucose
 
4.4.5 Harvesting ES cells
• Remove media and rinse plates with 1x PBS.
• Add 1x trypsin/EDTA (2 ml on a 10-cm-dish) and leave the plate at 37˚C for 5
min.
• Pipet the suspension up and down to remove cell clumps.
• Transfer the suspension into a 15-ml-falcon tube containing ES media and spin
1000 rpm for 5 min at RT (Multifuge 3 S-R, rotor 6445).
• Aspirate supernatant and resuspend cells in 3-8 ml of ES media. Then plate out
an appropriate fraction on a new dish. A rough estimate is that a confluent 10cm
dish should yield 1-4 x 107 cells and approximately 1-5 x 106 cells should be
seeded on a 10cm dish in 10 ml media.
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4.4.6 Freezing ES cells
• Trypsinize cells from a confluent 10-cm-dish as described.
• After spinning down in media, resuspend cells from one plate in 2 ml ES media
and cool down on ice for 5 min.
• Add 2 ml 2x freezing media and seperate into 1-ml freezing vials then freeze
immediately at 80˚C.
• Transfer to liquidN the next day.
 2x freezing media:
 50% Fetal Calf Serum
 20% DMSO
in DMEM high glucose
4.4.7 Preplating
For all western experiments it was desirable to harvest a pure colony of targeted ES
cells without contamination of wt feeder cells. In order to obtain this purity, ES cells
cultured on feeders were pleplated. This preplating event removes feeder cells to about
90%.
• For 10cm-dish add 3 ml trypsin/EDTA remove and add 3 ml again.
• Leave plate in the incubator for 15 min.
• Add 7 ml ES media and strongly pipet up and down to disrupt cell colonies.
• Spin 5 min at 1000rpm and remove supernatant.
• Resuspend in 10 ml ES media and transfer the cells onto a gelatine uncoated
tissue culture dish.
• Leave in the incubator for 20-30 min
• Carefully pipet off the supernatant and transfer ES cells (90% feeder-free) onto a
new 0.1% gelatinized dish.
4.4.8 Electroporation
To transform DNA constructs into ES cells the electroporation method was applied. For
electroporation it is best to use cells that are passaged twice after thawing.
• Trypsinize cells from a 10-cm-dish and make sure that it is really a single cell
suspension!
• After spinning in media for 5 min, aspirate the media, and resuspend the cell
pellet in 5 ml PBS. Take an aliquot for counting and spin 1000 rpm at RT for 5
min.
• During the centrifugation step, count the number of cells on a haemocytometer
• Aspirate the supernatant and resuspend cell pellet in an appropriate volume of
PBS, so that the final volume of 800µl for the electro execution contains 107
cells.
• Use 40 µg linearized targeting plasmid  in 50 µl PBS. Pipet linearized DNA into
the gene pulser cuvette (0.4 cm electrode gap) and add 800µl cell suspension.
• Set Bio-Rad electroporator at 240V, 500µF and pulse the cells (the pulse time
should be between 5 and 6s, time constant should be 5 to 6.
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• Transfer the electroporated cells to 60-80 ml media and distribute cell
suspension onto 6-8 gelatinized 10-cm-dishes.
4.4.9 Transformation
Stable transformation
• Thaw ES cell clone onto a feeder coated cell culture dish.
• After two passages perform electro-transformation as described.
• Plate transformed cells on six 10-cm feeder-coated dishes.
• Selection: After 24 to 40 hrs change media and add selection medium
Selection markers are ordered by stringency
Puro     1 µg/ml
Hygromycin 200 µg/ml
G418 (neomycin) 250 µg/ml
• Incubate for 8-10 days with occasional change of selection media.
• Pick about 96 undifferentiated colonies into feeder containing 48-well-dishes.
• After two days, trypsinize and transfer onto new feeder containing 48-well-
dishes.
• After another two days, split each clone in two: One third stays in the 48-well-
dish. Cool 5 min on ice then add 2x freezing media and freeze at -80°C. Transfer
the reamining two thirds trypsinized cell suspension into gelatinized 24-well-
dishes containing 800 µl ES selection media. After 3-5 days these wells will be
confluent and cells can be used for DNA extraction.
Transient transformation
Transient trasnformation in this thesis was applied to introduce the Cre recombination
plasmid pMC-Cre into mll2F/F ES cells.
• Thaw ES cells and passage twice before collecting 106 cells for electroporation.
• Use 40 µg unlinearized McCre plasmid resuspended in 50 µl 1x PBS and
perform electroexecution as described.
• After electroporation seed 5-50 x 103 cells per feeder coated plate and incubate
for 7-9 days with occasional media change (no selection !).
• Pick about 96 undifferentiated colonies into feeder containing 48-well-dishes.
• After two days, trypsinize and transfer onto new feeder containing 48-well-
dishes.
• After another two days, split each clone in three: One third stays in the 48-well-
dish. Cool 5 min on ice then add 2x freezing media and freeze at -80°C. One
third is transferred into G418 containing media to check for Cre mediated
deletion of the neomycin selection marker. Transfer the reamining one third
trypsinized cell suspension into gelatinized 24-well-dishes containing 800 µl ES
media. After 3-5 days these wells will be confluent and cells can be used for
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4.4.10 Apoptosis assay
Cleavage of genomic DNA during apoptosis may yield double-stranded, low molecular
weight DNA fragments as well as single strand breaks (“nicks”) in high molecular
weight DNA. Those DNA strand breaks can be identified by labeling free 3’OH termini
with modified nucleotides in an enzymatic reaction. The Kit performs in three
consecutive steps:
1. Labeling of DNA strand breaks, by Terminal deoxynucleotidyltransferase
(TdT), which catalyzes polymerization of labeled nucleotides to free 3’-OH
DNA ends in a template-independent manner (TUNEL reaction).
2. Detection of incorporated fluorescein by anti-fluorescein antibody Fab
fragments from sheep. Analysis under fluorescence microscope.
• Grow ES cells in 24-well-plate on coverslips.
• Wash with PBS.
•  Fix air-dried samples with freshly prepared fixation solution for  one hour at
RT.
• Wash with PBS.
• Incubate in permeabilisation solution for two min on ice.
• For positive control incubate fixed and permeabilized cells with DNAseI in
digestion buffer for 10 min at RT to induce DNA strand breaks, prior to labeling
procedures.
• Prepare TUNEL reaction mixture by adding 50 µl enzyme solution to 450 µl
label solution. Mix well to equilibrate components.
• Rinse slides twice with PBS.
• Take coverslips out of the well, dry by touching a paper towel and place upside
down onto a drop of 50 µl TUNEL reaction mixture.
• For negative control incubate fixed and permeabilized cells in 50 µl label
solution (without TdT) instead of TUNEL reaction mixture.
• Incubate for one hour at 37 °C in a humidified atmosphere in the dark.
• Dip coverslips 3x in PBS
• Samples can be analyzed in a drop of PBS under a fluorescence microscope at
this state. Use an excitation wavelength in the range of 450-500 nm and
detection in the range of 515-565 nm (green).
Fixation solution:
4% paraformaledehyde in PBS
Permeabilisation solution:
0.1% Triton X-100
0.1% sodium citrate in H2O
Digestion buffer:
3U/ml DNAseI
50mM Tris-HCl, pH 7.5
10mM MgCl2
1 mg/ml BSA
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Label solution:
nucleotide mixture in reaction buffer (content of “In Situ Cell Death Detection
Kit”)
Enzyme solution:
Td from calf thymus in storage buffer (10x) (content of “In Situ Cell Death
Detection Kit”)
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4.5. Histology
4.5.1 Perfusion of mouse
• Use a 27G3/4 0.4 x 19 syringe with tubing and peristaltic pump, adjust pump
every time. Mark 5mm with edding and bend syringe
• Anesthetize mouse with 0.2 ml / 10 g body weight i.p. injection. If bulb appears
appears on skin, injection is subcutan. Mouse is anesthetized after 1 min for
approx. 40 min. Check by pinching limb
• Dissect mouse, insert syringe in heart until 5mm mark , fix tubing
• Cut right ventricle with right hand immediately switch on the pump with left
hand
• Rinse mouse with PBS until liver and testis are colorless (usually 5 min.)
• Pause pump and change to PFA, rinse with 30 ml PFA (usually 30 min.)
• Check perfusion quality (liver and tail should be hard
4.5.2 Paraffin sections of testis
• Dissect testis
• Fix 6 hours in Bouins solution, cut testis in half after 2 hours
• 70% EtOH 2 x 2h
• 95% EtOH 2 x 2h
• 100% EtOH 3 x 2h (o/N)
• EtOH:Xylene [1:1] 30min at RT
• Xylene 2 x 2h at RT
• Xylene:wax 30min at 60ºC
• Wax 2 x 2h  at 60ºC
• Embed testis in wax form.
• Cut 5 mm sections float on DEPC-treated, distilled water
• Keep at 37ºC for 24h
Bouins solution (Sigma HT10-1-32)
85% saturated aqueous picric acid,
10%Formaldehyde      [40%W/v],
1% glacial acetic acid
Xylenes (FLUKA 95690 1liter)
instead of Xylene you can use Histolene/Histosol:
Histolene (Fronine Pty Ltd., Riverstone NSW) or Histosol (non-toxic citrus extract)
Harris Haematoxylin (Sigma)
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Haematoxylin stain
Xylene  2 x 5min
100% EtOH 2 x 5min
95% EtOH 2 x 5min
70% EtOH 2 x 5min
running tap water 5 min
distilled water 5 min
Haematoxylin 5sec
Wash in tap water
70% 5min
95% 5min
100% twice 5min
Xylene  2 x 5min
Mount in DPX under coverslips
Following in situ counterstain and mount with glycerol vinyl alcohol (GVA)
Histomount (Australian Laboratory Services, North Melbourne, AUS)
4.5.3 Paraffin sections of embryos
• Dissect embryos
• Fix 1-2 hours in formalin at 4ºC
• 70% EtOH 4 x 15 min
• 95% EtOH 4 x 15 min
• 100% EtOH 4 x 15 min
• EtOH:Xylene [1:1] 5 min at RT     (embryo should sink to bottom of tube)
• Xylene 2 x 10 min at RT (embryo should sink to bottom of tube)
• Xylene:wax 30 min at 60ºC
• Wax 2 x 1h at 60ºC
• Embed embryo in wax form.
• Cut 5 mm sections float on DEPC-treated, distilled water
• Keep at 37ºC for 24h
4.5.4 Immunohistochemistry on paraffin sections
• Deparaffinise sections and rehydrate to distilled water:
Xylene  2 x 5min
100% EtOH 2 x 5min
95% EtOH 2 x 5min
70% EtOH 2 x 5min
running tap water 5 min
distilled water 5 min
• Optional: place 10 min in 0.5%  hydrogen peroxide/methanol to block
endogenous peroxidases. Wash sections in tap water.
• High temperature antigen unmasking: place slides 20 min in a microwave at
700W in 1800 ml 10 mM citrate buffer ph 6.0 (buffer will boil)
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• Incubate 10 min at RT in blocking serum
• Incubate 1 h at RT in primary antibody diluted in blocking serum
• Wash 5 min in PBS
• Incubate 10 min at RT in in biotinylated secondary antybody
• Wash 5 min in PBS
• Incubate 10 min in streptavidin/peroxidase complex
• Wash 5 min in PBS
• Prepare peroxidase substrate solution (Liquid DAB substrate kit)
• To 5 ml dist. water: Add 2 drops of buffer stock solution and mix well
Add 4 drops of DAB stock solution and mix well
Add 2 drops of hydrogen peroxide sol. and mix well
If a black stain is required, add 2 drops of nickel sol.
• Incubate tissue section 2 to 10 min with the substrate solution at RT
• Wash 5 min in water
• Counterstain and mount slides
10 mM citrate buffer           (ph 6.0)
Citric acid      3.84 g
Add 1800 ml distilled water
Adjust ph 6.0 with NaOH
Add to 2000 ml with distilled water
4.5.5 TUNEL staining on paraffin sections
• Use the In situ Cell Death Detection Kit (Roche) : Cat. 1 684 809
• Rehydrate the section
2x 5min Xylene
2x 5min 100% EtOH
2x 5min 70% EtOH
2x 5min water
• 20 min at 37ºC in 10 ml  [10 mM Tris  with 10µg/ml Proteinase K ].
10 ml water
100 µl 1M Tris (ph 7.4)
10 µl Proteinase K from Stock (10mg/ml)
• wash 3x with PBS
• Prepare the Tunel reaction mixture [1:10] from vial1:vial2
For each slide you need 25 µl ,  (use 2,5 µl vial1 with 22.5 µl vial 2)
• Incubate 1h at 37 C in a humidified atmosphere in the dark.
• Wash 3x in PBS
• Incubate 30min at 37ºC with 50 µl converter-AP in a humidified atmosphere in
the dark.
• Wash 3x in PBS
• Incubate 10min at RT in 50 – 100 µl substrate solution
• Rinse 3x in PBS
• Mount under glass coverslip.
Haematoxylin / Eosin stainings are much stronger due to the Proteinase K digestion
Proper Haematoxylin dilutions and incubation times need to be established.
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4.5.6 Cryosection
• Fix sample in 4% PFA (1hour – o/n)
• Wash 4x 25min in PBS
• Transfer to sucrose gradient (8% / 15% / 30%) until the tissue sinks to the
bottom
• embed in tissue tek and freeze on dry ice
• cut 6 – 10 µm sections on a cryostat. Usually the blade should be cooled to
–22ºC and the sample to –20ºC, but temperatures have to be determined for
every session. Keep sections at –20ºC.
4.5.7 Immunohistochemisty on cryosection
• Permeabilize and block the sections in blocking buffer
• Incubate with 1st antybody in blocking solution o/n at 4ºC in a humidified
chamber
• Wash 6x 15min in TBS/Tween
• Incubate with 2nd antibody 1 hour at RT
• Wash 6x 15min, incubate 10min with DAPI [1:3000], wash again
• Mount slides
Blocking buffer
TBS
0.3 % Triton
50 mM Glycin
10% FCS
4.5.8 Whole mount LacZ staining of embryos
• Dissect embryos at RT in transport solution. Fix embryos in 4% PFA on ice for
30 min to 1 hour (depending on developmental stage of the embryo).
• Transfer into a 10-cm-dish containing cold PBS to wash.
• Transfer embryos into a 5-cm-dish containing freshly prepared staining solution.
• Incubate at 37°C o/n. To avoid evaporation and drying out of the embryos place
dishes into a box layed out with wet tissue.
• To take pictures wash embryos in PBS twice.
• If it is intended to make sections of the embryos, cryopreseve them in sucrose
solution o/n at 4°C.
Fixing solution:
4% Paraformaldehyde
Transport solution:
PBS/ 0.4% BSA
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Staining solution:
0.01% Sodium-Deoxycholate
0.02% NP40
2 mM MgCl2
8 mg Spermidin-trihydrochloride
fill to 30 ml with PBS. Stable at 4°C for several weeks.
10 mM Ferrocyanide add just before use
10mM Ferricyanide add just before use
2 mM Xgal add just before use
Sucrose solution:
30 % sucrose in PBS
4.5.9 Whole mount Fast-red staining of primordial germ cells (PGC)
• Dissect embryos (E 7.5 to E 9.5) in cold PBS.
• Fix for 1-2 h at 4º C in 4% PFA.
• Wash 3x 2min in PBS.
• Dehydrate in 70 % EtOH for 1-2 h at 4º C.
• Wash 3x 5min in distilled water.
• Stain in fresh naphtylphosphate / fast red TR solution for 15 – 20 min. at RT
• Wash in PBS.
• Transfer to 70% glycerol to clear and count PGC’s under a microscope
• For older embryos (E 9.0 – 9.5), the hindgut was isolated and transferred to 70%
glycerol.
1M Tris-maleate (ph 9.0)
use a large volume of 1M Tris
adjust  ph 9.0 by adding 1M Tris-maleate
Fast red solution
25 mM Tris-maleate (ph 9.0) Tris-maleate (Sigma T-3128)
1 mg/ml Fast red TR Fast-Red TR salt (Aldrich 20,155-3)
0.4 mg/ml naphtyl phosphate α−naphtylphosphate (Sigma N-7255)
8 mM MgCl
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4.6. Transgenic mice
4.6.1 Genotyping
Pups were weaned at three weeks of age. A 1cm tail cut was used for genotyping. Tail-
DNA extaction was performed according to the protocol in section 4.1.12. Genotyping
was based on a PCR strategy (for further details please refer to the results section)
4.6.2 Tamoxifen gavage of mouse
• 100 mg Tamoxifen-free base (Sigma, T5648) was suspended in 100 µl Ethanol
and solved in 900 µl peanut oil (Sigma). This 10 mg/100 µl tamoxifen solution
was shacked rigorously at 55°C (Tamoxifen precipitates at RT) and divided in
aliquots of 50 µl (1 daily dose = 5mg). Store at -20ºC.
• Heat to 37ºC before administration. Verify that tamoxifen is properly dissolved.
• Feed orally to mice with a feeding needle. Fix the mice at their neck and ridge
so that the belly is directed to the floor. Hold the mouse tightly so that it can not
move the head, but not too tight to avoid choking. Carefully introduce the
feeding needle in the mouth behind the tongue (max. 1 cm). It is helpful to mark
1 cm on the needle with an edding pen in order to see how deep you have
inserted the needle.
• Introduce slowly 50 µl of the Tamoxifen solution with the syringe. Make sure
that they swallow (can be seen).
• Repeat this procedure for 5 days once a day.
Gavage needles from Heiland,Germany
'Knopfkanülen', 1,2x4mm, Nr. 370-129
Phone +341-9976990,
Fax 0800-6666699
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5. Material
5.1 Chemicals
Acrylamide Sigma
Agarose Gibco
Ampicillin Sigma
APS Sigma
Bacto-Agar Difco
Beta-mercaptoethylamine Sigma
Bisacrylamide Sigma
Bromphenolblue Merck
BSA Sigma
CaCl2 Merck
Chloramphenicol Sigma
Chromiumpotassiumsulfate Sigma
Coomassie Merck
Cyclohexemide Sigma
DTT Biomol
EGTA Sigma
Ethidiumbromide Sigma
Ferricyanide Sigma
Ferrocyanide Sigma
Ficoll Sigma
G418 Gibco
Gelatine Merck
Glycine Merck
HCl Merck
Hepes Biomol
Hygromycin B Roche
IPTG Sigma
KAc Merck
Kanamycin sulfate Sigma
KCl Merck
KH2PO4 Merck
KH4Ac Merck
L-Arabinose Sigma
L-Cystein Sigma
Methyl green Sigma
Methylene blue Sigma
MgCl2 Sigma
Milkpowder Hairler
Mitomycin Sigma
MnCl2 Sigma
MOPS Sigma
Na2HPO4 Merck
Na-Citrate Merck
NaCl Merck
- 133 -
NaOAc Merck
NaOH Merck
N-lauroylsarcosine Sigma
OCT (tissuetek) Sacura
Paraformaldehyde Sigma
PI Sigma
RbCl2 Sigma
Retinoic acid Sigma
SDS Bio-Rad
Sodiumdeoxycholate Sigma
Spermidintrihydrochloride Sigma
Sucrose Sigma
Tetracycline Sigma
Titriplex (EDTA) Merck
Trizma Merck
Urea Merck
XCFF Merck
X-Gal Biomol
ZnSO4 Sigma
5.2 Solutions
Acrylamide-Bisacrylamide mix (30%) Severn Biotech LTD
Beta-mercaptoethanol Sigma
BioRad protein assay Bio-Rad
DMEM (Glutamax) Gibco
DMSO Sigma
ECL solutions Amersham-
Pharmacia
EN3HANCE NEN
Eosine Sigma
Ethanol Merck
Eukitt Fluka
FCS Gibco
Formamid Sigma
Glacial acetic acid Merck
Gluteraldehyde Sigma
Glycerol Merck
Isopropanol Merck
L-Glutamine Gibco
LIF-ESGRO Chemicon
Methanol Merck
Non essential amino acids Biochrom
NP40 Roche
Penicillin/Streptomycin Gibco
Phenol/Chlorophorm/Isoamylalkohol Sigma
Sodium Pyruvate Gibco
TEMED Sigma
TRI Reagent Sigma
- 134 -
Triton-X100 Sigma
Trypsin/EDTA Gibco
Tween 20 Sigma
5.3 Buffer
LB (Luria Bertoni media) 1% bacto tryptone
0.5% bacto yeast
1% NaCl
PBS 171mM NaCl
3.4mM KCl
10mM Na2HPO4
1.9mM KH2PO4
TE (pH 8.0) 10mM Tris
1mM EDTA (pH 8.0)
5.4 Other reagents
5.4.1 Enzymes, marker and nucleotides
1kb ladder Gibco
DNAse I Sigma
dNTP mix Amersham-
Pharmacia
Klenow large fragment NEB
Prestained protein marker, broad range NEB
Proteinase inhibitor cocktail Sigma
Proteinase K Merck
Restriction enzymes NEB
RNA polymerase T3/T7 NEB
RNAse A Sigma
rNTP mix Amersham-
Pharmacia
T4 DNA ligase NEB
Taq and PCR buffer Roche
5.4.2 Kits
Adsvantage-GC cDNA PCR Kit Clontech
In situ cell death detection Kit, AP Roche
Plasmid Maxi preparation Kit Qiagen
Qiaquick PCR purification Kit Qiagen
Random primed DNA labeling Kit Roche
Western Star protein detection Kit (AP conjugate) Tropix
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5.4.3 Antibodies
Anti-beta Actin (monoclonal) Sigma
Anti-dimethylH3/K4 (polyclonal) Abcam
Anti-mouse Ig, horseradish peroxidase, from sheep Amersham-Pharmacia
Anti-rabbit Ig, horseradish peroxidase, from donkey Amersham-Pharmacia
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